

## ENT COOPERATION TREA

PCT

NOTIFICATION OF THE RECORDING  
OF A CHANGE(PCT Rule 92bis.1 and  
Administrative Instructions, Section 422)

From the INTERNATIONAL BUREAU

To:

KENING, Li  
E.I. du Pont de Nemours and Company  
Legal Patent Records Center  
1007 Market Street  
Wilmington, DE 19898  
ETATS-UNIS D'AMERIQUE

Date of mailing (day/month/year) 18 September 2000 (18.09.00)	<b>IMPORTANT NOTIFICATION</b>
Applicant's or agent's file reference BB1339 PCT	
International application No. PCT/US00/01772	International filing date (day/month/year) 26 January 2000 (26.01.00)

1. The following indications appeared on record concerning:									
<input type="checkbox"/> the applicant	<input type="checkbox"/> the inventor								
<input checked="" type="checkbox"/> the agent	<input type="checkbox"/> the common representative								
Name and Address BEARDELL, Lori, Y. E.I. du Pont de Nemours and Company Legal Patent Records Center 1007 Market Street Wilmington, DE 19898 United States of America	<table border="1"> <tr> <td>State of Nationality</td> <td>State of Residence</td> </tr> <tr> <td colspan="2">Telephone No. 302 992 4926</td> </tr> <tr> <td colspan="2">Facsimile No. 302 773 0164</td> </tr> <tr> <td colspan="2">Teleprinter No.</td> </tr> </table>	State of Nationality	State of Residence	Telephone No. 302 992 4926		Facsimile No. 302 773 0164		Teleprinter No.	
State of Nationality	State of Residence								
Telephone No. 302 992 4926									
Facsimile No. 302 773 0164									
Teleprinter No.									
2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:									
<input checked="" type="checkbox"/> the person	<input type="checkbox"/> the name								
<input type="checkbox"/> the address	<input type="checkbox"/> the nationality								
<input type="checkbox"/> the residence									
Name and Address KENING, Li E.I. du Pont de Nemours and Company Legal Patent Records Center 1007 Market Street Wilmington, DE 19898 United States of America	<table border="1"> <tr> <td>State of Nationality</td> <td>State of Residence</td> </tr> <tr> <td colspan="2">Telephone No. 302 992 3749</td> </tr> <tr> <td colspan="2">Facsimile No. 302 773 0164</td> </tr> <tr> <td colspan="2">Teleprinter No.</td> </tr> </table>	State of Nationality	State of Residence	Telephone No. 302 992 3749		Facsimile No. 302 773 0164		Teleprinter No.	
State of Nationality	State of Residence								
Telephone No. 302 992 3749									
Facsimile No. 302 773 0164									
Teleprinter No.									
3. Further observations, if necessary:									
4. A copy of this notification has been sent to:									
<input checked="" type="checkbox"/> the receiving Office	<input type="checkbox"/> the designated Offices concerned								
<input type="checkbox"/> the International Searching Authority	<input checked="" type="checkbox"/> the elected Offices concerned								
<input checked="" type="checkbox"/> the International Preliminary Examining Authority	<input type="checkbox"/> other:								

<b>The International Bureau of WIPO</b> 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Sean Taylor Telephone No.: (41-22) 338.83.38
--	---

**THIS PAGE BLANK (USPTO)**

# INTERNATIONAL SEARCH REPORT

Internat. Application No  
PCT/US 00/01772

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/53 C12N15/82 C12N9/02 C12Q1/68 C12P17/06  
C12N5/10 A01H5/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C12Q C12P A01H

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SIMINSZKY B. ET AL.: "AC AF022462; 048926" EBI DATABASE, 8 January 1998 (1998-01-08) - 1 June 1998 (1998-06-01), XP002141043 the whole document	3,7
A	SCHOPFER, C. R. ET AL: "Identification of elicitor-induced cytochrome P450s of soybean (Glycine max L.) using differential display of mRNA" MOLECULAR AND GENERAL GENETICS, (1998) VOL. 258, NO. 4, PP. 315-322. 29 REF. ISSN: 0026-8925, XP002141044 the whole document	1-50

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

26 June 2000

Date of mailing of the international search report


12/07/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Kania, T



## INTERNATIONAL SEARCH REPORT

Internat. Application No

PCT/US 00/01772

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	AKASHI T. ET AL.: "Cloning of cytochrome P450 cDNAs from cultured Glycyrrhiza echinata L. cells and their transcriptional activation by elicitor-treatment" PLANT SCIENCE, vol. 126, 1997, pages 39-47, XP002101412 see esp. p. 43 fig.3; p.45 r. col. ---	1-50
A	HAKAMATSUKA T ET AL: "ISOFLAVONE SYNTHASE FROM CELL SUSPENSION CULTURES OF PUERARIA-LOBATA" CHEMICAL & PHARMACEUTICAL BULLETIN (TOKYO), vol. 37, no. 1, 1989, pages 249-252, XP000914902 ISSN: 0009-2363 the whole document ---	1-50
A	COLLIVER S P ET AL: "Differential modification of flavonoid and isoflavonoid biosynthesis with an antisense chalcone synthase construct in transgenic Lotus corniculatus." PLANT MOLECULAR BIOLOGY, vol. 35, no. 4, 1997, pages 509-522, XP002141045 ISSN: 0167-4412 the whole document ---	27-40
P,X	STEELE C. ET AL.: "Molecular characterization of the enzyme catalyzing the aryl migration reaction of isoflavonoid biosynthesis in soybean" ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol. 367, July 1999 (1999-07), pages 146-150, XP000921489 the whole document ---	3,7
P,X	AKASHI TOMOYOSHI ET AL: "Cloning and functional expression of a cytochrome P450 cDNA encoding 2-hydroxyisoflavanone synthase involved in biosynthesis of the isoflavonoid skeleton in licorice." PLANT PHYSIOLOGY (ROCKVILLE), vol. 121, no. 3, November 1999 (1999-11), pages 821-828, XP002141046 ISSN: 0032-0889 the whole document ---	3,7
P,X	WO 99 19493 A (UNIV NORTH CAROLINA ;DEWEY RALPH E (US); CORBIN FREDERICK T (US);) 22 April 1999 (1999-04-22) see table 1; pp.66-69 SEQ ID NO:13 -----	3,7

**THIS PAGE BLANK (USPTO)**

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## Continuation of Box I.2

Present claims 1,2 relate to an extremely large number of possible sequences. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the sequences claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the sequences encoding the cloned isoflavone synthases as listed in the sequence listing.

\*\*\*\*\*'indicate precisely what has been covered by the search e.g those compounds etc. prepared in the examples and closely related homologous compounds etc./those compounds etc. mentioned in the description at pages YY/given in Formula 1, where A = C4, B = C6 etc.!\*\*\*\*\*

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

**THIS PAGE BLANK (USPTO)**



# INTERNATIONAL SEARCH REPORT

Information on patent family members

Internat : Application No

PCT/US 00/01772

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9919493 A	22-04-1999	AU 9680698 A	03-05-1999

**THIS PAGE BLANK (USPTO)**

RECEIVED

MAY 21 2001

PCT

PATENT RECORDS  
CENTERNOTIFICATION OF TRANSMITTAL OF  
THE INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT

(PCT Rule 71.1)

From the  
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:

LI, Kening  
E.I. DU PONT DE NEMOURS AND COMPANY  
Legal Patent Records Center  
1007 Market Street  
Wilmington, Delaware 19898  
ETATS-UNIS D'AMERIQUEDate of mailing  
(day/month/year)

09.05.2001

Applicant's or agent's file reference  
BB1339

## IMPORTANT NOTIFICATION

International application No.  
PCT/US00/01772International filing date (day/month/year)  
26/01/2000Priority date (day/month/year)  
27/01/1999

Applicant

E.I. DU PONT DE NEMOURS AND COMPANY et al.

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

## 4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/

European Patent Office  
D-80298 Munich  
Tel. +49 89 2399 - 0 Tx: 523656 epmu d  
Fax: +49 89 2399 - 4465

Authorized officer

Emslander, S

Tel. +49 89 2399-8718

REY NOTED



27 JL 2001



# PATENT COOPERATION TREATY

## PCT

### INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference BB1339		<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US00/01772	International filing date (day/month/year) 26/01/2000	Priority date (day/month/year) 27/01/1999	
International Patent Classification (IPC) or national classification and IPC C12N15/53			
Applicant E.I. DU PONT DE NEMOURS AND COMPANY et al.			

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.



2. This REPORT consists of a total of 9 sheets, including this cover sheet.

☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☒ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☒ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand 27/07/2000	Date of completion of this report 09.05.2001
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer KurZ, B Telephone No. +49 89 2399 7319 



**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/US00/01772

**I. Basis of the report**

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

**Description, pages:**

1-60 as originally filed

**Claims, No.:**

1-50 as originally filed

**Drawings, sheets:**

1/28-28/28 as originally filed

**Sequence listing part of the description, pages:**

1-53, as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☒ contained in the international application in written form.
- ☒ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:



11/11/11



**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/US00/01772

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

*(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*

6. Additional observations, if necessary:

**II. Priority**

1. ☐ This report has been established as if no priority had been claimed due to the failure to furnish within the prescribed time limit the requested:

☐ copy of the earlier application whose priority has been claimed.

☐ translation of the earlier application whose priority has been claimed.

2. ☐ This report has been established as if no priority had been claimed due to the fact that the priority claim has been found invalid.

Thus for the purposes of this report, the international filing date indicated above is considered to be the relevant date.

3. Additional observations, if necessary:  
**see separate sheet**

**III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

☐ the entire international application.

☒ claims Nos. 1, 2 (partially).

because:

☐ the said international application, or the said claims Nos. relate to the following subject matter which does not require an international preliminary examination (*specify*):

☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):



**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/US00/01772

☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.

☒ no international search report has been established for the said claims Nos. 1, 2 (partially).

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

☐ the written form has not been furnished or does not comply with the standard.

☐ the computer readable form has not been furnished or does not comply with the standard.

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

1. Statement

Novelty (N)	Yes:	Claims	1, 2, 6, 8-50
	No:	Claims	3-5, 7
Inventive step (IS)	Yes:	Claims	-
	No:	Claims	1-50
Industrial applicability (IA)	Yes:	Claims	1-50
	No:	Claims	-

2. Citations and explanations  
**see separate sheet**

**VII. Certain defects in the international application**

The following defects in the form or contents of the international application have been noted:  
**see separate sheet**

**VIII. Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:  
**see separate sheet**



**R Item II**

**Priority**

The present application was filed on 26.01.2000 claiming as first priority date 27.01.1999. The respective priority document pertains to an isoflavone synthase (IFS) isolated from soy bean (Glycine max). The nucleotide and amino acid sequence of this enzyme are disclosed as Seq. ID Nos 1 and 2, respectively.

The present application relates to IFS sequences isolated from various sources. The nucleotide and amino acid sequences of these IFS enzymes are comprised in Seq. ID Nos 1-66. Only Seq. ID Nos. 1 and 2 of the present application are identical with the sequences disclosed in the priority document. For all other sequences priority is not validly claimed.

The second priority document is dated 20.07.1999 and comprises Seq. ID Nos 1-55. As the document cited as D 2 was published on 01.07.1999, it is relevant for assessing novelty and inventive step of all sequences which did not form part of the first priority document (i.e. it is relevant for Seq. ID Nos 7-66).

**Re Item V**

**Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

As indicated in the search report, search of claims 1 and 2 was restricted to those sequences which encode the cloned isoflavone synthases as listed in the sequence listing. As a consequence thereof, examination was carried out for the same subject-matter. Claims being dependent on claims 1 or 2 (e.g. claim 11) thus were examined on the basis of the restrictions as indicated above.

Reference is made to the following documents:

- D1: SIMINSZKY B. ET AL.: 'AC AF022462; O48926' EBI DATABASE, 8 January 1998 (1998-01-08) 1 June 1998 (1998-06-01)
- D2: STEELE C. ET AL.: 'Molecular characterization of the enzyme catalyzing the aryl migration reaction of isoflavonoid biosynthesis in soybean' ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol. 367, July 1999 (1999-07), pages 146-150



**1. Novelty (Article 33(2) PCT) and inventive step (Article 33(3) PCT) of sequences covered by the first priority date (see Item II)**

The sequences covered by the first priority date are Seq. ID Nos 1-6 of which Seq. ID No. 1 represents the nucleic acid sequence of IFS derived from soy bean and Seq. ID No. 2 represents the corresponding amino acid sequence. Closest prior art document is D1 which discloses the sequence of a soybean cytochrome P450 monooxygenase cDNA. However, this document does not give a function for the encoded protein. All other documents cited in the search report do not give any instruction on how to obtain exactly the sequences with the Seq. ID Nos. 1 and 2 and which code for or have the function of an isoflavone synthase.

In case that the objections raised under Item VIII will be remedied, claims relating directly to Seq. ID Nos. 1 and 2 of the present application or to methods making use of the primers with the Seq. ID Nos 3-6 could be considered as fulfilling the criteria novelty (Article 33(2) PCT) and inventive step (Article 33(3) PCT). For claims lacking technical features such as e.g. claims 3 and 4 (see Item VIII) no meaningful contribution over the art is recognisable and consequently they at least cannot be considered inventive.

**2. Novelty (Article 33(2) PCT) of sequences not covered by the first priority date (see Item II)**

The sequences with the Seq. ID Nos 7-66 are not covered by the first priority date. As a consequence thereof, document D2 which is cited in the search report as P,X is taken into account for assessing novelty and inventive step of claims relating to these sequences.

**2.1 Document D2 pertains to the isolation and characterisation of an IFS enzyme from soy bean. The enzyme is designated as 2-hydroxyisoflavanone synthase (2-HIS). The cDNA and the deduced amino acid sequences are disclosed and data concerning the function of the enzyme are provided. The sequence is stated to be nearly identical to the sequence disclosed in D1.**

With respect to the disclosure of D2 claims 3-5 and 7 are not novel. Novelty of claims 6 and 8 at present cannot be finally assessed as sequence comparisons

**THIS PAGE BLANK (USPTO)**



are missing. However, the objections raised under 3.1 (see below) apply.

**3. Inventive Step (Article 33(3) PCT) of sequences not covered by the first priority date (see Item II)**

- 3.1 Closest prior art document is D2. It discloses the nucleotide and amino acid sequence of the enzyme IFS from soy bean. The sequences of D2 are not 100% identical with the sequences of the present application. However, the knowledge of the sequence and its function enables the skilled person to identify further sequences having the same function in other plant species or in the same plant. The necessary methodology is general knowledge, and the effects of IFS are known in the art. The provision of further sequences with the same function can thus be considered as an alternative solution leading to the same result. The subject-matter of claims 1, 2, 6, and 8-25 is thus not inventive. The same argumentation applies to claims relating to methods of altering the IFS (expression) level in plants as claimed in claims 26-40 and to methods of isolating further IFS encoding sequences as claimed in claims 41-50.

**Re Item VII**

**Certain defects in the international application**

1. The units of measure employed on pages 50, lines 13-15 and p. 55, lines 8-10 are not additionally expressed in terms of the units stipulated by Rule 10.1(a) PCT.

**Re Item VIII**

**Certain observations on the international application**

Objections under Article 6 PCT (lack of clarity):

1. The IPEA is of the opinion that according to Article 6 and Rule 6.3 PCT the claims shall define the matter for which protection is sought in terms of technical features. (Poly)peptides, proteins, (oligo)nucleotides, genes etc. are considered to be chemical products which must be clearly and unambiguously characterised by their amino acid and/or nucleic acid sequences, i.e. by reference to their Seq. ID No.

**THIS PAGE BLANK (USPTO)**

In claims 3 and 4 of the present application the characterisation of a product only by the desired function without any real technical meaning (= result to be achieved) does not fulfil the requirements of Article 6 and Rule 6.3 PCT.

The disclaimer comprised in the wording of claim 4 does not contribute any technical or structural information which could help to characterise the sequences claimed.

2. Claims 5, 6, and 8 relate to sequences showing a certain degree of identity to known nucleotide sequences. However, no function of the claimed sequences is given. The present formulation thus encompasses sequences with a high degree of similarity but a totally different function or no function at all. Claims 5, 6, and 8 consequently lack clarity.
3. Claim 7 relates to a nucleic acid characterised by hybridising to Seq. ID No. 1. The nucleic acid claimed is not characterised by any structural information nor by length or function. In addition, no hybridisation conditions are given. The present formulation thus is unclear as it encompasses also low stringency conditions.
4. The formulation of claim 16 "...the eukaryotic cell of claim 13..." is unclear as claim 13, which is referred to, is not directed to eukaryotic cells.
5. The formulation "a seed from the plant..." in claims 24, 25, and 40 is unclear as seeds from transgenic plants themselves are not necessarily transgenic. Furthermore this formulation does not contain any technical information. Technical information might for example be provided by identifying the sequence(s) that have to be contained in the seed.
6. The term "substantial portion" in claims 41 and 42 is unclear as it leaves the reader in doubt about the length of the claimed sequence. The definition in the description does not seem to be helpful as IFS is closely related to numerous other P 450 monooxygenase enzymes. Short fragments are thus likely to cross-hybridise. Furthermore, the short fragments encompassed in the present wording lead to an inconsistency as paragraphs 41 e) and 42 c) foresee the demonstration of functional expression of IFS. It is not clear how such short fragments should be functional.

**THIS PAGE BLANK (USPTO)**

Furthermore, in claim 41 no hybridisation conditions (stringency, temperature) are given.

7. Concerning the formulation of the present claims 44 and 45, no unified criteria exist in the PCT Contracting States. The EPO, for example, considers a formulation as a "product obtainable by a process X" only admissible in case that the product itself fulfils the criteria of patentability.  
At present both claims do not contain any technical features and are thus unclear.
8. Claim 46 is unclear as a "phenylpropanoid pathway altering agent" is not defined in any way and is not generally accepted. The formulation is open to interpretation and leaves the skilled reader in doubt as to which agents are comprised in the wording.  
Furthermore, the statement that all agents altering the phenylpropanoid pathway are indeed also altering the expression level of isoflavonoids in a cell of claim 12 (i.e. a host cell comprising an IFS sequence) does not seem to be supported (Article 6 PCT).
9. The wording of claim 42 a) seems to be linguistically incorrect and thus unclear.
10. General statements in the description which imply that the extent of protection may be expanded in some vague and not precisely defined way, such as the "spirit" of an invention (see p. 26, l. 22), are objected to (Article 6 PCT and PCT Gazette Section IV, III-4.3a).

**THIS PAGE BLANK (USPTO)**

# PATENT COOPERATION TREATY

# PCT

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>BB1339 PCT</b>	<b>FOR FURTHER ACTION</b> see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. <b>PCT/US 00/ 01772</b>	International filing date (day/month/year) <b>26/01/2000</b>	(Earliest) Priority Date (day/month/year) <b>27/01/1999</b>
Applicant  <b>E. I. DU PONT DE NEMOURS AND COMPANY et al.</b>		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 5 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

**1. Basis of the report**

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.
- ☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).
- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :
- ☒ contained in the international application in written form.
- ☒ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☒ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

**4. With regard to the title,**

- ☒ the text is approved as submitted by the applicant.
- ☐ the text has been established by this Authority to read as follows:

**5. With regard to the abstract,**

- ☒ the text is approved as submitted by the applicant.
- ☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

**6. The figure of the drawings to be published with the abstract is Figure No.**

- ☐ as suggested by the applicant.
- ☐ because the applicant failed to suggest a figure.
- ☐ because this figure better characterizes the invention.
- ☒ None of the figures.





FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## Continuation of Box I.2

Present claims 1,2 relate to an extremely large number of possible sequences. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the sequences claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the sequences encoding the cloned isoflavone synthases as listed in the sequence listing.

\*\*\*\*\*indicate precisely what has been covered by the search e.g those compounds etc. prepared in the examples and closely related homologous compounds etc./those compounds etc. mentioned in the description at pages YY/given in Formula 1, where A = C4, B = C6 etc.!\*\*\*\*\*

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.



## INTERNATIONAL SEARCH REPORT

International Application No.

US 00/01772

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/53 C12N15/82 C12N9/02 C12Q1/68 C12P17/06  
 C12N5/10 A01H5/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C12Q C12P A01H

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SIMINSZKY B. ET AL.: "AC AF022462; 048926" EBI DATABASE, 8 January 1998 (1998-01-08) - 1 June 1998 (1998-06-01), XP002141043 the whole document ---	3,7
A	SCHOPFER, C. R. ET AL: "Identification of elicitor-induced cytochrome P450s of soybean (Glycine max L.) using differential display of mRNA" MOLECULAR AND GENERAL GENETICS, (1998) VOL. 258, NO. 4, PP. 315-322. 29 REF. ISSN: 0026-8925, XP002141044 the whole document --- -/--	1-50



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&amp;" document member of the same patent family

Date of the actual completion of the international search

26 June 2000

Date of mailing of the international search report

12/07/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Kania, T

**THIS PAGE BLANK (USPTO)**



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C12N 15/53, 15/82, 9/02, C12Q 1/68,</b> <b>C12P 17/06, C12N 5/10, A01H 5/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/44909</b> <b>(43) International Publication Date:</b> 3 August 2000 (03.08.00)
<b>(21) International Application Number:</b> PCT/US00/01772 <b>(22) International Filing Date:</b> 26 January 2000 (26.01.00)  <b>(30) Priority Data:</b> 60/117,769 27 January 1999 (27.01.99) US 60/144,783 20 July 1999 (20.07.99) US 60/156,094 24 September 1999 (24.09.99) US  <b>(71) Applicant (for all designated States except US):</b> E.I. DU PONT DE NEMOURS AND COMPANY [US/US]; 1007 Market Street, Wilmington, DE 19898 (US).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> FADER, Gary, M. [US/US]; 1000 Woods Lane, Landenberg, PA 19350 (US). JUNG, Woosuk [KR/US]; 109-D, Congressional Drive, Greenville, DE 19807 (US). MCGONIGLE, Brian [US/US]; 115A Senatorial Drive, Wilmington, DE 19806 (US). ODELL, Joan, T. [US/US]; P.O. Box 826, Unionville, PA 19375 (US). YU, Xiaodan [CN/US]; Apartment D, 18 Presidential Drive, Wilmington, DE 19807 (US).  <b>(74) Agent:</b> BEARDELL, Lori, Y.; E.I. du Pont de Nemours and Company, Legal Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US).		<b>(81) Designated States:</b> AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> NUCLEIC ACID SEQUENCES ENCODING ISOFLAVONE SYNTHASE  <b>(57) Abstract</b>  This invention relates to an isolated nucleic acid sequence encoding isoflavone synthase. The invention also relates to the construction of chimeric sequences encoding all or a substantial portion of the enzymes, in sense or antisense orientation, wherein expression of the chimeric sequence results in production of altered levels of the enzyme in a transformed host cell.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

TITLE

## NUCLEIC ACID SEQUENCES ENCODING ISOFLAVONE SYNTHASE

This application claims the benefit of U.S. Provisional Application No. 60/117,769, filed January 27, 1999, U.S. Provisional Application No. 60/144,783, filed July 20, 1999, and U.S. Provisional Application No. 60/156,094, filed September 24, 1999.

FIELD OF THE INVENTION

This invention is in the field of plant molecular biology. More specifically, this invention pertains to nucleic acid sequences encoding isoflavone synthase and their use in producing isoflavones.

BACKGROUND OF THE INVENTION

Isoflavonoids represent a class of secondary metabolites produced in legumes by a branch of the phenylpropanoid pathway and include such compounds as isoflavones, isoflavanones, rotenoids, pterocarpanes, isoflavans, quinone derivatives, 3-aryl-4-hydroxycoumarins, 3-arylcoumarins, isoflav-3-enes, coumestans, alpha-methyldeoxybenzoins, 2-arylbenzofurans, isoflavanol, coumaronochromone and the like. In plants, these compounds are known to be involved in interactions with other organisms and to participate in the defense responses of legumes against phytopathogenic microorganisms (Dewick, P. M. (1993) in *The Flavonoids, Advances in Research Since 1986*, Harborne, J. B. Ed., pp. 117-238, Chapman and Hall, London). Isoflavonoid-derived compounds also are involved in symbiotic relationships between roots and rhizobial bacteria which eventually result in nodulation and nitrogen-fixation (Phillips, D. A. (1992) in *Recent Advances in Phytochemistry*. Vol. 26, pp 201-231, Stafford, H. A. and Ibrahim, R. K., Eds, Plenum Press, New York), and overall they have been shown to act as antibiotics, repellents, attractants, and signal compounds (Barz, W. and Welle, R. (1992) *Phenolic Metabolism in Plants*, pg 139-164, Ed by H. A. Stafford and R. K. Ibrahim, Plenum Press, New York).

Isoflavonoids have also been reported to have physiological activity in animal and human studies. For example, it has been reported that the isoflavones found in soybean seeds possess antihemolytic (Naim, M., et al. (1976) *J. Agric. Food Chem.* 24:1174-1177), antifungal (Naim, M., et al. (1974) *J. Agr. Food Chem.* 22:806-810), estrogenic (Price, K. R. and Fenwick, G. R. (1985) *Food Addit. Contam.* 2:73-106), tumor-suppressing (Messina, M. and Barnes, S. (1991) *J. Natl. Cancer Inst.* 83:541-546; Peterson, G., et al. (1991) *Biochem. Biophys. Res. Commun.* 179:661-667), hypolipidemic (Mathur, K., et al. (1964) *J. Nutr.* 84:201-204), and serum cholesterol-lowering (Sharma, R. D. (1979) *Lipids* 14:535-540) effects. These epidemiological studies indicate that isoflavones in soybean protein products, when taken as a dietary supplement, may produce many significant health benefits.

Free isoflavones rarely accumulate to high levels in soybeans. Instead they are usually conjugated to carbohydrates or organic acids. Soybean seeds contain three types of

isoflavones in four different forms: the aglycones, daidzein, genistein and glycitein; the glucosides, daidzin, genistin and glycitin; the acetylglucosides, 6"-O-acetyldaidzin, 6"-O-acetylgenistin and 6"-O-acetylglycitin; and the malonylglucosides, 6"-O-malonyldaidzin, 6"-O-malonylgenistin and 6"-O-malonylglycitin. In accordance with the present invention,  
5 all of these compounds are included in the term isoflavonoids. The content of isoflavonoids in soybean seeds is quite variable and is affected by both genetics and environmental conditions such as growing location and temperature during seed fill (Tsukamoto, C., et al. (1995) *J. Agric. Food Chem.* 43:1184-1192; Wang, H. and Murphy, P. A. (1994) *J. Agric. Food Chem.* 42:1674-1677). In addition, isoflavonoid content in legumes can be stress-  
10 induced by pathogenic attack, wounding, high UV light exposure and pollution (Dixon, R. A. and Paiva, N. L. (1995) *Plant Cell* 7:1085-1097).

The biosynthetic pathway for isoflavonoids in soybean and their relationship with several other classes of phenylpropanoids is presented in Figure 1. Many of the enzymes involved in the synthesis of isoflavonoids in legumes have been identified and many of the  
15 genes in the pathway have been cloned. These include three P450-dependent monooxygenases, cinnamate 4-hydroxylase (Potts, J. R. M., et al. (1974) *J. Biol. Chem.* 249:5019-5026), isoflavone 2'-hydroxylase (Akashi, T. et al. (1998) *Biochem. Biophys. Res. Commun.* 251:67-70), and dihydroxypterocarpan 6a-hydroxylase (Schopfer, C. R., et al. (1998) *FEBS Lett.* 432:182-186). However, to date the gene encoding isoflavone synthase,  
20 the first step in the phenylpropanoid branch that commits metabolic intermediates to the synthesis of isoflavonoids, has been neither identified nor cloned from any species. In this central reaction, 2S-flavanone is converted into an isoflavonoid such as genistein and daidzein. The enzymatic reaction for this oxidative aryl migration step was first reported by Hagmann, M. L. and Grisebach, H. ((1984) *FEBS Lett.* 175:199-202). The reaction involves  
25 a P450 monooxygenase-mediated conversion of the 2S-flavanone to a 2-hydroxyisoflavanone, followed by conversion to the isoflavonoid. This last step is possibly mediated by a soluble dehydratase (Kochs, G. and Grisenbach, H. (1985) *Eur. J. Biochem.* 155:311-318). However, the 2-hydroxyisoflavanone intermediate was described as unstable and could convert directly to genistein.

30 Cytochrome P450-dependant monooxygenases comprise a large group of heme-containing enzymes, most of which catalyze NADPH- and O<sub>2</sub>-dependant hydroxylation reactions. Most of these enzymes do not use NADPH directly, but rely upon an interaction with a flavoprotein known as a P450 reductase that transfers electrons from the cofactor to the P450. Cloning of plant P450s by traditional protein purification strategies has been  
35 difficult, as these membrane-bound proteins are often very unstable and are typically present in low abundance. PCR-based cloning strategies using sequence homologies between P450s has increased dramatically the number of P450 genes cloned. However, the *in vivo* activity



of many of these cloned genes remains unknown and they are classified simply as P450s, and are grouped into families based solely on sequence homology (Chapple, C. (1998) *Annu. Rev. Plant Physiol. Plant Mol. Bio.* 49:311-343). Proteins that are greater than 55% identical are designated as members of the same subfamily, while P450s that are 97% identical, or greater, are assumed to be allelic variants of the same gene (Chapple, C. (1998) *Annu. Rev. Plant Physiol. Plant Mol. Bio.* 49:311-343).

Efforts to determine *in vivo* activities of existing P450 clones are increasing. Most efforts involve expressing genes or cDNAs for P450s in yeast or insect cell systems, and then screening for a particular activity. For example, isoflavone 2'-hydroxylase (Akashi, T., et al. (1998) *Biochem. Biophys. Res. Commun.* 251:67-70) and dihydroxypterocarpan 6a-hydroxylase (Schopfer, C. R., et al. (1998) *FEBS Letters* 432:182-186) were identified in this manner.

The physiological activities associated with isoflavonoids in both plants and humans makes the manipulation of their contents in crop plants highly desirable. For example, increasing levels of isoflavonoid in soybean seeds would increase the efficiency of extraction and lower the cost of isoflavone-related products sold today for use in either reduction of serum cholesterol or in estrogen replacement therapy. Decreasing levels of isoflavonoid in soybean seeds would be beneficial for production of soy-based infant formulas where the estrogenic effects of isoflavonoid are undesirable. Raising levels of isoflavonoid phytoalexins in vegetative plant tissue could increase plant defenses to pathogen attack, thereby improving plant disease resistance and lowering pesticide use rates. Manipulation of isoflavonoid levels in roots could lead to improved nodulation and increased efficiencies of nitrogen fixation. To date, however, it has proven difficult to develop soybean or other plant lines with consistently high levels of isoflavonoid. Because isoflavone synthase is the central reaction in pathways producing isoflavonoids, identification of this functional gene is extremely important, and its manipulation via molecular techniques is expected to allow production of soybeans and other plants with high, stable levels of isoflavonoid. Introduction of the isoflavone synthase gene in non-legume crop species including, but not limited to, corn, wheat, rice, sunflower, and canola could lead to synthesis of isoflavonoids. The expression of isoflavonoids would confer to these species disease resistance and/or properties which produce human/livestock health benefits.

Substrates for isoflavone synthase may be limiting for synthesizing very high levels of isoflavonoids in soybean, or for synthesizing isoflavonoids in non-legumes. It is desirable to increase the flux of metabolites through the phenylpropanoid pathway to provide additional amounts of substrate to those occurring naturally. Different stress conditions such as UV irradiation, phosphate starvation, prolonged exposure to cold, and chemical (such as

herbicide) treatment can cause activation of the phenylpropanoid pathway. While these treatments may produce the desired substrate availability, it is more desirable to have a genetic means of activating the phenylpropanoid pathway. It is known that expression of genes encoding certain transcription factors can regulate the expression of various genes that encode enzymes of the phenylpropanoid pathway. These include, but are not limited to, the C1 myb-type transcription factor of maize and the AmMyb305 of *Antirrhinum majus*. The C1 myb-type transcription factor of maize, in conjunction with the myc-type transcription factor R, activates chalcone synthase and chalcone isomerase genes (Grotewold, E., et al. (1998) *Plant Cell* 10:721-740). The *Antirrhinum majus* AmMyb305 activates the phenylalanine ammonia lyase promoter (Sablowski, R. W., et al. (1994) *EMBO J.* 13:128-137). Transcription factors such as these may be expressed in host plant cells to activate expression of genes in the phenylpropanoid pathway thereby increasing the encoded enzyme activities and the flux of compounds through the pathway. Increases in the precursors to substrates of isoflavone synthase would enhance the production of isoflavonoids.

### SUMMARY OF THE INVENTION

The instant invention relates to isolated nucleic acid sequences encoding isoflavone synthase. In addition, this invention relates to nucleic acid sequences that are complementary to nucleic acid sequences encoding isoflavone synthase. The nucleic acid sequences may be of genomic or cDNA origin and may contain introns.

In another embodiment, the instant invention relates to chimeric genes encoding isoflavone synthase or to chimeric genes that comprise nucleic acid sequences that are complementary to the nucleic acid sequences encoding the enzyme, operably linked to suitable regulatory sequences, wherein expression of the chimeric genes results in production of levels of isoflavone synthase in transformed host cells that are altered (i.e., increased or decreased) from the levels produced in untransformed host cells.

In a further embodiment, the instant invention concerns a transformed host cell comprising in its genome a chimeric gene encoding an isoflavone synthase that is operably linked to suitable regulatory sequences. Expression of the chimeric gene results in production of altered levels of the enzyme in the transformed host cell. The transformed host cell can be of eukaryotic or prokaryotic origin, and includes cells derived from higher plants and microorganisms. The invention also includes transformed plants that arise from transformed host cells of higher plants, and seeds derived from such transformed plants.

An additional embodiment of the instant invention concerns a method of altering the level of expression of a plant isoflavone synthase in a transformed host cell comprising transforming a host cell with a chimeric gene comprising a nucleic acid sequence (cDNA or genomic DNA) encoding an isoflavone synthase operably linked to suitable regulatory

sequences and growing the transformed host cell under conditions that are suitable for expression of the chimeric gene wherein expression of the chimeric gene results in production of altered levels of isoflavone synthase in the transformed host cell. The altered levels of isoflavone synthase may be higher due to overexpression, or may be lower due to cosuppression or anti sense suppression.

A further embodiment of the instant invention is a method for increasing the amount of one or more isoflavonoids in a host cell. The method comprising the steps of transforming a host cell with a chimeric gene comprising a nucleic acid sequence encoding an isoflavone synthase operably linked to suitable regulatory sequences and growing the transformed host cell under conditions that are suitable for expression of the chimeric gene wherein expression of the chimeric gene results in production of an amount of isoflavonoids in the transformed host cell that is greater than the amount of isoflavonoids that are produced in a cell that is not transformed with the chimeric gene.

A further embodiment of the instant invention is a method for decreasing the amount of one or more isoflavonoids in a host cell. The method comprising the steps of transforming a host cell with a chimeric gene comprising a nucleic acid sequence encoding all or a substantial portion of an isoflavone synthase operably linked to suitable regulatory sequences and growing the transformed host cell under conditions that are suitable for expression of the chimeric gene wherein expression of the chimeric gene results in production of an amount of isoflavonoids in the transformed host cell that is less than the amount of isoflavonoids that are produced in a cell that is not transformed with the chimeric gene. The invention also includes transformed plants that arise from transformed host cells of higher plants, and seeds derived from such transformed plants.

An additional embodiment of the instant invention concerns a method for obtaining a nucleic acid sequence encoding all or substantially all of an amino acid sequence encoding isoflavone synthase.

A still further embodiment of the instant invention concerns a transformed host cell comprising a chimeric gene encoding isoflavone synthase and at least one chimeric gene encoding a transcription factor that can regulate expression of one or more genes in the phenylpropanoid pathway. The invention also includes transformed plants that arise from transformed host cells of higher plants, and seeds derived from such transformed plants.

A further embodiment is a method of increasing the amount of one or more isoflavonoids in a host cell comprising transforming a host cell with a chimeric gene having a nucleic acid sequence encoding an isoflavone synthase operably linked to suitable regulatory sequences and with at least one chimeric gene having a nucleic acid sequence encoding a transcription factor that regulates expression of genes in the phenylpropanoid pathway, and growing the transformed host cell under conditions that are suitable for

expression of the chimeric genes wherein expression of the chimeric genes result in production of an amount of one or more isoflavonoids in the transformed host cell that is greater than the amount of the isoflavonoids that are produced in a cell that is not transformed with the chimeric genes. The invention also includes transformed plants that arise from transformed host cells of higher plants, and seeds derived from such transformed plants.

Yet a further embodiment of the present invention is a method of altering the level of isoflavonoids in a plant cell that is transformed with a chimeric isoflavone synthase gene comprising exposing said cell to a phenylpropanoid pathway-altering agent. The phenylpropanoid pathway-altering agent may be a transcription factor or stress, for example. Stress includes and is not limited to ultraviolet light, temperature, pressure, phosphate level, and herbicide treatment. The transcription factors may be a C1 myb-type transcription factor of maize and a myc-type transcription factor R, or a chimera containing the maize R region between the C1 DNA binding domain and the C1 activation domain.

#### BIOLOGICAL DEPOSIT

The following transformed yeast strain and vector plasmid have been deposited with the American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, VA 20110-2209, and bears the following designation, accession number and date of deposit.

<u>Yeast Strain</u>	<u>Accession Number</u>	<u>Date of Deposit</u>
Isoflavone Synthase GM1	ATCC 203606	January 27, 1999
Plasmid DP7951	ATCC PTA-371	July 20, 1999

#### BRIEF DESCRIPTION OF THE DRAWINGS AND SEQUENCE DESCRIPTIONS

The invention can be more fully understood from the following detailed description and the accompanying drawings and Sequence Listing which form a part of this application.

Figure 1 depicts the phenylpropanoid metabolic pathway, and illustrates particularly the biosynthesis of isoflavonoids.

Figure 2A and B presents the results of HPLC analyses of naringenin standards. Figure 2A presents the absorption spectra recorded at 260 nm and Figure 2B presents the absorption spectra recorded at 280 nm.

Figure 3A and B presents the results of HPLC analyses of genistein standards. Figure 3A presents the absorption spectra recorded at 260 nm and Figure 3B presents the absorption spectra recorded at 280 nm.

Figure 4A and B presents the results of HPLC analyses of genistein and naringenin from microsomes derived from elicitor-treated soybean hypocotyls. Absorption spectra was

recorded at 260 nm (Figure 4A) and 280 nm (Figure 4B). Naringenin and genistein peaks are indicated.

Figure 5A and B presents the results of HPLC analyses of genistein and naringenin from microsomes derived from non-treated soybean hypocotyls. Absorption spectra was recorded at 260 nm (Figure 5A) and 280 nm (Figure 5B). Naringenin and genistein peaks are indicated.

Figure 6A and B presents the results of HPLC analyses of genistein and naringenin from microsomes derived from elicitor-treated soybean cell suspension cultures. Absorption spectra was recorded at 260 nm (Figure 6A) and 280 nm (Figure 6B). Naringenin and genistein peaks are indicated.

Figure 7A and B presents the results of HPLC analyses of genistein and naringenin from microsomes derived from non-treated soybean cell suspension cultures. Absorption spectra was recorded at 260 nm (Figure 7A) and 280 nm (Figure 7B). Naringenin peak is indicated.

Figure 8A and B presents the results of HPLC analyses of genistein and naringenin in 75 µg of yeast microsomal proteins prior to incubation in the presence of NADPH cofactor (negative control). Absorption spectra was recorded at 260 nm (Figure 8A) and 280 nm (Figure 8B).

Figure 9A and B presents the results of HPLC analyses of genistein and naringenin in 75 µg of yeast microsomal proteins after 1 h incubation in the presence of NADPH cofactor. Absorption spectra was recorded at 260 nm (Figure 9A) and 280 nm (Figure 9B).

Figure 10A and B presents the results of HPLC analyses of genistein and naringenin in 75 µg of yeast microsomal proteins after 2 h incubation in the presence of NADPH cofactor. Absorption spectra was recorded at 260 nm (Figure 10A) and 280 nm (Figure 10B).

Figure 11A and B presents the results of HPLC analyses of genistein and naringenin in 75 µg of yeast microsomal proteins after 3 h incubation in the presence of NADPH cofactor. Absorption spectra was recorded at 260 nm (Figure 11A) and 280 nm (Figure 11B).

Figure 12 A and B presents the results of HPLC analyses of genistein and naringenin in 75 µg of yeast microsomal proteins after 4 h incubation in the presence of NADPH cofactor. Absorption spectra was recorded at 260 nm (Figure 12A) and 280 nm (Figure 12B).

Figure 13A and B presents the results of HPLC analyses of genistein and naringenin in 75 µg of yeast microsomal proteins after 14 h incubation in the presence of NADPH cofactor. Absorption spectra was recorded at 260 nm (Figure 13A) and 280 nm (Figure 13B).

Figure 14A and B presents the results of HPLC analyses of genistein and naringenin in 75 µg of yeast microsomal proteins after 40 minutes incubation in the presence of NADPH

cofactor. Absorption spectra was recorded at 260 nm (Figure 14A) and 280 nm (Figure 14B).

Figure 15A and B presents the results of HPLC analyses of genistein and naringenin in 150 µg of yeast microsomal proteins after 40 minutes incubation in the presence of NADPH cofactor. Absorption spectra was recorded at 260 nm (Figure 15A) and 280 nm (Figure 15B).

Figure 16A and B presents the results of HPLC analyses of genistein and naringenin in 75 µg of yeast microsomal proteins after 4 h incubation in the absence of NADPH cofactor. Absorption spectra was recorded at 260 nm (Figure 16A) and 280 nm (Figure 16B).

Figure 17A and B presents a comparison of the absorption spectra recorded by a diode array detector of a genistein standard (Figure 17A; with an HPLC retention time of 3.128), and a reference spectrum (Figure 17B).

Figure 18A and B presents a comparison of the absorption spectra recorded by a diode array detector of the newly synthesized peak located at the retention time of 3.131 in the HPLC analysis of yeast microsomes incubated for 14 h in the presence of NADPH on Figure 18A and the reference spectrum on Figure 18B.

Figure 19A, B, C, D and E presents the electropositive mass spectrum obtained for the peaks observed by HPLC analysis of yeast microsome samples incubated with liquiritigenin. Figure 19A corresponds to the peak at 273.2 *m/z*, Figure 19B corresponds to the peak at 271 *m/z*, Figure 19C corresponds to "peak 2", Figure 19D corresponds to liquiritigenin standard (the substrate), and Figure 19E corresponds to daidzein standard (the product).

Figure 20 depicts the plasmid map of pOY160.

Figure 21 depicts the plasmid map of pOY206.

Figure 22 depicts the plasmid map of pDP7951, having an ATCC accession No. PTA-371.

Figure 23 depicts the plasmid map of pOY162.

Figure 24 depicts the plasmid map of pKS93s.

Figure 25 depicts the distribution of the isoflavonoid content of 25 transgenic lines transformed with the isoflavone synthase sequence from clone sgs1c.pk006.o20 and a control line. Bars represent the mean of three analyses for each line. The result of single factor ANOVA is presented along with the least significant difference (LSD) at  $P \leq 0.01$ . The asterisk above the bars represents those lines with mean isoflavonoid concentrations significantly lower than control (bars 1 through 6), or those lines with mean isoflavonoid concentrations significantly greater than control (bars 15 through 25) based on the LSD test at  $P \leq 0.01$ .

Figure 26 depicts the comparison of the rates of genistein and daidzein synthesis by microsomes of the yeast transformant GM1. Samples representing incubation periods of 2,

4, 6, 8 and 10 h were analyzed by HPLC and the peak areas for genistein and daidzein were quantitated by calibration with authentic genistein and daidzein standards. Assays were repeated three times and the average amount of isoflavonoid synthesized at each time point was plotted, with vertical lines representing error bars.

Figure 27 presents the results of HPLC analyses of daidzein and liquiritigenin in extracts from BMS cells before incubation in the presence of NADPH cofactor (Panels A and B) and after 10 h incubation in the presence of NADPH cofactor (Panels C and D). Absorption spectra was recorded at 260 nm (Panels A and C) and 280 nm (Panels B and D).

Figure 28 depicts the plasmid map of pCW109-IFS.

The following sequence descriptions and Sequences Listing attached hereto comply with the rules governing nucleotide and/or amino acid sequence disclosures in patent applications as set forth in 37 C.F.R. §1.821-1.825. The Sequence Listing contains the one letter code for nucleotide sequence characters and the three letter codes for amino acids as defined in conformity with the IUPAC-IUB standards described in *Nucleic Acids Research* 13:3021-3030 (1985) and in the *Biochemical Journal* 219 (No. 2):345-373 (1984) which are herein incorporated by reference. The symbols and format used for nucleotide and amino acid sequence data comply with the rules set forth in 37 C.F.R. §1.822.

SEQ ID NO:1 is the nucleotide sequence comprising the soybean cDNA insert in clone sgs1c.pk006.o20 encoding an enzymatically active isoflavone synthase.

SEQ ID NO:2 is the deduced amino acid sequence of an enzymatically active soybean isoflavone synthase derived from the nucleotide sequence of SEQ ID NO:1.

SEQ ID NO:3 is the nucleotide sequence of an oligonucleotide primer used in the construction of yeast strain WHT1.

SEQ ID NO:4 is the nucleotide sequence of an oligonucleotide primer used in the construction of the yeast strain WHT1.

SEQ ID NO:5 is the nucleotide sequence of an oligonucleotide primer used to amplify the cDNA insert from clone sgs1c.pk006.o20.

SEQ ID NO:6 is the nucleotide sequence of an oligonucleotide primer used to amplify the cDNA insert from clone sgs1c.pk006.o20.

SEQ ID NO:7 is the nucleotide sequence of an oligonucleotide primer used for PCR amplification of the soybean clone with sequence corresponding to the one found in NCBI General Identifier No. 2739005. This oligonucleotide sequence corresponds to nucleotides 3 to 26 of the NCBI sequence.

SEQ ID NO:8 is the nucleotide sequence of an oligonucleotide primer used for PCR amplification of the soybean clone with sequence corresponding to the one found in NCBI General Identifier No. 2739005. This oligonucleotide sequence corresponds to the complement of nucleotides 1798 to 1824 of the NCBI sequence.

SEQ ID NO:9 is the nucleotide sequence of an enzymatically active soybean isoflavone synthase having an NCBI General Identifier No. 2739005.

SEQ ID NO:10 is the deduced amino acid sequence of an enzymatically active soybean isoflavone synthase derived from of SEQ ID NO:9 and having an NCBI General Identifier No. 2739006.

SEQ ID NO:11 is the nucleotide sequence of an oligonucleotide primer used for PCR amplification of the isoflavone synthase genes from mung bean, red clover, white clover, lentil, hairy vetch, alfalfa, lupine and snow pea.

SEQ ID NO:12 is the nucleotide sequence of an oligonucleotide primer used for PCR amplification of the isoflavone synthase genes from mung bean, red clover, white clover, lentil, hairy vetch, alfalfa, lupine and snow pea.

SEQ ID NO:13 is the nucleotide sequence of an oligonucleotide primer used in the second round of PCR amplification of the white clover, lentil, hairy vetch, alfalfa and lupine isoflavone synthase genes.

SEQ ID NO:14 is the nucleotide sequence of an oligonucleotide primer used in the second round of PCR amplification of the white clover, lentil, hairy vetch, alfalfa and lupine isoflavone synthase genes.

SEQ ID NO:15 is the nucleotide sequence comprising the alfalfa cDNA insert in clone alfalfa1 encoding an almost entire alfalfa isoflavone synthase.

SEQ ID NO:16 is the deduced amino acid sequence of an almost entire alfalfa isoflavone synthase derived from the nucleotide sequence of SEQ ID NO:15.

SEQ ID NO:17 is the nucleotide sequence comprising the hairy vetch cDNA insert in clone hairy vetch1 encoding an almost entire hairy vetch isoflavone synthase.

SEQ ID NO:18 is the deduced amino acid sequence of an almost entire hairy vetch isoflavone synthase derived from the nucleotide sequence of SEQ ID NO:17.

SEQ ID NO:19 is the nucleotide sequence comprising the lentil cDNA insert in clone lentil1 encoding an almost entire lentil isoflavone synthase.

SEQ ID NO:20 is the deduced amino acid sequence of an almost entire lentil isoflavone synthase derived from the nucleotide sequence of SEQ ID NO:19.

SEQ ID NO:21 is the nucleotide sequence comprising the lentil cDNA insert in clone lentil2 encoding an almost entire lentil isoflavone synthase.

SEQ ID NO:22 is the deduced amino acid sequence of an almost entire lentil isoflavone synthase derived from the nucleotide sequence of SEQ ID NO:21.

SEQ ID NO:23 is the nucleotide sequence comprising the mung bean cDNA insert in clone mung bean1 encoding an entire mung bean isoflavone synthase.

SEQ ID NO:24 is the deduced amino acid sequence of an entire mung bean isoflavone synthase derived from SEQ ID NO:23.



SEQ ID NO:25 is the nucleotide sequence comprising the mung bean cDNA insert in clone mung bean2 encoding an entire mung bean isoflavone synthase.

SEQ ID NO:26 is the deduced amino acid sequence of an entire mung bean isoflavone synthase derived from SEQ ID NO:25.

5 SEQ ID NO:27 is the nucleotide sequence comprising the mung bean cDNA insert in clone mung bean3 encoding an entire mung bean isoflavone synthase.

SEQ ID NO:28 is the deduced amino acid sequence of an entire mung bean isoflavone synthase derived from SEQ ID NO:27.

10 SEQ ID NO:29 is the nucleotide sequence comprising the mung bean cDNA insert in clone mung bean4 encoding an entire mung bean isoflavone synthase.

SEQ ID NO:30 is the deduced amino acid sequence of an entire mung bean isoflavone synthase derived from SEQ ID NO:30.

SEQ ID NO:31 is the nucleotide sequence comprising the red clover cDNA insert in clone red clover1 encoding an entire red clover isoflavone synthase.

15 SEQ ID NO:32 is the deduced amino acid sequence of an entire red clover isoflavone synthase derived from SEQ ID NO:31.

SEQ ID NO:33 is the nucleotide sequence comprising the red clover cDNA insert in clone red clover2 encoding an entire red clover isoflavone synthase.

20 SEQ ID NO:34 is the deduced amino acid sequence of an entire red clover isoflavone synthase derived from SEQ ID NO:33.

SEQ ID NO:35 is the nucleotide sequence comprising the snow pea cDNA insert in clone snow pea1 encoding an entire snow pea isoflavone synthase.

SEQ ID NO:36 is the deduced amino acid sequence of an entire snow pea isoflavone synthase derived from SEQ ID NO:37.

25 SEQ ID NO:37 is the nucleotide sequence comprising the white clover cDNA insert in clone white clover1 encoding an almost entire white clover isoflavone synthase.

SEQ ID NO:38 is the deduced amino acid sequence of an almost entire white clover isoflavone synthase derived from SEQ ID NO:37.

30 SEQ ID NO:39 is the nucleotide sequence comprising the white clover cDNA insert in clone white clover2 encoding an almost entire white clover isoflavone synthase.

SEQ ID NO:40 is the deduced amino acid sequence of an almost entire white clover isoflavone synthase derived from SEQ ID NO:39.

SEQ ID NO:41 is the nucleotide sequence of an oligonucleotide primer used for PCR amplification of the isoflavone synthase coding region in clone sgs1c.pk006.o20.

35 SEQ ID NO:42 is the nucleotide sequence of an oligonucleotide primer used for PCR amplification of the isoflavone synthase coding region in clone sgs1c.pk006.o20.

SEQ ID NO:43 is the nucleotide sequence of an oligonucleotide primer used to determine the transcription of the soybean isoflavone synthase in transgenic tobacco.

SEQ ID NO:44 is the nucleotide sequence of an oligonucleotide primer used to determine the transcription of the soybean isoflavone synthase in transgenic tobacco.

5 SEQ ID NO:45 is the nucleotide sequence of an oligonucleotide primer to the maize R coding region used to amplify genomic DNA to determine the presence of a chimera containing the maize R region between the region encoding the C1 DNA binding domain and the C1 activation domain (CRC) in transgenic corn cells.

10 SEQ ID NO:46 is the nucleotide sequence of an oligonucleotide primer to the 3' untranslated region from potato protease inhibitor II gene used to amplify genomic DNA to determine the presence of CRC in transgenic corn cells.

SEQ ID NO:47 is the nucleotide sequence comprising the sugarbeet cDNA insert in clone sugarbeet1, encoding an almost entire sugarbeet isoflavone synthase.

15 SEQ ID NO:48 is the deduced amino acid sequence of an almost entire sugarbeet isoflavone synthase derived from SEQ ID NO:47.

SEQ ID NO:49 is the nucleotide sequence of an oligonucleotide primer used for the PCR amplification of the soybean isoflavone synthase coding region in clone sgs1c.pk006.o20.

20 SEQ ID NO:50 is the nucleotide sequence of an oligonucleotide primer used for the PCR amplification of the soybean isoflavone synthase coding region in clone sgs1c.pk006.o20.

SEQ ID NO:51 is the nucleotide sequence of an oligonucleotide primer used to amplify the genomic sequence comprising the isoflavone synthase in clone sgs1c.pk006.o20.

25 SEQ ID NO:52 is the nucleotide sequence of a genomic fragment encoding the isoflavone synthase in clone sgs1c.pk006.o20.

SEQ ID NO:53 is the nucleotide sequence of a genomic fragment encoding the CYP93C1 isoflavone synthase.

SEQ ID NO:54 is the nucleotide sequence comprising the lupine cDNA insert in clone lupine1 encoding an entire lupine isoflavone synthase.

30 SEQ ID NO:55 is the deduced amino acid sequence of an entire lupine isoflavone synthase derived from SEQ ID NO:54.

SEQ ID NO:56 is the nucleotide sequence comprising the alfalfa cDNA insert in clone alfalfa2 encoding an almost entire alfalfa isoflavone synthase.

35 SEQ ID NO:57 is the amino acid sequence of an almost entire alfalfa isoflavone synthase derived from SEQ ID NO:56.

SEQ ID NO:58 is the nucleotide sequence comprising the alfalfa cDNA insert in clone alfalfa3 encoding an almost entire alfalfa isoflavone synthase.

SEQ ID NO:59 is the amino acid sequence of an almost entire alfalfa isoflavone synthase derived from SEQ ID NO:58.

SEQ ID NO:60 is the amino acid sequence comprising the sugarbeet cDNA insert in clone sugarbeet2, encoding an almost entire sugarbeet isoflavone synthase.

5 SEQ ID NO:61 is the deduced amino acid sequence of an almost entire sugarbeet isoflavone synthase derived from SEQ ID NO:60.

SEQ ID NO:62 is the nucleotide sequence of an oligonucleotide primer used for the PCR amplification of the soybean chalcone reductase coding region in clone src3c.pk009.e4.

10 SEQ ID NO:63 is the nucleotide sequence of an oligonucleotide primer used for the PCR amplification of the soybean chalcone reductase coding region in clone src3c.pk009.e4.

SEQ ID NO:64 is the nucleotide sequence of an oligonucleotide primer used for the PCR amplification of the soybean chalcone reductase present in monocot cells.

SEQ ID NO:65 is the nucleotide sequence of an oligonucleotide primer used for the PCR amplification of the soybean chalcone reductase present in monocot cells.

15 SEQ ID NO:66 is the amino acid sequence of the consensus sequence produced by the Megalign Program using the Clustal method and the amino acid sequences depicted in SEQ ID NOs:2, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 48, 55, 57, 59, and 61.

#### DETAILED DESCRIPTION OF THE INVENTION

20 The instant invention discloses nucleotide and amino acid sequences for isoflavone synthases from legumes such as soybean, alfalfa, lupine, hairy vetch, lentil, mung bean, red clover, snow pea, and white clover and non-legumes such as sugarbeet. As the enzyme that catalyzes the first step of the isoflavonoid branch of the phenylpropanoid pathway (see Figure 1), altering the level of this enzyme may be useful for changing isoflavonoid content.

25 Plant P450 enzymes catalyze a diverse range of reactions, including molecular transformations in primary metabolism, and in the metabolism and detoxification of xenobiotics. Although tentative identification of any given gene or conceptual translation product as a P450 is relatively simple based on its similarity to other known P450s, the assignment of actual catalytic function cannot necessarily be inferred from nucleic acid or protein sequence information alone. The instant disclosure demonstrates and teaches the  
30 identification of a cDNA from soybean that encodes isoflavone synthase based on the ability of the encoded polypeptide to convert the normal substrate for the reaction, 2S-flavanone, to genistein. Demonstration of activity has been accomplished in subcellular fractions of a yeast strain, WHT1, which has been specifically altered to also express a P450 reductase from *Helianthus tuberosum*. In this manner, and using the materials identified and described  
35 herein, other nucleic acid sequences from soybean and from other plants that are predicted to encode P450s may be tested to determine whether any of those P450's possess isoflavone synthase activity.

“The isoflavonoids are biogenetically related to the flavonoids but constitute a distinctly separate class in that they contain a rearranged C15 skeleton and may be regarded as derivatives of 3-phenylchroman.” Isoflavonoids. Dewick, P.M. (1982) in *The Flavonoids: Advances in Research*, Harborne, J. B. and Mabry, T.J., Ed., pp 535-640, Chapman and Hall Ltd, New York. Oxidative rearrangement of a flavanone precursor with a 2,3-aryl shift yields an isoflavonoid. Isoflavones are the most abundant of the natural isoflavonoid derivatives, with over 160 isoflavone aglycones being recognized.

In the context of this disclosure, a number of terms shall be utilized. As used herein, a “nucleic acid sequence” is a polymer of RNA or DNA that is single- or double-stranded, optionally containing synthetic, non-natural or altered nucleotide bases. A nucleic acid sequence in the form of a polymer of DNA may be comprised of one or more segments of cDNA, genomic DNA or synthetic DNA.

As used herein, “substantially similar” refers to nucleic acid sequences wherein changes in one or more nucleotide bases results in substitution of one or more amino acids, but do not affect the functional properties of the polypeptide encoded by the nucleotide sequence. “Substantially similar” also refers to nucleic acid sequences wherein changes in one or more nucleotide bases does not affect the ability of the nucleic acid sequence to mediate alteration of gene expression by gene silencing through for example antisense or co-suppression technology. “Substantially similar” also refers to modifications of the nucleic acid fragments of the instant invention such as deletion or insertion of one or more nucleotides that do not substantially affect the functional properties of the resulting transcript vis-à-vis the ability to mediate gene silencing or alteration of the functional properties of the resulting protein molecule. It is therefore understood that the invention encompasses more than the specific exemplary nucleotide or amino acid sequences and includes functional equivalents thereof.

For example, it is well known in the art that antisense suppression and co-suppression of gene expression may be accomplished using nucleic acid fragments representing less than the entire coding region of a gene, and by nucleic acid fragments that do not share 100% sequence identity with the gene to be suppressed. Moreover, alterations in a nucleic acid sequence which result in the production of a chemically equivalent amino acid at a given site, but do not effect the functional properties of the encoded polypeptide, are well known in the art. Thus, a codon for the amino acid alanine, a hydrophobic amino acid, may be substituted by a codon encoding another less hydrophobic residue, such as glycine, or a more hydrophobic residue, such as valine, leucine, or isoleucine. Similarly, changes which result in substitution of one negatively charged residue for another, such as aspartic acid for glutamic acid, or one positively charged residue for another, such as lysine for arginine, can also be expected to produce a functionally equivalent product. Nucleotide changes which

result in alteration of the N-terminal and C-terminal portions of the polypeptide molecule would also not be expected to alter the activity of the polypeptide. Each of the proposed modifications is well within the routine skill in the art, as is determination of retention of biological activity of the encoded products.

5        Moreover, substantially similar nucleic acid sequences may also be characterized by their ability to hybridize. Estimates of such homology are provided by either DNA-DNA or DNA-RNA hybridization under conditions of stringency as is well understood by those skilled in the art (Hames and Higgins, Eds. (1985) *Nucleic Acid Hybridisation*, IRL Press, Oxford, U.K.). Stringency conditions can be adjusted to screen for moderately similar  
10       sequences, such as homologous sequences from distantly related organisms, to highly similar sequences, such as genes that duplicate functional enzymes from closely related organisms. Post-hybridization washes determine stringency conditions. One set of preferred conditions uses a series of washes starting with 6X SSC, 0.5% SDS at room temperature for 15 min, then repeated with 2X SSC, 0.5% SDS at 45°C for 30 min, and then repeated twice with  
15       0.2X SSC, 0.5% SDS at 50°C for 30 min. A more preferred set of stringent conditions uses higher temperatures in which the washes are identical to those above except for the temperature of the final two 30 min washes in 0.2X SSC, 0.5% SDS was increased to 60°C. Another preferred set of highly stringent conditions uses two final washes in 0.1X SSC, 0.1% SDS at 65°C.

20       Substantially similar nucleic acid sequences of the instant invention may also be characterized by their percent identity to the nucleic acid sequences disclosed herein, as determined by algorithms commonly employed by those skilled in this art. Preferred are those nucleic acid sequences whose sequences are at least about 85% identical and more preferably at least about 90% identical to the nucleotide sequences reported herein. More  
25       preferred are nucleic acid sequences that are at least about 90% identical and more preferably at least about 95% identical to the nucleotide sequences reported herein. More preferred are nucleic acid sequences that are 95% identical to the nucleotide sequences reported herein. Sequence alignments and percent identity calculations were performed using the Megalign program of the LASARGENE bioinformatics computing suite  
30       (DNASTAR Inc., Madison, WI). Multiple alignment of the sequences was performed using the Clustal method of alignment (Higgins and Sharp (1989) *CABIOS*. 5:151-153) with the default parameters (GAP PENALTY=10, GAP LENGTH PENALTY=10). Default parameters for pairwise alignments using the Clustal method were KTUPLE 2, GAP PENALTY=5, WINDOW=4 and DIAGONALS SAVED=4.

35       Substantially similar nucleic acid sequences of the instant invention may also be characterized by the percent identity of the amino acid sequences that they encode to the amino acid sequences disclosed herein, as determined by algorithms commonly employed

by those skilled in this art. Preferred are those nucleic acid sequences whose nucleotide sequences encode amino acid sequences that are at least about 95% identical and even more preferably at least about 98% identical to the amino acid sequences reported herein.

Sequence alignments and percent identity calculations were performed using the Megalign program of the LASARGENE bioinformatics computing suite (DNASTAR Inc., Madison, WI). Multiple alignment of the sequences was performed using the Clustal method of alignment (Higgins and Sharp (1989) *CABIOS* 5:151-153) with the default parameters (GAP PENALTY=10, GAP LENGTH PENALTY=10). Default parameters for pairwise alignments using the Clustal method were KTUPLE 1, GAP PENALTY=3, WINDOW=5 and DIAGONALS SAVED=5.

A "substantial portion" of an amino acid or nucleotide sequence comprises an amino acid or a nucleotide sequence that is sufficient to afford putative identification of the protein or gene that the amino acid or nucleotide sequence comprises. Amino acid and nucleotide sequences can be evaluated either manually by one skilled in the art, or by using computer-based sequence comparison and identification tools that employ algorithms such as BLAST (Basic Local Alignment Search Tool; Altschul et al. (1993) *J. Mol. Biol.* 215:403-410; see also [www.ncbi.nlm.nih.gov/BLAST/](http://www.ncbi.nlm.nih.gov/BLAST/)). In general, a sequence of ten or more contiguous amino acids or thirty or more contiguous nucleotides is necessary in order to putatively identify a polypeptide or nucleic acid sequence as homologous to a known protein or gene. Moreover, with respect to nucleotide sequences, gene-specific oligonucleotide probes comprising 30 or more contiguous nucleotides may be used in sequence-dependent methods of gene identification (e.g., Southern hybridization) and isolation (e.g., *in situ* hybridization of bacterial colonies or bacteriophage plaques). In addition, short oligonucleotides of 12 or more nucleotides may be used as amplification primers in PCR in order to obtain a particular nucleic acid sequence comprising the primers. Accordingly, a "substantial portion" of a nucleotide sequence comprises a nucleotide sequence that will afford specific identification and/or isolation of a nucleic acid sequence comprising the sequence. The instant specification teaches amino acid and nucleotide sequences encoding polypeptides that comprise one or more particular plant proteins. The skilled artisan, having the benefit of the sequences as reported herein, may now use all or a substantial portion of the disclosed sequences for purposes known to those skilled in this art. Accordingly, the instant invention comprises the complete sequences as reported in the accompanying Sequence Listing, as well as substantial portions of those sequences as defined above.

"Codon degeneracy" refers to divergence in the genetic code permitting variation of the nucleotide sequence without effecting the amino acid sequence of an encoded polypeptide. Accordingly, the instant invention relates to any nucleic acid sequence comprising a nucleotide sequence that encodes all or a substantial portion of the amino acid

sequences set forth herein. The skilled artisan is well aware of the "codon-bias" exhibited by a specific host cell in usage of nucleotide codons to specify a given amino acid. Therefore, when synthesizing a nucleic acid sequence for improved expression in a host cell, it is desirable to design the nucleic acid fragment such that its frequency of codon usage approaches the frequency of preferred codon usage of the host cell.

"Synthetic nucleic acid fragments" can be assembled from oligonucleotide building blocks that are chemically synthesized using procedures known to those skilled in the art. These building blocks are ligated and annealed to form larger nucleic acid sequences which may then be enzymatically assembled to construct the entire desired nucleic acid sequence.

"Chemically synthesized", as related to nucleic acid sequence, means that the component nucleotides were assembled *in vitro*. Manual chemical synthesis of nucleic acid sequences may be accomplished using well established procedures, or automated chemical synthesis can be performed using one of a number of commercially available machines. Accordingly, the nucleic acid sequences can be tailored for optimal gene expression based on optimization of nucleotide sequence to reflect the codon bias of the host cell. The skilled artisan appreciates the likelihood of successful gene expression if codon usage is biased towards those codons favored by the host. Determination of preferred codons can be based on a survey of genes derived from the host cell where sequence information is available.

"Gene" refers to a nucleic acid sequence that expresses a specific protein, including regulatory sequences preceding (5' non-coding sequences) and following (3' non-coding sequences) the coding sequence. "Native gene" refers to a gene as found in nature with its own regulatory sequences. "Chimeric gene" refers any gene that is not a native gene, comprising regulatory and coding sequences that are not found together in nature. Accordingly, a chimeric gene may comprise regulatory sequences and coding sequences that are derived from different sources, or regulatory sequences and coding sequences derived from the same source, but arranged in a manner different than that found in nature.

"Endogenous gene" refers to a native gene in its natural location in the genome of an organism. A "foreign" gene refers to a gene not normally found in the host organism, but that is introduced into the host organism by gene transfer. Foreign genes can comprise native genes inserted into a non-native organism, or chimeric genes. A "transgene" is a gene that has been introduced into the genome by a transformation procedure.

"Coding sequence" refers to a nucleotide sequence that codes for a specific amino acid sequence. "Regulatory sequences" refer to nucleotide sequences located upstream (5' non-coding sequences), within, or downstream (3' non-coding sequences) of a coding sequence, and which influence the transcription, RNA processing or stability, or translation of the associated coding sequence. Regulatory sequences may include promoters, translation leader sequences, introns, and polyadenylation recognition sequences.

“Promoter” refers to a nucleotide sequence capable of controlling the expression of a coding sequence or functional RNA. In general, a coding sequence is located 3' to a promoter sequence. The promoter sequence consists of proximal and more distal upstream elements, the latter elements often referred to as enhancers. Accordingly, an “enhancer” is a nucleotide sequence which can stimulate promoter activity. It may be an innate element of the promoter or a heterologous element inserted to enhance the level and/or tissue-specificity of a promoter. Promoters may be derived in their entirety from a native gene, or be composed of different elements derived from different promoters found in nature, or even comprise synthetic nucleotide segments. It is understood by those skilled in the art that different promoters may direct the expression of a gene in different tissues or cell types, or at different stages of development, or in response to different environmental conditions. Promoters which cause a nucleic acid sequence to be expressed in most cell types at most times are commonly referred to as “constitutive promoters”. “Organ-specific” or “development-specific” promoters are those that direct gene expression almost exclusively in specific organs, such as leaves or seeds, or at specific development stages in an organ, such as in early or late embryogenesis, respectively. New promoters of various types useful in plant cells are constantly being discovered; numerous examples may be found in the compilation by Okamuro and Goldberg (1989) *Biochemistry of Plants* 15:1-82. It is further recognized that since in most cases the exact boundaries of regulatory sequences have not been completely defined, nucleic acid sequences of different lengths may have identical promoter activity.

The expression of foreign genes in plants is well established (De Blaere et al. (1987) *Meth. Enzymol.* 143:277-291). Proper level of expression of mRNAs may require the use of different chimeric genes utilizing different promoters. Such chimeric genes can be transferred into host plants either together in a single expression vector or sequentially using more than one vector. Expression in plants will use regulatory sequences functional in such plants.

The origin of the promoter chosen to drive the expression of the coding sequence is not critical as long as it has sufficient transcriptional activity to accomplish the invention by expressing translatable mRNA for the desired protein genes in the desired host tissue.

The “translation leader sequence” refers to a nucleotide sequence located between the promoter sequence of a gene and the coding sequence. The translation leader sequence is present in the fully processed mRNA upstream of the translation start sequence. The translation leader sequence may affect processing of the primary transcript to mRNA, mRNA stability or translation efficiency. Examples of translation leader sequences have been described (Turner and Foster (1995) *Molecular Biotechnology* 3:225-236).



The "3' non-coding sequences" refer to nucleotide sequences located downstream of a coding sequence and include polyadenylation recognition sequences and other sequences encoding regulatory signals capable of affecting mRNA processing or gene expression. The polyadenylation signal is usually characterized by affecting the addition of polyadenylic acid tracts to the 3' end of the mRNA precursor. The use of different 3' non-coding sequences is exemplified by Ingelbrecht et al. (1989) *Plant Cell* 1:671-680.

"RNA transcript" refers to the product resulting from RNA polymerase-catalyzed transcription of a DNA sequence. When the RNA transcript is a perfect complementary copy of the DNA sequence, it is referred to as the primary transcript or it may be a RNA sequence derived from posttranscriptional processing of the primary transcript and is referred to as the mature RNA. "Messenger RNA (mRNA)" refers to the RNA that is without introns and that can be translated into polypeptide by the cell. "cDNA" refers to a double-stranded DNA that is complementary to and derived from mRNA. "Sense" RNA refers to an RNA transcript that includes the mRNA and so can be translated into a polypeptide by the cell. "Antisense RNA" refers to an RNA transcript that is complementary to all or part of a target primary transcript or mRNA and that blocks the expression of a target gene (see U.S. Patent No. 5,107,065, incorporated herein by reference). The complementarity of an antisense RNA may be with any part of the specific nucleotide sequence, i.e., at the 5' non-coding sequence, 3' non-coding sequence, introns, or the coding sequence. "Functional RNA" refers to sense RNA, antisense RNA, ribozyme RNA, or other RNA that may not be translated but yet has an effect on cellular processes.

The term "operably linked" refers to the association of two or more nucleic acid sequences on a single nucleic acid sequence so that the function of one is affected by the other. For example, a promoter is operably linked with a coding sequence when it is capable of affecting the expression of that coding sequence (i.e., that the coding sequence is under the transcriptional control of the promoter). Coding sequences can be operably linked to regulatory sequences in sense or antisense orientation.

The term "expression", as used herein, refers to the transcription and stable accumulation of sense (mRNA) or antisense RNA derived from the nucleic acid sequence of the invention. Expression may also refer to translation of mRNA into a polypeptide. "Antisense inhibition" refers to the production of antisense RNA transcripts capable of suppressing the expression of the target protein. "Overexpression" refers to the production of a gene product in transgenic organisms that exceeds levels of production in normal or non-transformed organisms. "Co-suppression" refers to the production of sense RNA transcripts capable of suppressing the expression of identical or substantially similar foreign or endogenous genes (U.S. Patent No. 5,231,020, incorporated herein by reference).

"Altered levels" refers to the production of gene product(s) in transgenic organisms in amounts or proportions that differ from that of normal or non-transformed organisms.

"Transformation" refers to the transfer of a nucleic acid sequence into the genome of a host organism, resulting in genetically stable inheritance. Host organisms containing the transformed nucleic acid fragments are referred to as "transgenic" organisms. Examples of methods of plant transformation include *Agrobacterium*-mediated transformation (De Blaere et al. (1987) *Meth. Enzymol.* 143:277) and particle-accelerated or "gene gun" transformation technology (Klein et al. (1987) *Nature (London)* 327:70-73; U.S. Patent No. 4,945,050, incorporated herein by reference).

Standard recombinant DNA and molecular cloning techniques used herein are well known in the art and are described more fully in Sambrook et al. *Molecular Cloning: A Laboratory Manual*; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 1989 (hereinafter "Sambrook").

A nucleic acid sequence encoding a soybean isoflavone synthase was isolated and identified from a cDNA library. Nucleic acid sequences encoding three alfalfa, one hairy vetch, one snow pea, one lupine, two lentil, two red clover, two white clover, two sugarbeet, and four mung bean isoflavone synthases have been isolated-using RT-PCR. Nucleic acid sequences encoding two soybean isoflavone synthases have been isolated from genomic DNA. The nucleic acid sequences of the instant invention may be used to isolate cDNAs and genes encoding homologous enzymes from the same or other plant species. Isolation of homologous genes using sequence-dependent protocols is well known in the art. Examples of sequence-dependent protocols include, but are not limited to, methods of nucleic acid hybridization, and methods of DNA and RNA amplification as exemplified by various uses of nucleic acid amplification technologies (e.g., polymerase chain reaction, ligase chain reaction).

For example, genes encoding other isoflavone synthase proteins, either as cDNAs or genomic DNAs, could be isolated directly by using all or a portion of the instant nucleic acid sequence as aDNA hybridization probe to screen libraries from any desired plant employing methodology well known to those skilled in the art. Specific oligonucleotide probes based upon the instant nucleic acid sequence can be designed and synthesized by methods known in the art (Sambrook). Moreover, the entire sequence can be used directly to synthesize DNA probes by methods known to the skilled artisan such as random primers DNA labeling, nick translation, or end-labeling techniques, or RNA probes using available *in vitro* transcription systems. In addition, specific primers can be designed and used to amplify a part of or full-length of the instant sequences. The resulting amplification products can be labeled directly during amplification reactions or labeled after amplification reactions, and

used as probes to isolate full-length cDNA or genomic fragments under conditions of appropriate stringency.

In addition, two short segments of the instant nucleic acid sequences may be used in polymerase chain reaction protocols to amplify longer nucleic acid sequences encoding homologous genes from DNA or RNA. The polymerase chain reaction may also be performed on a library of cloned nucleic acid sequences wherein the sequence of one primer is derived from the instant nucleic acid sequences, and the sequence of the other primer takes advantage of the presence of the polyadenylic acid tracts to the 3' end of the mRNA precursor encoding plant genes. Alternatively, the second primer sequence may be based upon sequences derived from the cloning vector. For example, the skilled artisan can follow the RACE protocol (Frohman et al. (1988) *Proc. Natl. Acad. Sci. USA* 85:8998-9002) to generate cDNAs by using PCR to amplify copies of the region between a single point in the transcript and the 3' or 5' end. Primers oriented in the 3' and 5' directions can be designed from the instant sequences. Using commercially available 3' RACE or 5' RACE systems (BRL), specific 3' or 5' cDNA sequences can be isolated (Ohara et al. (1989) *Proc. Natl. Acad. Sci. USA* 86:5673-5677; Loh et al. (1989) *Science* 243:217-220). Products generated by the 3' and 5' RACE procedures can be combined to generate full-length cDNAs (Frohman and Martin (1989) *Techniques* 1:165).

Availability of the instant nucleotide and deduced amino acid sequences facilitates immunological screening of cDNA expression libraries. Synthetic peptides representing portions of the instant amino acid sequences may be synthesized. These peptides can be used to immunize animals to produce polyclonal or monoclonal antibodies with specificity for peptides or proteins comprising the amino acid sequences. These antibodies can be then be used to screen cDNA expression libraries to isolate full-length cDNA clones of interest (Lerner (1984) *Adv. Immunol.* 36:1; Sambrook).

The nucleic acid sequence of the instant invention may be used to create transgenic plants and transgenic seeds in which expression of nucleic acid sequences (or their complements) encoding the disclosed enzyme result in levels of the corresponding endogenous enzyme that are higher or lower than normal. Alternatively, expression of the instant nucleic acid sequence may result in the production of the encoded enzyme in cell types or developmental stages in which they are not normally found. Either strategy would have the effect of altering the level of isoflavonoids.

For example, overexpression of isoflavone synthase may result in an increase in isoflavonoid content in legumes. Increased isoflavonoid content in legumes has been shown to be associated with beneficial health effects in humans. In contrast, certain soy food products would benefit from lower levels of isoflavonoid due to adverse effects on flavor.

Overexpression of the proteins of the instant invention may be accomplished by first constructing a chimeric gene in which the coding region is operably linked to a promoter capable of directing expression of a gene in the desired tissues at the desired stage of development. The chimeric gene may comprise promoter sequences and translation leader  
5 sequences derived from the same genes. 3' Non-coding sequences encoding transcription termination signals may also be provided. The instant chimeric gene may also comprise one or more introns in order to facilitate gene expression.

Plasmid vectors comprising the isolated polynucleotide (or chimeric gene) may be constructed. The choice of plasmid vector is dependent upon the method that will be used to  
10 transform host plants. The skilled artisan is well aware of the genetic elements that must be present on the plasmid vector in order to successfully transform, select and propagate host cells containing the chimeric gene. The skilled artisan will also recognize that different independent transformation events will result in different levels and patterns of expression (Jones et al. (1985) *EMBO J.* 4:2411-2418; De Almeida et al. (1989) *Mol. Gen. Genetics*  
15 218:78-86), and thus that multiple events must be screened in order to obtain lines displaying the desired expression level and pattern. Such screening may be accomplished by Southern analysis of DNA, Northern analysis of mRNA expression, Western analysis of protein expression, or phenotypic analysis.

The nucleic acid sequence of the instant invention may be used to create transgenic  
20 plants that have increased expression of the disclosed enzyme and that are additionally transformed with a chimeric gene encoding a transcription factor that regulates expression of one or more genes in the phenylpropanoid pathway. The chimeric transcription factor gene has regulatory sequences such that its expression is coordinated with that of the isoflavone synthase gene developmentally and preferably within the same cell type. This combination  
25 of expression of isoflavone synthase and transcription factor regulating phenylpropanoid pathway genes has the effect of enhancing the level of isoflavonoid synthesis due to increased levels of substrates for isoflavone synthase. The chimeric transcription factor gene regulates expression of at least one gene in the phenylpropanoid pathway. While not  
30 intending to be bound by any theory or theories of operation it is believed to regulate as many as two, three or four genes in the phenylpropanoid pathway.

For example, a plant cell that does not naturally produce isoflavonoids and does not have an active phenylpropanoid pathway would not produce the substrates for isoflavone synthase to convert to isoflavonoids. Activation of the phenylpropanoid pathway in the  
35 desired cells or at the desired developmental stage would provide these substrates allowing the synthesis of isoflavonoids.

The present invention is also directed to a method of altering the level of isoflavonoids in a cell comprising exposing said cell to a phenylpropanoid pathway altering agent. The

cell may be a plant cell such as a monocot, including and not limited to corn, or a dicot, such as soybean, for example. A phenylpropanoid pathway altering agent may be any agent that results in an increase or decrease in the level of expression of an enzyme in the phenylpropanoid pathway, such as isoflavone synthase, phenylalanine ammonia lyase, chalcone synthase, among others. Such phenylpropanoid pathway altering agents include and are not limited to a transcription factor and stress. Transcription factors include and are not limited to chimeric transcription factors, a chimera containing the maize R region between the region encoding the C1 DNA binding domain and the C1 activation domain (CRC) for example. Stresses to a plant cell include ultraviolet light, temperature, pressure, chemicals including and not limited to herbicides, and phosphate level. Phosphate levels may be increased or decreased such that decreasing phosphate levels may result in phosphate starvation.

It may also be desirable to reduce or eliminate expression of genes encoding the instant polypeptides in plants for some applications. In order to accomplish this, a chimeric gene designed for co-suppression of the instant polypeptide can be constructed by linking a gene or gene sequence encoding that polypeptide to plant promoter sequences. Alternatively, a chimeric gene designed to express antisense RNA for all or part of the instant nucleic acid sequence can be constructed by linking the gene or gene sequence in reverse orientation to plant promoter sequences. Either the co-suppression or antisense chimeric genes could be introduced into plants via transformation wherein expression of the corresponding endogenous genes are reduced or eliminated.

Molecular genetic solutions to the generation of plants with altered gene expression have a decided advantage over more traditional plant breeding approaches. Changes in plant phenotypes can be produced by specifically inhibiting expression of one or more genes by antisense inhibition or cosuppression (U. S. Patent Nos. 5,190,931, 5,107,065 and 5,283,323). An antisense or cosuppression construct would act as a dominant negative regulator of gene activity. While conventional mutations can yield negative regulation of gene activity these effects are most likely recessive. The dominant negative regulation available with a transgenic approach may be advantageous from a breeding perspective. In addition, the ability to restrict the expression of specific phenotype to the reproductive tissues of the plant by the use of tissue specific promoters may confer agronomic advantages relative to conventional mutations which may have an effect in all tissues in which a mutant gene is ordinarily expressed.

The person skilled in the art will know that special considerations are associated with the use of antisense or cosuppression technologies in order to reduce expression of particular genes. For example, the proper level of expression of sense or antisense genes may require the use of different chimeric genes utilizing different regulatory elements known to the

skilled artisan. Once transgenic plants are obtained by one of the methods described above, it will be necessary to screen individual transgenics for those that most effectively display the desired phenotype. Accordingly, the skilled artisan will develop methods for screening large numbers of transformants. The nature of these screens will generally be chosen on practical grounds. For example, one can screen by looking for changes in gene expression by using antibodies specific for the protein encoded by the gene being suppressed, or one could establish assays that specifically measure enzyme activity. A preferred method will be one which allows large numbers of samples to be processed rapidly, since it will be expected that a large number of transformants will be negative for the desired phenotype.

The instant isoflavone synthases (or portions of the enzymes) may be produced in heterologous host cells, particularly in the cells of microbial hosts, and can be used to prepare antibodies to the enzymes by methods well known to those skilled in the art. The antibodies are useful for detecting the enzymes in situ in cells or in vitro in cell extracts. Preferred heterologous host cells for production of isoflavone synthase are yeast hosts. Yeast expression systems and expression vectors containing regulatory sequences that direct high level expression of foreign proteins are well known to those skilled in the art. Any of these could be used to construct chimeric genes for production of the instant isoflavone synthase. These chimeric genes could then be introduced into appropriate hosts via transformation to provide high level expression of the enzymes. An example of a vector for high level expression of the instant isoflavone synthase in a yeast host is provided (Example 5).

All or a substantial portion of the nucleic acid sequences of the instant invention may also be used as probes for genetically and physically mapping the genes that they are a part of, and as markers for traits linked to those genes. Such information may be useful in plant breeding in order to develop lines with desired phenotypes. For example, the instant nucleic acid sequences may be used as restriction sequence length polymorphism (RFLP) markers. Southern blots (Maniatis) of restriction-digested plant genomic DNA may be probed with the nucleic acid sequences of the instant invention. The resulting banding patterns may then be subjected to genetic analyses using computer programs such as MapMaker (Lander et al. (1987) *Genomics* 1:174-181) in order to construct a genetic map. In addition, the nucleic acid sequences of the instant invention may be used to probe Southern blots containing restriction endonuclease-treated genomic DNAs of a set of individuals representing parent and progeny of a defined genetic cross. Segregation of the DNA polymorphisms is noted and used to calculate the position of the instant nucleic acid sequence in the genetic map previously obtained using this population (Botstein et al. (1980) *Am. J. Hum. Genet.* 32:314-331).

The production and use of plant gene-derived probes for use in genetic mapping is described in Bernatzky and Tanksley (1986) *Plant Mol. Biol. Reporter* 4(1):37-41. Numerous publications describe genetic mapping of specific cDNA clones using the methodology outlined above or variations thereof. For example, F2 intercross populations, backcross populations, randomly mated populations, near isogenic lines, and other sets of individuals may be used for mapping. Such methodologies are well known to those skilled in the art.

Nucleic acid probes derived from the instant nucleic acid sequences may also be used for physical mapping (i.e., placement of sequences on physical maps; see Hoheisel et al. In: *Nonmammalian Genomic Analysis: A Practical Guide*, Academic press 1996, pp. 319-346, and references cited therein).

In another embodiment, nucleic acid probes derived from the instant nucleic acid sequences may be used in direct fluorescence *in situ* hybridization (FISH) mapping (Trask (1991) *Trends Genet.* 7:149-154). Although current methods of FISH mapping favor use of large clones (several to several hundred KB; see Laan et al. (1995) *Genome Research* 5:13-20), improvements in sensitivity may allow performance of FISH mapping using shorter probes.

A variety of nucleic acid amplification-based methods of genetic and physical mapping may be carried out using the instant nucleic acid sequences. Examples include allele-specific amplification (Kazazian (1989) *J. Lab. Clin. Med.* 114(2):95-96), polymorphism of PCR-amplified fragments (CAPS; Sheffield et al. (1993) *Genomics* 16:325-332), allele-specific ligation (Landegren et al. (1988) *Science* 241:1077-1080), nucleotide extension reactions (Sokolov (1990) *Nucleic Acid Res.* 18:3671), Radiation Hybrid Mapping (Walter et al. (1997) *Nature Genetics* 7:22-28) and Happy Mapping (Dear and Cook (1989) *Nucleic Acid Res.* 17:6795-6807). For these methods, the sequence of a nucleic acid fragment is used to design and produce primer pairs for use in the amplification reaction or in primer extension reactions. The design of such primers is well known to those skilled in the art. In methods employing PCR-based genetic mapping, it may be necessary to identify DNA sequence differences between the parents of the mapping cross in the region corresponding to the instant nucleic acid sequence. This, however, is generally not necessary for mapping methods.

The physiological activities associated with isoflavonoids in both plants and humans makes the manipulation of their contents in crop plants highly desirable. For example, increasing levels of isoflavonoids in soybean seeds would increase the efficiency of extraction and lower the cost of isoflavonoid-related products sold. Decreasing levels of isoflavonoids in soybean seeds would be beneficial for production of soy-based infant formulas where the estrogenic effects of isoflavonoids are undesirable. Decreasing levels of

isoflavonoids may also increase palatability of soy foods. Raising levels of isoflavonoid phytoalexins in vegetative plant tissue could increase plant defenses to pathogen attack, thereby improving resistance and lowering the need for pesticide use. Manipulation of isoflavonoid levels in roots could lead to improved nodulation and increased efficiencies of nitrogen fixation. To date, however, it has proven difficult to develop soybean or other plant lines with consistently high levels of isoflavonoids.

Identification of the functional isoflavone synthase gene is extremely important because isoflavone synthase catalyzes the central reaction in pathways producing isoflavonoids. Manipulation of the isoflavone synthase gene via molecular techniques is expected to allow production of soybeans and other plants with high, stable levels of isoflavonoids. Introduction of the isoflavone synthase gene in non-legume crop species including, but not limited to, corn, wheat, rice, sunflower, and canola could lead to synthesis of isoflavonoids in these species. Synthesis of isoflavonoids would 1) confer disease resistance to the crops and/or 2) produce crops which would benefit human and/or livestock health.

### EXAMPLES

The present invention is further defined in the following Examples, in which all parts and percentages are by weight and degrees are Celsius, unless otherwise stated. It should be understood that these Examples, while indicating preferred embodiments of the invention, are given by way of illustration only. From the above discussion and these Examples, one skilled in the art can ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.

#### EXAMPLE 1

##### Microsome Preparation from Elicitor-Treated Soybean Hypocotyls and Elicitor-Treated Cell Suspension Culture

###### *Elicitor Treatment of Soybean Seeds*

Soybean seeds were placed on a bed of vermiculite (5 to 6 cm thick) and covered with a layer of vermiculite about 2 cm thick. Seeds were germinated for five days in a growth chamber until the average length of hypocotyls reached to about 3 to 4 cm. The growth chamber was kept at a cycle that consisted of a 14 h light period at 25°C and a 10 h dark period at 21°C. Illumination was supplied from cool white fluorescent and incandescent lamps that provide a photon flux density of 450  $\mu\text{Em}^{-2}\text{s}^{-1}$ . Soybean hypocotyls were pulled out from the vermiculite bed and were placed on wet paper towels. The soybean hypocotyls were divided into two groups: one of the groups was treated with elicitor and the other was not treated.



Elicitor treatment was conducted as follows. The epidermal surfaces of the hypocotyls were opened using a razor blade. The incisions were approximately 2 cm long and 1 to 2 mm deep; one was made on each hypocotyl. Fungal-derived elicitors were prepared by the method of Sharp et al. (Sharp, J. K. et al. (1984) *J. Biol. Chem.* 259:11312-11320). Twenty micrograms of acidified fungal elicitors were dissolved in 20  $\mu$ L of 10 mM  $\text{KH}_2\text{PO}_4$ , and were then applied to the wound of a hypocotyl. The treated hypocotyls were incubated for 15 h in the dark at room temperature and 100% humidity. At the end of the incubation period, the hypocotyls were sectioned closely below the cotyledonal node and were immediately frozen in liquid nitrogen and stored at  $-76^\circ\text{C}$  until used. Non-elicitor-treated hypocotyls were handled in the same manner as were elicitor-treated hypocotyls, except for wounding and elicitor application. The non-treated hypocotyls were used as a negative control of isoflavone synthase induction.

#### *Elicitor Treatment of Soybean Cell Suspension Culture*

Soybean suspension cell cultures were grown at  $25^\circ\text{C}$  in 250 mL flasks that were tightly covered with two layers of aluminum foil to prevent illumination. Cells were grown in 35 mL of Murashige and Skoog medium (Gibco BRL) supplemented with 0.75 mg/L 2,4-dichlorophenoxyacetic acid and 0.55 mg/mL 6-benzyl aminopurine. Cells were diluted (1:3 ratio) into fresh medium every 7 days and elicitor treatment was conducted 3 days after cell dilution. One hundred fifty milligrams of the same fungal elicitor used to treat the hypocotyls was dissolved in 15 mL of 10 mM  $\text{KH}_2\text{PO}_4$  and was filter sterilized. Five milligrams of sterile fungal elicitor dissolved in 333  $\mu$ L 10 mM  $\text{KH}_2\text{PO}_4$  was added per flask. Cells were harvested 15 h after addition of elicitor. The same suspension culture conditions were used before and after elicitor treatment. Cells were recovered using a Nalgene PES filter unit (0.2  $\mu\text{m}$ ) followed by 3 minutes of air flow. Filtered cells were immediately frozen in liquid nitrogen and kept at  $-76^\circ\text{C}$  until used. Non-elicitor-treated cells were handled in the same manner, except for the addition of elicitor.

#### *Microsome preparation from soybean hypocotyls and suspension-cultured cells*

For preparation of the crude extracts, 3 to 5 g of previously frozen, elicitor-treated and non-treated soybean hypocotyls and elicitor-treated and non-treated suspension cultured cells were ground in liquid nitrogen using a pre-chilled pestle and mortar. The powder was added to 25 mL of extraction buffer (buffer A: 0.1M Tris-HCl, pH 7.5, 14 mM  $\beta$ -mercaptoethanol, 20% (w/v) sucrose and 0.8 g of Dowex 1X2 resin (mesh 200-400)), and the slurry was stirred for 20 to 30 minutes in an ice-water bath. The slurry was transferred to Nalgene Oak Ridge tubes and centrifuged at 8000 g for 10 minutes at  $4^\circ\text{C}$ . The supernate was carefully transferred into 13 mL polyallomer tubes which fit into a Sorvall TH641 rotor and centrifuged at 160,000 g for 40 minutes to 2 h at  $4^\circ\text{C}$ . The precipitated microsomes were washed twice with the storage buffer (buffer B: 80 mM  $\text{KH}_2\text{PO}_4$ , pH 8.5, 14 mM

β-mercaptoethanol, 30% (v/v) glycerol) and resuspended with storage buffer. The microsomal pellet was gently homogenized by hand using a disposable plastic pestle, and the suspension was divided into several aliquots which were frozen on dry-ice. Bradford protein micro assays were used to quantify the protein content of the microsomal preparations (Bio-Rad, Richmond, CA). Two microliters of a microsome preparation were diluted with 198 μL of distilled water. Forty microliters of this dilution was mixed with 10 μL of Bio-Rad protein assay solution in a microtiter plate, and the total protein concentration was determined by reading the sample in a kinetic microplate reader (Molecular Devices Inc.), according to the manufacturer's instructions (Bio-Rad). Microsomes were stored at -76°C until used.

## EXAMPLE 2

### Development of Isoflavone Synthase Assay

An assay to measure isoflavone synthase activity was developed using either of the two substrates of isoflavone synthase, (±) naringenin (4',5,7-trihydroxyflavanone; Sigma, N-5893) or liquiritigenin monohydrate (4',7-dihydroxyflavanone; Indofine, 02-1150S), dissolved in 80% ethanol. The reaction mixture was prepared at room temperature and consisted of 100 μM naringenin or liquiritigenin, 80 mM K<sub>2</sub>HPO<sub>4</sub>, 0.5 mM glutathione (Sigma, G-4251), 20% w/v sucrose, and 30 to 150 μg of microsome preparation. The reaction mixtures were preincubated for 5 minutes without NADPH (synthesis of genistein and daidzein requires NADPH as a co-factor). The volume of microsomes and substrate added to any one reaction did not exceed 5% and 1%, respectively, of the total reaction volume. A typical reaction volume was 250 μL. The reaction was started by the addition of 40 nmol of NADPH per each 100 μL of final reaction volume. The pH of the reaction mixture was 8.0 before the addition of the substrate, NADPH and microsomes.

Microsomes were thawed, an aliquot removed and the remaining sample was immediately frozen on dry ice and stored in the freezer. The reactions using microsomes prepared from soybean elicitor-treated hypocotyls were run for incubation periods of up to 24 h, while the reactions using the yeast microsomes were allowed to run for incubation periods of up to 14 h. Following incubation, 200 μL of ethyl acetate was added directly to the mixture and the mixture was shaken for 1 minute using a vortex mixer. Separation of the organic phase was accelerated by centrifugation for 2 minutes at 4°C. The organic phase was removed and analyzed.

Qualitative and quantitative analyses were performed using a Hewlett Packard 1100 series HPLC and a Hewlett-Packard/Micromass LC/MS. Samples were assayed on a Hewlett Packard 1100 series HPLC system using either a Li-Chrospher 100 RP-18 column (5 μm) or a Phenomenex Luna 3u C18 (2) column (150 X 4.6 mm). Using either column, samples from in vitro microsome assays in ethyl acetate, were isocratically separated for

5 minutes employing 65% methanol as the mobile phase. The second column was used for plant samples where the ethyl acetate was evaporated and the samples resuspended in 80% methanol. In these cases separation used a 10 minutes linear gradient from 20% methanol/80% 10 mM ammonium acetate, pH 8.3 to 100% methanol using a flow rate of 0.8 ml per minute. Genistein and daidzein were monitored by the absorbance at 260 nm and naringenin and liquiritigenin were monitored by the absorbance at 280 nm. Peak areas were converted to nanograms using, as standards for calibration, authentic naringenin, liquiritigenin, genistein, and daidzein (Indofine Chemical Company, Inc., Somerville, NJ) dissolved in ethanol.

Analyses using LC/MS employed 10  $\mu$ L of the ethyl acetate phase that had been first evaporated with nitrogen gas and resuspended in 100  $\mu$ L of 25% acetonitrile in water. These samples were analyzed by a Hewlett-Packard/Micromass LC/MS instrument. A twenty-five microliter sample was run on a Zorbax Eclipse XDB-C8 reverse-phase column (3 X 150 mm, 3.5 micron) isocratically with 25% of solvent B in solvent A. Solvent A was 0.1% formic acid in water, and solvent B was 0.1% formic acid in acetonitrile. Mass spectrometry was carried out by electro-spray scanning from 200-400 m/e, using +60 volt cone voltage. The diode array signals were monitored between 200-400 nm in both instruments.

The genistein and liquiritigenin signals observed in the *in vitro* assay samples were verified by comparisons of retention time, diode array detected absorption spectra and mass spectrometry data to the standards. Figure 2 presents the results of HPLC analyses of naringenin standards and Figure 3 presents the results of HPLC analyses of genistein standards.

Incubations in the absence of an essential component required for isoflavone synthase-catalyzed synthesis of isoflavonoid (e.g., NADPH, naringenin, liquiritigenin, or microsomes) were performed as negative controls.

Positive control samples consisting of soybean microsomes which were prepared from elicitor-treated hypocotyls and suspension culture cells were used to establish the *in vitro* assay system. Optimization of this *in vitro* assay system was critical for validation of the yeast expression system for functional cloning. We observed positive results (i.e., the synthesis of genistein) in assays that used either the microsomes of elicitor-treated soybean hypocotyls (Figure 4) or those obtained from elicitor-treated cell suspension cultures (Figure 6). We observed about six times higher specific enzyme activities of isoflavone synthase in the microsomes of elicitor-treated hypocotyls and cell cultures (Figure 4 and Figure 6, respectively) than in the microsomes obtained from non-treated hypocotyls and cell cultures (Figure 5 and Figure 7, respectively).

### EXAMPLE 3

#### Composition of Soybean cDNA Library, Isolation and Sequencing of cDNA Clone

A cDNA library was prepared using mRNAs from soybean seeds that had been  
5 allowed to germinate for 4 hours. The library was prepared in Uni-ZAP™ XR vector  
according to the manufacturer's protocol (Stratagene Cloning Systems, La Jolla, CA).  
Conversion of the Uni-ZAP™ XR library into a plasmid library was accomplished according  
to the protocol provided by Stratagene. Upon conversion, cDNA inserts were contained in  
the plasmid vector pBluescript. cDNA inserts from randomly picked bacterial colonies  
10 containing recombinant pBluescript plasmids were amplified via polymerase chain reaction  
using primers specific for vector sequences flanking the inserted cDNA sequences or  
plasmid DNA was prepared from cultured bacterial cells. Amplified insert DNAs or plasmid  
DNAs were sequenced in dye-primer sequencing reactions to generate partial cDNA  
sequences (expressed sequence tags or "ESTs"; see Adams, M. D. et al. (1991) *Science*  
15 252:1651-1656). The resulting ESTs were analyzed using a Perkin Elmer Model 377  
fluorescent sequencer.

### EXAMPLE 4

#### Identification and Characterization of a cDNA Clone for Isoflavone Synthase

20 ESTs encoding candidate isoflavone synthases were identified by conducting BLAST  
(Basic Local Alignment Search Tool; Altschul, S. F., et al., (1993) *J. Mol. Biol.*  
215:403-410; see also [www.ncbi.nlm.nih.gov/BLAST/](http://www.ncbi.nlm.nih.gov/BLAST/)) searches for similarity to sequences  
contained in the BLAST "nr" database (comprising all non-redundant GenBank CDS  
translations, sequences derived from the 3-dimensional structure Brookhaven Protein Data  
25 Bank, the last major release of the SWISS-PROT protein sequence database, EMBL, and  
DDBJ databases). The cDNA sequences obtained in Example 3 were analyzed for similarity  
to all publicly available DNA sequences contained in the "nr" database using the BLASTN  
algorithm provided by the National Center for Biotechnology Information (NCBI). The  
DNA sequences were translated in all reading frames and compared for similarity to all  
30 publicly available protein sequences contained in the "nr" database using the BLASTX  
algorithm (Gish, W. and States, D. J. (1993) *Nature Genetics* 3:266-272) provided by the  
NCBI.

The insert in cDNA clone sgs1c.pk006.o20 was identified as a candidate isoflavone  
synthase gene by a BLAST search against the NCBI database. The 5' sequence of this insert  
35 was determined to be related to *Glycine max* cytochrome P450 monooxygenase CYP93C1p  
(CYP93C1) mRNA, the complete coding sequence of which may be found as NCBI General  
Identifier No. 2739005. The CYP93C1p cDNA sequence was obtained using random

isolation and screening to identify soybean P450s involved in herbicide metabolism (Siminszky B., et al. (1999) *Proc. Natl. Acad. Sci. U.S.A.* 96:1750-1755). Isoflavone synthase catalyzes in soybeans the oxidation of 7,4'-dihydroxyflavanone (liquiritigenin) or 5,7,4'-trihydroxyflavanone (naringenin) to daidzein or genistein respectively. Earlier published work (Kochs and Griesbach (1986) *Eur. J. Biochem* 155:311-318; Hashim et al. (1990) *FEBS* 271:219-222) suggested that the enzyme that catalyzes this reaction is a cytochrome P450. Accordingly, in order to confirm the identity of the polypeptide encoded by the insert in cDNA clone sgs1c.pk006.o20 as an isoflavone synthase, the polypeptide encoded by this insert was evaluated for its ability to catalyze the formation of genistein from naringenin.

The ability of the cDNA insert in clone sgs1c.pk006.o20 to encode an isoflavone synthase was evaluated by expression of the encoded polypeptide in an engineered yeast (*Saccharomyces cerevisiae*) strain. Microsomes prepared from the engineered yeast strain transformed with a plasmid encoding the putative isoflavone synthase were assayed for their ability to mediate the synthesis of genistein in the presence of substrate (naringenin).

Yeast strain W303-1B was used as the starting material and modified by homologous recombination. The coding sequence of the P450 reductase HT1 isolated from *Helianthus tuberosus* (NCBI General Identifier No. 1359894) was inserted into the integrative plasmid pYeDP110 (Pompon, D. et al. (1996) *Meth. Enz.* 272:51-64). Insertion was achieved after PCR amplification for addition of Bam HI and Eco RI restriction sites 5' and 3' of the coding region, respectively, using the primers listed as SEQ ID NO:3 and SEQ ID NO:4.

5'-CGGGATCCATGCAACCGGAAACCGTCG-3' [SEQ ID NO:3]

5'-CCGGAATTCTCACCAAACATCACGGAGGTATC-3' [SEQ ID NO:4]

Transformation of W303-1B with the linearized plasmid led to homologous recombination with the promoter and terminator sequences of the endogenous yeast reductase (CPR1) resulting in the disruption of the CPR1 gene and replacement with the URA3 gene and HT1 under the control of the galactose-inducible promoter GAL10-CYC1. The resulting strain is designated WHT1.

Plasmid DNA (200 ng) from cDNA clone sgs1c.pk006.o20 was used as template for PCR with primers that are homologous to the vector sequences flanking the cDNA cloning site (SEQ ID NO:5 and SEQ ID NO:6).

5'-TCAAGGAGAAAAAACCCCGGATCCATGTTGCTGGAAGTGCACCTTGG-3' [SEQ ID NO:5]

5'-GGCCAGTGAATTGTAATACGACTCACTATAGGGCG-3' [SEQ ID NO:6]

Amplification was performed using the GC melt kit (Clontech) with a 1 M final concentration of GC melt reagent. Amplification took place in a Perkin Elmer 9700 thermocycler for 30 cycles as follows: 94°C for 30 seconds, 60°C for 30 seconds, and 72°C for 1 minute. The amplified insert was then incubated with a modified pRS315 plasmid (NCBI General Identifier No. 984798; Sikorski, R. S. and Hieter, P. (1989) *Genetics* 122:19-27) that had been digested with Not I and Spe I. Plasmid pRS315 had been previously modified by the insertion of a bidirectional gal1/10 promoter between the Xho I and Hind III sites. The plasmid was then transformed into the WHT1 yeast strain using standard procedures. The insert recombines through gap repair to form the desired plasmid (Hua, S. B., et al. (1997) *Plasmid* 38:91-96.). The resulting transformed yeast strain is named Isoflavone Synthase GM1 (hereinafter referred to as "GM1"), and bears ATCC Accession No. 203606.

Yeast microsomes were prepared according to the methods of Pompon et al. (Pompon, D., et al. (1996) *Meth. Enz.* 272:51-64). Briefly, a yeast colony was grown overnight (to saturation) in SG (-Leucine) medium at 30°C with good aeration. A 1:50 dilution of this culture was made into 500 mL of YPGE medium with adenine supplementation and allowed to grow at 30°C with good aeration to an OD<sub>600</sub> of 1.6 (24-30 h). Fifty mL of 20% galactose was added, and the culture was allowed to grow overnight at 30°C. The cells were recovered by centrifugation at 5,500 rpm for five minutes in a Sorvall GS-3 rotor. The cell pellet was resuspended in 80 mL of TEK buffer (0.1M KCl in TE) and left at room temperature for five minutes. The cells were recovered by centrifugation as described above. The cell pellet was resuspended in 5 mL of TES-B (0.6M sorbitol in TE), and glass beads (0.5 mm diameter) were gently added until they reached the surface of the suspension. The cells were disrupted by shaking up and down for five minutes, with an agitation frequency of at least once every 0.5 second. Five mL of TES-B were added to the crude extract, and the beads were washed with some agitation. The supernatant was withdrawn and saved. The wash was repeated twice and the liquid fractions were pooled. The combined fractions were clarified by spinning at 11,000 rpm in a Sorvall SS34 rotor. The pellet was discarded and the microsomes were precipitated by the addition of NaCl to a final concentration of 0.15 M. PEG 4000 was added to a final concentration of 0.1 g/mL. The mixture was incubated on ice for at least 15 minutes, and the microsomal fraction was recovered by at 8,500 rpm for 10 minutes in an SS34 rotor. The pellets were resuspended in TEG (glycerol, 20% by volume, in TE) at a concentration of 20-40 mgs of protein per mL at which point they may be stored at -70°C for months without any detectable loss of activity.

### EXAMPLE 5

#### Demonstration of Functional Expression of Isoflavone Synthase in Yeast

The synthesis of genistein or daidzein from either naringenin or liquiritigenin was observed in an *in vitro* assay that was mediated by yeast microsomes prepared from the yeast transformant GM1 expressing the polypeptide encoded by the insert in soybean cDNA clone sgs1c.pk006.o20. Samples were prepared and run on a LiChrospher 100 RP-18 column (5  $\mu$ m) or a Phenomenex Luna 3u C18 (2) column (150 X 4.6 mm) as described in Example 2. Peaks in the yeast microsome assay samples were identified as being genistein or daidzein by their HPLC retention time and absorption spectrum. The retention time and the absorption spectrum of the peak found in the expected location of genistein was identical to the retention time and spectrum of authentic genistein (compare Figures 3 and 4, Figures 17 and 18). The daidzein peak also had identical retention time and absorption spectrum to the standard. More direct evidence was obtained using LC/MS. Data for daidzein is shown in Figure 19. The molecular weights of the materials corresponding to the expected genistein and daidzein peaks from the yeast microsome assay samples were 270.32 and 255.2, respectively. The molecular weights of authentic genistein and daidzein are 270.23 and 255.2, respectively.

The synthesis of genistein in yeast microsomes obtained from the yeast strain Isoflavone Synthase GM1 was monitored over the course of incubation with the substrate naringenin. Samples representing incubation periods of 0 minutes and 1, 2, 3, 4 and 14 h were analyzed. Results are presented in Figures 8 through 13. A simultaneous increase of genistein, the product, and decrease of naringenin, the substrate of isoflavone synthase, was observed. A detectable amount of genistein was synthesized as early as 40 minutes (Figure 14). Incubation of microsomes with either naringenin or liquiritigenin as substrate shows an increase in accumulation of genistein and daidzein (the product) over ten hours as seen in Figure 26.

Genistein synthesis corresponds quantitatively with the amount of input GM1 microsomes (Figure 14 and Figure 15). The genistein peak in the assay using GM1 as a source was about 10 times higher than the peak observed from soybean microsome prepared from elicitor-treated hypocotyls (compare Figure 4 and Figure 13). Genistein synthesis by yeast microsomes using GM1 also demonstrated an absolute requirement for NADPH. Without the cofactor, the reaction mixture did not synthesize any detectable genistein over a 4-h incubation (Figure 16).

An unidentified peak, designated "peak 2," with a retention time of 1.59, was also detected during monitoring of reactions catalyzed by yeast microsomes at 280 nm (see Figure 9 to Figure 15). This peak was not significant in negative controls (Figure 8 and Figure 16). Koch and Grisebach proposed a hypothesis for the synthesis of an intermediate

during the conversion of naringenin to genistein (Kochs, G. and Grisenbach, H. (1985) *Eur. J. Biochem.* 155:311-318). This proposal stated that the oxidative aryl migration required to convert naringenin to genistein proceeds via a cytochrome P450 monooxygenase-mediated conversion of the 2S-flavanone to a 2-hydroxyisoflavone, followed by dehydration to the isoflavonoid, possibly mediated by a soluble dehydratase. The 2-hydroxyisoflavone intermediate was described as unstable and could spontaneously convert to genistein. In electrospray LC/MS the most prominent peak in the spectrum of "peak 2" is at  $m/z = 289$ , consistent with it being the  $[MH]^+$  form of the proposed hydroxylated intermediate. The height of "peak 2" detected in the 4 h incubation sample was bigger than that for "peak 2" in the 14 h incubation sample. That sample showed the largest genistein peak among the microsome assays that were performed. It is suspected that "peak 2" may represent this proposed intermediate that may be formed transiently during the synthesis of genistein by isoflavone synthase. A similar intermediate (at  $m/z = 273$ ) was also detected in the conversion of liquiritigenin to daidzein (Figure 19).

To compare the rates of genistein and daidzein synthesis by microsomes of the yeast transformant GM1, samples representing incubation periods of 2, 4, 6, 8 and 10 h were analyzed. The peak areas for genistein and daidzein were quantitated by calibration with authentic genistein and daidzein standards. Assays were repeated three times and the average amount of isoflavonoid synthesized at each time point was plotted, with vertical lines representing error bars (Figure 26).

#### EXAMPLE 6

##### Identification of CYP93C1 as a Soybean Isoflavone Synthase

The sequence of the mRNA encoding CYP93C1, a cytochrome P450 monooxygenase, is found in the NCBI database having General Identifier No. 2739005. The function of the protein encoded by this mRNA has yet to be identified. The cDNA insert in clone sgs1c.pk006.o20 encodes an isoflavone synthase and has sequence similarities with CYP93C1. To determine whether CYP93C1 encodes a functional isoflavone synthase, cDNA was prepared and cloned into the yeast vector pRS315-gal and transformed into yeast strain WHT1 to assay for its ability to produce genistein. The CYP93C1 mRNA was amplified from RNA isolated from soybean tissue (cv. S1990) infected with the fungal pathogen *Sclerotinia sclerotiorum* using RT-PCR. Fungal infection causes an increase in the amount of isoflavonoid produced and thus the amount of isoflavone synthase transcript was increased in the infected tissue. Soybean plants were infected 45 days after planting seeds and were harvested two days later. Total RNA was prepared using the TRIzol Reagent following the manufacturer's instructions (Gibco BRL) and 1  $\mu$ g of the resulting total RNA was converted into a first strand cDNA using the Superscript™ Preamplification system and



using oligodT as the reverse transcription primer. One microliter of first strand cDNA was amplified by PCR using the primers listed as SEQ ID NO:7 and SEQ ID NO:8:

5'-AAAATTAGCCTCACAAAAGCAAAG-3' [SEQ ID NO:7]

5'-ATATAAGGATTGATAGTTTATAGTAGG-3' [SEQ ID NO:8]

The nucleotide sequence in SEQ ID NO:7 corresponds to nucleotides 3 to 26 of the sequence found in NCBI General Identifier No. 2739005. The nucleotide sequence in SEQ ID NO:8 corresponds to the complement of nucleotides 1798 to 1824 of the sequence found in NCBI General Identifier No. 2739005. Amplification was performed on a Perkin Elmer Applied Biosystems GeneAmp PCR System using the Advantage-GC cDNA polymerase mix (Clontech), following the manufacturer's instructions, with a 1 M final concentration of GC melt reagent. Previous to amplification, the mixture was incubated at 94°C for 5 minutes. Amplification was performed using 30 cycles of: 94°C for 30 seconds, 53°C for 30 seconds and 72°C for 2 minutes. Following amplification, the mixture was incubated at 72°C for 7 minutes. The amplified product was then cloned into pCR2.1 using "The Original TA Cloning Kit" (Invitrogen). Plasmid DNA was purified using QIAFilter cartridges (Qiagen Inc) according to the manufacturer's instructions. Sequence was generated on an ABI Automatic sequencer using dye terminator technology and using a combination of vector and insert-specific primers. Sequence editing was performed using DNASTar (DNASTAR, Inc.). The sequence generated represents coverage at least two times in each direction. The sequence of the resulting clone, presented in SEQ ID NO:9, was identical with that of CYP93C1 (NCBI General Identifier No. 2739005); the deduced amino acid sequence of this cDNA is shown in SEQ ID NO:10.

The above plasmid was then cloned into the yeast vector pRS315-gal using gap repair as described in Example 4. Standard procedures were used to transform the resulting plasmid into the WHT1 yeast strain. Microsomes were prepared from the WHT1 yeast strain containing the soybean CYP93C1 sequence and assayed for the production of genistein and daidzein as described in Example 5. The resulting microsomes exhibited isoflavone synthase activities. To compare the rates of genistein and daidzein synthesis by microsomes of the yeast transformant containing the soybean CYP93C1 sequence, samples representing incubation periods of 2, 4, 6, 8 and 10 h were analyzed. The peak areas for genistein and daidzein were quantitated by calibration with authentic genistein and daidzein standards as prepared in Example 2. Daidzein and genistein accumulated linearly over the time course.

EXAMPLE 7Amplification and Identification ofIsoflavone Synthase From Other Legume Species

Nucleic acid sequences encoding isoflavone synthases from lupine, mung bean, snow pea, alfalfa, red clover, white clover, hairy vetch and lentil were derived from total RNA prepared from young seedlings. Mung bean sprouts and snow pea sprouts were obtained from the local grocery store. Seeds for alfalfa, red clover, white clover, hairy vetch, and lentil were obtained from Pinetree Garden Seeds while seeds for lupine (cv Russell Mix) were obtained from Botanical Interests, Inc. Seedlings were germinated in a controlled temperature growth chamber (14 h light at 25°C and 10 h dark at 21°C) and harvested after approximately two weeks except for lupine, which was harvested after approximately three weeks. Total RNA was prepared using TRIzol Reagent (Gibco BRL) according to the manufacturer's instructions. For each plant, a first strand cDNA was prepared from 1 µg total RNA using the Superscript™ Preamplification System (Gibco BRL) following the manufacturer's instructions. OligodT was used as the reverse transcription primer in all cases except white clover where random hexamers were used.

Amplification was performed on a Perkin-Elmer Applied Biosystems GeneAmp PCR System 9700PCR using Advantage-GC cDNA polymerase mix (Clontech) according to the manufacturer's instructions and with a final concentration of GC melt reagent equal to 1 M. Amplification was preceded in all cases by incubation at 94°C for 5 minutes and was followed by incubation at 72°C for 7 minutes. Two sets of primers were used for PCR amplification. Primer set one is composed of SEQ ID NO:11 and SEQ ID NO:12 and primer set two is composed of SEQ ID NO:13 and SEQ ID NO:14:

25	5'-ATGTTGCTGGAACCTTGCACTT-3'	[SEQ ID NO:11]
	5'-TTAAGAAAGGAGTTTAGATGCAACG-3'	[SEQ ID NO:12]
	5'-TGTTTCTGCACTTGCGTCCCAC-3'	[SEQ ID NO:13]
30	5'-CCGATCCTTGCAAGTGGAACAC-3'	[SEQ ID NO:14]

The initial amplification of all samples was done using 1 µL of first strand cDNA and primer set one (SEQ ID NO:11 and SEQ ID NO:12). Amplification of mung bean was performed using 30 cycles of 94°C for 30 seconds, 48°C for 30 seconds and 72°C for 2 minutes. Amplification of red clover was performed using 30 cycles of 94°C for 30 seconds, 50°C for 30 seconds and 72°C for 1 minute. Amplification of white clover, lentil, hairy vetch, alfalfa and lupine was carried out in two steps. The first amplification reaction was performed using 30 cycles of 94°C for 30 seconds, 50°C for 30 seconds and

72°C for one minute. A second amplification reaction was done with 1 µL of the resulting product and primer set two (SEQ ID NO:13 and SEQ ID NO:14) using 30 cycles of 94°C for 30 seconds, 50.5°C for 30 seconds and 72°C for one minute. Amplification of snow pea was performed in three different PCR reactions. The first reaction was performed using 30 cycles of 94°C 30 seconds, 50.5°C for 30 seconds and 72°C for one minute. One microliter from the resulting product was used for a second amplification reaction using primer set one and 30 cycles of 94°C for 30 seconds, 60°C for 30 seconds and 72°C for one minute. The resulting reaction was analyzed on a 1% agarose gel and the band at the expected size was gel purified using the QIAquick Gel Extraction Kit (Qiagen). The purified DNA was resuspended in 30 µL of water and 1 µL was used as a template for a third PCR reaction using primer set one with 30 cycles of 94°C for 30 seconds, 60°C for 30 seconds and 72°C for 90 seconds.

The resulting mung bean, red clover and snow pea PCR sequences were cloned into pCR2.1 using "The Original TA Cloning Kit" (Invitrogen). The resulting white clover, lentil, hairy vetch, alfalfa and lupine PCR sequences were cloned into pCR2.1 using TOPO™ TA Cloning Kit (Invitrogen). Plasmid DNA was purified using QIAfilter cartridges (Qiagen Inc) or Wizard Plus Minipreps DNA Purification System (Promega) following the manufacturer's instructions. Sequence was generated on an ABI Automatic sequencer using dye terminator technology and using a combination of vector and insert-specific primers. Sequence editing was performed using DNASTar (DNASTAR, Inc.). All sequences represent coverage at least two times in both directions.

The nucleotide sequence of comprising the cDNA insert in clone alfalfa 1 is shown in SEQ ID NO:15; the deduced amino acid sequence of this DNA is shown in SEQ ID NO:16. The nucleotide sequence comprising the cDNA insert in clone alfalfa 2 is shown in SEQ ID NO:57; the deduced amino acid sequence of this DNA is shown in SEQ ID NO:58. The nucleotide sequence comprising the cDNA insert in clone alfalfa 3 is shown in SEQ ID NO:59; the deduced amino acid sequence of this DNA is shown in SEQ ID NO:60. The nucleotide sequence comprising the cDNA insert in clone hairy vetch 1 is shown in SEQ ID NO:17; the deduced amino acid sequence of this DNA is shown in SEQ ID NO:18. The nucleotide sequence comprising the cDNA insert in clone lentil 1 is shown in SEQ ID NO:19; the deduced amino acid sequence of this DNA is shown in SEQ ID NO:20. The nucleotide sequence comprising the cDNA insert in clone lentil 2 is shown in SEQ ID NO:21; the deduced amino acid sequence of this DNA is shown in SEQ ID NO:22. The nucleotide sequence comprising the cDNA insert in clone mung bean 1 is shown in SEQ ID NO:23; the deduced amino acid sequence of this DNA is shown in SEQ ID NO:24. The nucleotide sequence comprising the cDNA insert in clone mung bean 2 is shown in SEQ ID NO:25; the deduced amino acid sequence of this DNA is shown in SEQ ID NO:26. The

nucleotide sequence comprising the cDNA insert in clone mung bean 3 is shown in SEQ ID NO:27; the deduced amino acid sequence of this DNA is shown in SEQ ID NO:28. The nucleotide sequence comprising the cDNA insert in clone mung bean 4 is shown in SEQ ID NO:29; the deduced amino acid sequence of this DNA is shown in SEQ ID NO:30. The  
5 nucleotide sequence comprising the cDNA insert in clone red clover 1 is shown in SEQ ID NO:31; the deduced amino acid sequence of this DNA is shown in SEQ ID NO:32. The nucleotide sequence comprising the cDNA insert in clone red clover 2 is shown in SEQ ID NO:33; the deduced amino acid sequence of this DNA is shown in SEQ ID NO:34. The  
10 nucleotide sequence comprising the cDNA insert in clone snow pea 1 is shown in SEQ ID NO:35; the deduced amino acid sequence of this DNA is shown in SEQ ID NO:36. The nucleotide sequence comprising the cDNA insert in clone white clover 1 is shown in SEQ ID NO:37; the deduced amino acid sequence of this DNA is shown in SEQ ID NO:38. The  
15 nucleotide sequence comprising the cDNA insert in clone white clover 2 is shown in SEQ ID NO:39; the deduced amino acid sequence of this DNA is shown in SEQ ID NO:40. The nucleotide sequence comprising the cDNA insert in clone lupine 1 is shown in SEQ ID NO:54; the deduced amino acid sequence of this DNA is shown in SEQ ID NO:55.

Plasmids corresponding to mung bean 2, red clover 2 and snow pea 1 were amplified and the plant-specific DNA (corresponding to SEQ ID NO:25, SEQ ID NO:33 and SEQ ID NO:35) were transferred to the yeast vector pRS315-gal following the gap repair method  
20 explained in Example 4 to produce the yeast expression strains isoflavone synthase VR2, isoflavone synthase TP2, and isoflavone synthase PS1, respectively. The eight amino acids at the amino- and carboxy-terminus correspond to those translated from the primers used in PCR amplification and not necessarily belong to the endogenous genes. Microsomes were  
25 isolated from the resulting yeast WHT1 strains containing the mung bean, red clover or snow pea genes, and assayed for isoflavone synthase activity as described in Example 5, with minor modifications. After incubation for 16 hours, 200  $\mu$ L of ethyl acetate was added to recover the isoflavonoids from the assay solution, the ethyl acetate was evaporated under  
30 nitrogen using a heating module evaporation system and the sample resuspended in 200  $\mu$ L of 80% methanol. A 10  $\mu$ L sample of this solution was injected into a Phenomenex Luna 3  $\mu$  C18 (2) column (size: 150 x 4.6 mm. The samples were eluted over 10 minutes using an  
35 increasing methanol gradient (from 20% methanol/80% 100 mM ammonium acetate buffer (pH 5.9) to 100% methanol (v/v)) at a flow rate of 1 mL per minute. The levels of genistein and naringenin in the eluted samples were monitored through the absorption spectrum at 260 and 290 nm. The genistein signal was verified by comparisons of retention time, diode array  
detected absorption spectra. As seen in Table 1, microsomes from all three strains produced genistein and therefore exhibited isoflavone synthase activity.

**TABLE 1**  
Genistein Synthesis Using *in vitro* Yeast Assay System

Yeast expression strain	Genistein Synthesized
Isoflavone Synthase VR2	1298 ng
Isoflavone Synthase TP2	59 ng
Isoflavone Synthase PS1	19 ng
pRS315-gal	Not detectable

### EXAMPLE 8

#### Amplification and Identification of

#### Isoflavone Synthase From Non-Legume Species

Isoflavonoids are most often found in the legumes, although there are occasional examples of isoflavonoids in non-legume plants (Dewick, P. M., *Isoflavonoids in The Flavonoids: Advances in Research* edited by J. B. Harborne and T. J. Mabry pp. 535-640).

To obtain isoflavone synthases with greater molecular diversity, isoflavone synthase genes from *Beta vulgaris* (sugarbeet) were cloned and their activity tested. Sugarbeet, a member of the family Chenopodiaceae, is one of the few non-legume species to have been shown to have isoflavonoids present (Geigert, et al. (1973) *Tetrahedron*. 29:2703-2706).

Sugarbeet seeds were germinated in a growth chamber as described in Example 7 (14 h light at 25°C and 10 h dark at 21°C) and harvested after two weeks. Total RNA was prepared using TRIzol Reagent (Gibco BRL) according to the manufacturer's instructions. First strand cDNA was prepared from 1 µg total RNA using the Superscript™ Preamplification System (Gibco BRL) following the manufacturer's instructions with OligodT as the reverse transcription primer.

Amplification was performed on a Perkin-Elmer Applied Biosystems GeneAmp PCR System 9700PCR using Advantage-GC cDNA polymerase mix (Clontech) according to the manufacturer's instructions and with a final concentration of GC melt reagent equal to 1 M. Amplification was preceded in all cases by incubation at 94°C for 5 minutes and was followed by incubation at 72°C for 7 minutes.

Amplification was carried out in two steps. The first amplification reaction was performed using 1 µL of first strand cDNA and primer set one (SEQ ID NO:11 and SEQ ID NO:12) with 30 cycles of 94°C for 30 seconds, 50°C for 30 seconds and 72°C for one minute. A second amplification reaction was done with 1 µL of the resulting product with primer set two (SEQ ID NO:13 and SEQ ID NO:14) and using 30 cycles of 94°C for 30 seconds, 50.5°C for 30 seconds and 72°C for one minute. The resulting PCR sequence was cloned into pCR2.1 using TOPO™ TA Cloning Kit (Invitrogen). Plasmid DNA was purified using QIAFilter cartridges (Qiagen Inc) or Wizard Plus Minipreps DNA Purification System (Promega) following the manufacturer's instructions. Sequence was generated on an

ABI Automatic sequencer using dye terminator technology and using a combination of vector and insert-specific primers. Sequence editing was performed using DNASTar (DNASTAR, Inc.). All sequences represent coverage at least two times in both directions. The nucleotide sequence comprising the cDNA insert in clone sugarbeet 1 is shown in SEQ ID NO:47; the deduced amino acid sequence of this DNA is shown in SEQ ID NO:48. The nucleotide sequence comprising the cDNA insert in clone sugarbeet 2 is shown in SEQ ID NO:61; the deduced amino acid sequence of this DNA is shown in SEQ ID NO:61.

The data in Table 2 summarizes the relationship of the isoflavone synthase nucleotide and amino acid sequences disclosed herein. Reported are the percent identity of the nucleotide sequences set forth in SEQ ID NOs:9, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 47 and 54 to instant soybean isoflavone synthase sequence set forth in SEQ ID NO:1. In addition, the percent identity of the amino acid sequences deduced from the instant nucleotide sequences as set forth in SEQ ID NOs:10, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 48 and 55 are compared to the amino acid sequence set forth in SEQ ID NO:2.

TABLE 2

Percent Identity of Nucleotide Coding Sequences and Amino Acid Sequences of Polypeptides Homologous to Isoflavone Synthase

SEQ ID NO.		Crop	length (nts)*	Percent Identity to SEQ ID NO:1/2	
nt	aa			nucleotides (nt)	amino acids (aa)
9	10	Soybean	1824	85.9	96.7
15	16	Alfalfa1	1501	99.5	99.0**
56	57	Alfalfa2	1501	92.2	96.2**
58	59	Alfalfa3	1501	92.3	96.6**
17	18	Hairy vetch	1501	92.3	96.2**
19	20	Lentil1	1501	97.9	98.8**
21	22	Lentil2	1501	92.3	96.4**
23	24	Mung bean1	1566	92.5	96.7
25	26	Mung bean2	1566	92.5	96.7
27	28	Mung bean3	1566	92.6	96.7
29	30	Mung bean4	1566	92.7	96.7
31	32	Red clover	1566	92.5	96.4
33	34	Red clover	1566	92.6	96.7
35	36	Snow pea	1563	99.3	99.0
37	38	White clover1	1496	99.3	98.4**
39	40	White clover2	1501	98.3	99.0**

SEQ ID NO.		Crop	length (nts)*	Percent Identity to SEQ ID NO:1/2	
nt	aa			nucleotides (nt)	amino acids (aa)
60	61	Sugarbeet1	1497	91.9	95.6**
47	48	Sugarbeet2	1501	92.3	96.6**
54	55	Lupine	1501	92.2	96.2**

\*SEQ ID NO:1 contains 1756 nucleotides.

\*\*These sequences are 22 amino acids shorter because the primers used for PCR were derived from the soybean sequence.

5

The data presented in Table 2 indicates that the nucleotide and amino acid sequences encoding the various isoflavone synthases are highly conserved among divergent species. Sequence alignments and percent identity calculations were performed using the Megalign program of the LASARGENE bioinformatics computing suite (DNASTAR Inc., Madison, WI). Multiple alignment of the sequences was performed using the Clustal method of alignment (Higgins and Sharp (1989) *CABIOS*. 5:151-153) with the default parameters (GAP PENALTY=10, GAP LENGTH PENALTY=10).

10

A consensus sequence was determined by aligning the amino acid sequences of the present invention using the Clustal method of alignment and this sequence is shown in SEQ ID NO:66. Amino acids not conserved are indicated by Xaa. These are:

15

Xaa <sub>10</sub>	Phe or Leu
Xaa <sub>16</sub>	Ser or Leu
Xaa <sub>23</sub>	Ser or Thr
Xaa <sub>25</sub>	Ile or Lys
Xaa <sub>39</sub>	Lys or Arg
Xaa <sub>48</sub>	Pro or Leu
Xaa <sub>60</sub>	Pro or Leu
Xaa <sub>73</sub>	Leu or His
Xaa <sub>74</sub>	Ser or Tyr
Xaa <sub>95</sub>	Ala or Thr
Xaa <sub>96</sub>	Asn or His
Xaa <sub>102</sub>	Asn or Ser
Xaa <sub>110</sub>	Ile, Val, or Thr
Xaa <sub>112</sub>	Arg or His
Xaa <sub>117</sub>	Asn or Ser
Xaa <sub>118</sub>	Ser or Leu
Xaa <sub>121</sub>	Met or Arg
Xaa <sub>122</sub>	Ala or Val

20

25

30

	Xaa <sub>124</sub>	Phe or Ile
	Xaa <sub>129</sub>	Lys or Arg
	Xaa <sub>147</sub>	Lys or Glu
	Xaa <sub>159</sub>	Leu or Phe
5	Xaa <sub>162</sub>	Ala or Val
	Xaa <sub>166</sub>	Ser or Gly
	Xaa <sub>170</sub>	Gln or Arg
	Xaa <sub>175</sub>	Val or Leu
	Xaa <sub>183</sub>	Ala or Thr
10	Xaa <sub>187</sub>	Thr or Ile
	Xaa <sub>191</sub>	Met or Val
	Xaa <sub>209</sub>	Phe or Tyr
	Xaa <sub>219</sub>	Arg or Trp
	Xaa <sub>223</sub>	Tyr or His
15	Xaa <sub>253</sub>	Gly or Glu
	Xaa <sub>259</sub>	Lys or Glu
	Xaa <sub>263</sub>	Val or Asp
	Xaa <sub>264</sub>	Val, Asp, or Ile
	Xaa <sub>268</sub>	Ala or Val
20	Xaa <sub>272</sub>	Phe or Leu
	Xaa <sub>285</sub>	Thr or Met
	Xaa <sub>293</sub>	Glu or Asp
	Xaa <sub>294</sub>	Thr, or Ile
	Xaa <sub>301</sub>	Phe or Leu
25	Xaa <sub>306</sub>	Thr or Ile
	Xaa <sub>311</sub>	Val or Glu
	Xaa <sub>312</sub>	Val or Ala
	Xaa <sub>325</sub>	Arg or Lys
	Xaa <sub>328</sub>	Gln or Glu
30	Xaa <sub>334</sub>	Val or Ala
	Xaa <sub>342</sub>	Arg or Ile
	Xaa <sub>377</sub>	Thr or Ile
	Xaa <sub>381</sub>	Glu or Gly
	Xaa <sub>385</sub>	Tyr, His, or Cys
35	Xaa <sub>387</sub>	Ile or Thr
	Xaa <sub>393</sub>	Val or Ile
	Xaa <sub>394</sub>	Leu or Pro



Xaa <sub>402</sub>	Arg or Lys
Xaa <sub>404</sub>	Ser or Pro
Xaa <sub>413</sub>	Ser or Phe
Xaa <sub>422</sub>	Glu or Gly
Xaa <sub>428</sub>	Gly or Arg
Xaa <sub>429</sub>	Pro or Leu
Xaa <sub>435</sub>	Gln or Arg
Xaa <sub>447</sub>	Arg or Gly
Xaa <sub>453</sub>	Asn, Ser, or Ile
Xaa <sub>459</sub>	Met or Thr, and
Xaa <sub>485</sub>	Asp or Gly

To verify that the similarity between the isoflavone synthase nucleotide sequences from soybean and from sugarbeet were not due to artifacts of PCR, a nucleic acid sequence containing the soybean isoflavone synthase set forth in SEQ ID NO:1 was used as a probe for Southern blot analysis against sugarbeet genomic DNA. Hybridization was done overnight at 65°C in 6X SSC, 5X Denhardt's. Filters were washed 2 times in 2X SSC, 1% SDS at room temperature and 2 times in 0.2X SSC, 0.5% SDS at 65°C. Hybridizing bands were detected indicating that sugarbeet does contain genes with high homology to the soybean isoflavone synthase sequence.

#### EXAMPLE 9

##### Preparation of Transgenic Tobacco with Chimeric Isoflavone Synthase Gene

The ability to obtain isoflavone synthase activity by expressing the gene from soybean clone sgs1c.pk006.o20 in other plants was tested by preparing transgenic tobacco plants expressing the isoflavone synthase gene and assaying for genistein production. The 1.6 Kb isoflavone synthase coding region from clone sgs1c.pk006.o20 (SEQ ID NO:1) was amplified using a standard PCR reaction in a GeneAmp PCR System with the primers shown in SEQ ID NO:41 and SEQ ID NO:42:

5'-TTGCTGGAACTTGCACTTGGT-3' [SEQ ID NO:41]

5'-GTATATGATGGGTACCTTAATTAAGAAAGGAG-3' [SEQ ID NO:42]

The resulting DNA sequence (IFS) contains from the second codon to the stop codon of the soybean isoflavone synthase gene sequence followed by a Kpn I site. The following three sequences (in 5' to 3' order) were assembled in pUC18 vector (New England Biolabs) to yield plasmid pOY160 (depicted in Figure 20):

- 35S/cabL, a promoter sequence comprising 1.3 Kb from the cauliflower mosaic virus (CaMV) 35S promoter extending to 8 bp downstream from the transcription

start site followed by a 60 bp leader sequence derived from the chlorophyll a/b binding protein gene 22L (Harpster M. H. et al. (1988) *Mol. Gen. Genet.* 212:182-190);

- IFS, the isoflavone synthase gene fragment generated by PCR amplification using the primers from SEQ ID NO:41 and SEQ ID NO:42.
- Nos3'; an 800 bp fragment which contains the polyadenylation signal sequence from the nopaline synthase gene (Depicker A. et al. (1982) *J. Mol. Appl. Genet.* 1:561-573).

The 5' end of IFS was ligated to Nco I-digested, filled-in, 35S/cabL. The 3' end of IFS was digested with Kpn I and ligated to Kpn I-digested Nos3'.

The following three fragments were ligated to create plasmid pOY204:

- 1) The Hind III/Pst I fragment comprising the 35S/cabL-5'IFS from pOY160,
- 2) The Pst I/Sal I fragment comprising the 3'IFS-Nos3' from pOY160,
- 3) The Hind III/Sal I fragment from vector pPZP211.

The vector pPZP211 contains an npt II gene fragment under the control of the 35S CaMV promoter conferring kanamycin resistance as the plant selectable marker (Hajdukiewicz P. et al. (1994) *Plant Mol. Biol.* 25:989-994).

The plasmid pOY204 was transformed into the *Agrobacterium tumefaciens* strain LBA4404 and was subsequently introduced into *Nicotiana tabacum* by leaf disc co-cultivation following standard procedures (De Blaere et al. 1987 *Meth. Enzymol.* 143:277). The leaf discs were incubated for three weeks on selection medium (MS salts with vitamins (Gibco BRL), 1 mg/L 6-benzylaminopurine (BA), 100 mg/L kanamycin, and 500 mg/L Claforan). The regenerating plants were transferred to rooting medium (selection medium without BA) for another two weeks. Transformed plants were identified by the appearance of roots in this selection media. Following standard protocols, DNA samples were prepared from six randomly-selected shoots and used as templates for PCR using the primers from SEQ ID NO:41 and SEQ ID NO:42. Verification of the presence of the isoflavone synthase coding region in the genome of the tested tobacco shoots was done by separating the reaction product using a 1% agarose gel and staining with ethidium bromide. The expected 1.6 Kb fragment was obtained as the reaction product in all the transgenic tobacco shoots and not in the untransformed tobacco controls.

#### *Transcription of Soybean Isoflavone Synthase in Transgenic Tobacco Shoots*

Transcription of the isoflavone synthase gene in the transgenic tobacco shoots was confirmed using RT-PCR. Total steady-state plant RNA was extracted from four randomly-selected tobacco shoots resulting from transformation with pOY204 using the RNeasy Plant Mini Kit (Qiagen) following standard protocols. RT-PCR amplification was performed using "The SuperScript One Step RT-PCR Kit" (Gibco BRL) with the primers:

5'-GACGCCTCACTTACGACAACTCTGTG-3'

[SEQ ID NO:43]

5'-CCTCTCGGGACGGAATTCTGATGGT-3'

[SEQ ID NO:44]

5 After incubation at 50°C for 45 minutes, amplification was carried out using 37 cycles of 93°C for 30 seconds, 64°C for 30 seconds and 72°C for 1 minute. The resulting DNA was separated on a 1% agarose gel. Samples from the putative isoflavone synthase-containing tobacco showed an 840 bp band not seen in the sample from the untransformed tobacco control.

#### 10 EXAMPLE 10

##### Expression of Soybean Isoflavone Synthase in Transgenic Tobacco

###### *Activity of Soybean Isoflavone Synthase in Tobacco Shoots*

The activity of the soybean isoflavone synthase in the transgenic tobacco was determined by analyzing shoots for the presence of genistein. Approximately one gram of  
15 tissue from shoots of five-week-old rooting transformants and from untransformed tobacco plants were ground in liquid nitrogen and extracted for 20 minutes at room temperature using 10 mL of 80% ethanol. After filtration through Acrodisc CR-PTFE syringe filters (Gelman Sciences), 3 mL from each extraction solution were concentrated to 1 mL by evaporation under nitrogen gas flow using a 50°C heating block. To hydrolyze any malonyl or  
20 glucosyl-derivatized compounds present, 3 mL of 1 N HCl were added and the samples incubated at 95°C for 2 h followed by extraction using 1 mL ethyl acetate. Five hundred µL of the ethyl acetate phase were dried under nitrogen and resuspended in 20 µL chloroform. The presence of genistein in the samples was determined by gas chromatography/mass spectroscopy (GC/MS) analysis.

25 Before injection into a Hewlett Packard 6890 gas chromatograph, the hydroxyl groups in the samples were derivatized to trimethylsilylate by the addition of 100 µL of BSTFA (N, O-bis(trimethylsilyl)-trifluoroacetamide; Supelco) and incubation at 37°C for 1 h. The samples were dried under nitrogen gas and re-dissolved in 20 µL chloroform immediately before manual injection into the gas chromatograph. Two µL of sample were manually  
30 injected onto a 15 meter dry bed GC capillary column (J&W, Jones Chromatography, Mid Glamorgan, UK) through an injector port operated in the split mode (5:1). The initial oven temperature was set at 200°C and the column was set at a linear temperature gradient from 200°C to 300°C in 20 minutes with a helium gas flow rate of 1.5 mL/minute. The mass spectrum was monitored using a Hewlett Packard 5973 mass-selective detector at an  
35 ionization potential of 70 eV. The mass ions identified from the cracking pattern of pure genistein treated as mentioned above are 414 and 399 m/z. These peaks represent the products of partially derivatized genistein, the form obtained following the above procedure. Twenty nine of thirty three tobacco transformants analyzed by gas chromatography had an

identifiable genistein peak at 8.7 minutes. The presence of genistein in these peaks was confirmed by the detection of peaks at 414 and 399 m/z in the mass spectra. These results confirmed that the soybean isoflavone synthase coding region is expressed in tobacco plants under control of the 35S CaMV promoter and causes novel production of genistein in tobacco shoot tissue.

#### *Presence of Genistein in Tobacco Flowers*

Flowers from the tobacco transformants were assayed for the presence of genistein. Extracts were prepared as described above, except that after hydrolysis, the dried ethyl acetate extracts were resuspended in 1 mL of 80% methanol. The HPLC protocol was the same as in Example 2 using a Phenomenex Luna 3u C18 (2) column (150 X 4.6 mm). As compared to extracts from wild type plants, the transformant flowers contained two additional large peaks in the HPLC profile. One of these peaks was identified as genistein while the other is unknown. Detection of the large genistein peak in the HPLC profile of the tobacco flower extracts indicated that there was a much higher amount of genistein present in the tobacco flowers than in the tobacco shoots, since the genistein in the shoot samples was only detectable by GC/MS. The prevalence of genistein in the flowers relates to the expression of the anthocyanin biosynthetic pathway, which is active in the flowers as indicated by the pink flower color. An active anthocyanin pathway produces the naringenin substrate for isoflavone synthase.

#### EXAMPLE 11

##### Expression of Soybean Isoflavone Synthase in Transgenic *Arabidopsis*

*Arabidopsis thaliana* was transformed with the plasmid pOY204 via *in planta* vacuum infiltration following standard protocols (Bechtold et al. (1993) *CR Life Sciences* 316:1194-1199). Briefly, three-week-old *Arabidopsis thaliana* ecotype WS plants were submerged in 500 mL of *Agrobacterium*, strain GV3101 harboring pOY204, suspended in basic MS media (Gibco BRL) and vacuum was applied repeatedly for 10 minutes. The infiltrated plants were allowed to set seeds for another three weeks. The harvested seeds were surface-sterilized, then germinated and grown for three weeks on plates containing 75 mg/L kanamycin. Approximately 120 green healthy plants were recovered in the first round of screening and were transferred to soil for two more weeks. The plants at this stage had green immature pods and few leaves. Extracts were prepared and analyzed by HPLC and GC/MS as described in Example 2, except that after hydrolysis, the dried ethyl acetate extracts were resuspended in 1 mL of 80% methanol. Five of twelve randomly-selected *Arabidopsis* transformants analyzed by HPLC had an identifiable genistein peak at 8.7 minutes. GC MS analysis confirmed the presence of genistein in these peaks by detection of the characteristic peaks at 414 and 399 m/z in the mass spectra. These results

show that the soybean isoflavone synthase gene is functional in the *Arabidopsis* plants and genistein is produced.

### EXAMPLE 12

#### Enhancing Isoflavonoid Levels in Transgenic *Arabidopsis*

5 To determine whether activation of the phenylpropanoid pathway results in increased accumulation of isoflavonoids in IFS-transformed *Arabidopsis*, the pathway was activated by UV light treatments. Homozygous *Arabidopsis* transformants of line A109-4, which synthesize genistein, were identified through germination on kanamycin-containing medium by first selecting a transformant that segregated kanamycin resistance in a 3:1 ratio. A  
10 resistant progeny from this generation that then produced 100% resistant progeny was identified as a homozygote. Plants from this population and wild type *Arabidopsis* plants were transferred to 2-inch pots 10 days after germination and grown for 10 more days. Plants were placed directly under 366 nm UV light for 16 h (46 mWatt/cm<sup>2</sup>, using an UVL-56 BLAK-Ray Lamp from UV Products, Inc., San Gabriel, CA). Control plants were  
15 placed under the same described environment except for the UV illumination. The above ground parts of *Arabidopsis* plants were pulverized in liquid nitrogen to fine powder immediately after UV treatment. The tissues were extracted with 10 mL 80% methanol per 1 gram of fresh weight. The genistein content from tissue extracts of UV-treated and untreated plants was determined by HPLC using a Phenomenex Luna 3u (2) column (150 X  
20 4.6 mm) and a mobil phase linear gradient which goes in 15 minutes from 20% methanol, 80% 10 mM ammonium acetate, pH 8.3 to 100% methanol followed by 100% methanol for 5 minutes as described in Example 2. Aliquots from the same extracts were also assayed for anthocyanin accumulation using photospectrometry as described by Bariola, P. A., et. al. ((1999) *Plant Physiol.* 119:331-342). Briefly, one mL of extract was mixed with one mL of  
25 0.5% (v/v) HCl followed by the addition of two mL of chloroform and vortexing for ten seconds. The mixture was allowed to separate to two phases at room temperature. The absorbance of the aqueous phase was assayed at 530 nm and 657 nm. The anthocyanin content was calculated by subtracting the absorbance value at 657 from the absorbance value at 530 and normalizing to fresh weight. As seen in Table 3, the anthocyanin content and  
30 genistein level in IFS-transformed *Arabidopsis* varies with UV treatment (The average and standard deviations of four independent plants from each group are shown).

**TABLE 3**  
**Anthocyanin Content and Genistein Levels in**  
**Transgenic *Arabidopsis* Plants**

Sample	Anthocyanin (A530-A657)		Genistein (by HPLC) (mAu / 25uL)	
	Control	UV	Control	UV
Control Plants (no IFS gene)	0.0463 ± 0.0148	0.0591 ± 0.0202	0	0
A109-4 (35S-IFS)	0.0339 ± 0.0100	0.0368 ± 0.0116	121 ± 41	303 ± 58

5 Anthocyanins are products of one branch of the phenylpropanoid pathway, and the level of their accumulation is an indication of the activity of this pathway. As seen in the table above, genistein was not detectable and the anthocyanin levels increased by about 28% after UV treatment in the control plants. In plants expressing IFS the anthocyanin levels were not significantly increased while the genistein levels more than doubled. A duplication of this experiment also showed an increase in genistein level (anthocyanin levels without UV treatment: 0.1426 +/- 0.0245; and with UV treatment: 0.1463 +/- 0.0145 (units as described above); genistein without UV treatment: 602 +/- 94; and with UV treatment: 857 +/- 46 (units as described above)). In this case the level of anthocyanins in non-treated plants was much higher, probably due to insect infestation. The level of genistein was higher in non-treated plants and the increase with UV treatment was not as large as in the first experiment. These results demonstrate that activation of the phenylpropanoid pathway, in this case by stress treatment (UV or insect infestation), results in an increased level of genistein accumulation in transformants expressing isoflavone synthase.

#### EXAMPLE 13

##### Expression of Soybean Isoflavone Synthase in Monocot Cells

20 The ability to obtain isoflavone synthase activity in monocot cells was tested by transforming the soybean gene from clone sgs1c.pk006.o20 into corn suspension cells and assaying for genistein production. The soybean isoflavone synthase gene was cloned in a vector for expression in monocot cells and its activity determined by the expression of genistein in corn. A chimeric isoflavone synthase gene plasmid was prepared (pOY206) using the pGEM9Zf cloning vector (Promega) for expression of the instant isoflavone synthase in monocots. The following fragments were inserted between two copies of the 3 Kb SAR fragment (the A element, originally located between 8.7 and 11.7 kb upstream of the chicken lysozyme gene coding region (Loc P. V. and Stratling W. H. (1988) *EMBO J.* 7:655-664):

1. the 35S/cabL promoter fragment from Example 9,

2. a 490 bp fragment containing the sixth intron from the maize *Adh1* gene (Mascarenhas, D. et al. (1990) *Plant Mol. Biol.* 15:913-920) and ending with an Nco I site,
3. IFS, the isoflavone synthase fragment from Example 9,
4. a 285 bp fragment containing the polyadenylation signal sequence from the nopaline synthase gene (Depicker A. et al. (1982) *J. Mol. Appl. Genet.* 1:561-573).

#### *Gene Combinations used for Corn Cell Transformation*

The plasmid pOY206 (Figure 21) containing the chimeric isoflavone synthase gene for expression in monocots was transformed into corn cells in conjunction with plasmid pDETRIC. Plasmid pDETRIC contains the *bar* gene from *Streptomyces hygroscopicus* that confers resistance to the herbicide glufosinate (Thompson et al. (1987) *EMBO J.* 6:2519). In the pDETRIC plasmid the *bar* gene is under the control of the CaMV 35S promoter, its translation-initiation codon has been changed from GTG to ATG for proper translation initiation in plants (De Block et al. (1987) *EMBO J.* 6:2513), and uses the *Agrobacterium tumefaciens* octopine synthase polyadenylation signal.

Since the phenylpropanoid pathway is not active in corn suspension cells a third plasmid containing a gene encoding a transcription factor that activates the phenylpropanoid pathway was, in some cases, bombarded into the corn cells in conjunction with isoflavone synthase gene. This plasmid, pDP7951 (depicted in Figure 22 and bearing ATCC accession number PTA-371), contains in the 5'-3' orientation:

- the *Agrobacterium* nopaline synthase gene promoter region,
- a tobacco mosaic virus (TMV) omega enhancer sequence,
- the fifth intron from the maize *adh1* gene,
- CRC (a chimera containing the maize R region between the region encoding the C1 DNA binding domain and the C1 activation domain),
- the potato protease inhibitor II polyadenylation signal sequence.

Additionally, a chimeric gene consisting of the CRC coding region expressed from the CaMV 35S promoter was prepared and used in corn cell transformations. The Sma I fragment of DP7951 containing CRC was ligated to Nco I and Kpn I ends that had been blunt ended with Mung bean nuclease (New England Biolabs) to create the chimeric gene: 35S/cabL-IFS-Nos3'. This plasmid is called pOY162, and its restriction enzyme map is shown in Figure 23.

#### *Transformation of monocot cells*

Black Mexican Sweet (BMS) suspension culture is a commonly used, corn-derived, monocot cell line. Cultures were maintained in MS2D medium (MS salts with vitamins (Gibco BRL), 20 g/L sucrose, 2 mg/L 2,4-dichlorophenoxyacetic acid, pH 5.8), incubated

with shaking (125 rpm) at 26°C in the dark, and subcultured with fresh medium every five days.

Transformations were performed by microprojectile bombardment using a DuPont Biolistic PDS 1000/He system (Klein T. M. et al. (1987) *Nature* 327:70-73). Gold particles (0.6 microns) were coated with mixtures of plasmid DNAs as indicated in Table 4:

TABLE 4

Plasmid Groups used in Maize Transformations

Group	Plasmids
1	3 µg pDETRIC + 6 µg pOY206
2	3 µg pDETRIC + 6 µg pOY206 + 6 µg pDP7951
3	3 µg pDETRIC + 6 µg pDP7951
4	3 µg pDETRIC + 6 µg pOY206 + 6 µg pOY162

Two days after subculture, BMS suspension culture aliquots (6 mL each), were evenly distributed over Whatman#1 filter disks, transferred onto solid MS2D medium (MS2D, 7 g/L agar) and incubated at 26°C overnight. Filter disks containing the BMS cells were positioned approximately 3.5 inches away from the retaining screen and bombarded twice. Membrane rupture pressure was set at 1,100 psi and the chamber was evacuated to -28 inches of mercury. Bombarded tissues were incubated for four days at 26°C in the dark and then transferred to MS2D selection medium (solid MS2D medium containing 3 mg/L Bialaphos). Resistant tissue was transferred to fresh MS2D selection medium after seven weeks and tissue was harvested for analysis two weeks later.

*Analysis of transformed corn cells for synthesis of anthocyanins and genistein*

All control tissue and BMS lines transformed with group 1 were white in color. Approximately half of the Bialaphos-selected resistant tissue that grew in plates bombarded with groups containing CRC (groups 2 and 3) showed the wild type white color, while the other half showed various degrees of red coloration, a visual indication of anthocyanin accumulation. The red phenotype indicates that expression of CRC in these lines is sufficient to transcriptionally activate the expression of genes in the phenylpropanoid pathway leading to anthocyanin synthesis and accumulation (Grotewold E. et al. (1998) *Plant Cell* 10:721-740). Presence of the isoflavone synthase gene in these tissues was confirmed by the appearance of the appropriate sized fragments when performing PCR on genomic DNA using primers from SEQ ID NO:43 and SEQ ID NO:44. The presence of the CRC coding region in these tissues was verified by the production of an appropriate fragment when performing PCR on genomic DNA using the primers from SEQ ID NO:45 (to the R region) and SEQ ID NO:46 (to the 3' untranslated region from potato protease inhibitor II gene).



5'-GCGGTGCACGGGCGGACTCTTCTTC-3'

[SEQ ID NO:45]

5'-CGCCCAATACGCAAACCGCCTCTCC-3'

[SEQ ID NO:46]

5

Tissue from 25 lines transformed with Group 1, 5 white lines resulting from transformation with Group 2, 7 red lines transformed with Group 2, 6 white lines transformed with Group 3, and 6 red lines transformed with Group 3 was harvested and analyzed for the presence of genistein using HPLC and GC-MS. Extracts were prepared and analyzed as described in Example 2. The genistein HPLC peak and the identifying 414 and 399 *m/z* MS peaks were detected in the extracts from all seven red lines transformed with Group 2 while no genistein was detected in any of the white lines transformed with the same plasmids. Lines transformed with Group 3 did not have genistein whether they were red or white. Sixteen lines transformed with Group 4 also produced genistein. A summary of these results is shown in Table 5.

15

TABLE 5

## Genistein Synthesis in Transformed BMS Tissue

Group	No.	Tissue Color	Naringenin Produced	Genistein Produced
1	25	White	NO	NO
2	5	White	NO	NO
2	7	Red	YES	YES
3	6	White	NO	NO
3	6	Red	YES	NO
4	16	Red	YES	YES

20

The synthesis of genistein in BMS lines transformed with a soybean isoflavone synthase-containing construct indicated that the soybean protein was expressed and was functional in monocot cells. Genistein was only produced in cell lines producing naringenin indicating that the soybean isoflavone synthase gene was only effective in the presence of an activated phenylpropanoid pathway. The intermediate naringenin in the phenylpropanoid pathway provided the substrate for isoflavone synthase to produce genistein.

25

EXAMPLE 14Synthesis of Daidzein in Monocot Cells

The activity of chalcone reductase determines the relative levels of substrates available for isoflavone synthase to produce genistein or daidzein (see Figure 1). Chalcone reductase reduces 4,2',4',6'-tetrahydroxychalcone to 4,2',4'-trihydroxychalcone, thus producing liquiritigenin as the substrate for isoflavone synthase to produce daidzein. Chalcone reductases are present in legumes, but have not been found in most non-legume plants

30

including *Arabidopsis*, tobacco, and corn. To produce daidzein in non-legume plants, a plasmid DNA containing a soybean chalcone reductase gene was introduced into corn suspension cells by microprojectile bombardment, together with a selection marker, CRC, and IFS constructs as described in Example 13.

5 A soybean cDNA clone encoding chalcone reductase was identified by homology to known chalcone reductase genes of alfalfa (Ballance and Dixon (1995) *Plant Phys.* 107:1027-1028). The cDNA library was prepared using mRNAs from eight-day-old soybean roots inoculated with cyst Nematode for four days, and sequenced as described in Example 3. BLAST analysis was performed as described in Example 4. The DNA  
10 containing the entire coding region from the identified clone, src3c.pk009.e4, was amplified using PCR with the primers shown in SEQ ID NO:62 and SEQ ID NO:63

5'-GTTACCATGGCTGCTGCTATTG-3' [SEQ ID NO:62]

15 5'-TTAAACGTAAAATGAAACAAGAGG-3' [SEQ ID NO:63]

The 5' primer had an Nco I site at the start of the coding region. The 1.3 kb PCR product was subcloned into the pTOPO2.1 vector (Invitrogen Inc., Carlsbad, CA). The 1.3 kb coding region fragment was excised as a Nco I/Kpn I fragment, using the Nco I site  
20 and the Kpn I site from the vector. This fragment was isolated and ligated between the 35S/CabL promoter and Nos 3' polyadenylation signal sequence in the pUC18 vector as described in Example 9, to produce plasmid pCHR40, which was used in the BMS transformation experiments.

Transformation of corn suspension cells was done as described in Example 13, using  
25 pDETRIC, pCHR40, pOY206 and pOY162. Selection and culturing were as described in Example 13. Each selected line was assayed for the presence of the IFS and CRC genes using PCR as in Example 13. The presence of the CHR gene was determined by the appearance of a 0.6 kb fragment when performing PCR on the tissues using the primers shown in SEQ ID NO:64 and SEQ ID NO:65:  
30

5'-GACACTTCGACACTGCTGCTGCTTAT-3' [SEQ ID NO:64]

5'-TCTCAAACCTCACCTGGGCTATGGAT-3' [SEQ ID NO:65]

35 Of 32 lines screened, five carried all three transgenes. Extracts were prepared, as described in Example 13, from these 32 lines and a control line that carries the CRC and IFS genes, but not the CHR gene. All of the extracts were treated with 1 N HCl to hydrolyze all possible oligosaccharide derivatives as described in Example 10. HPLC and GC-MS were performed as described in Examples 2 and 10. One out of the five lines was shown to

produce daidzein. In the HPLC assay, in addition to the peaks of naringenin and genistein, a small peak occurred at the same retention time as the daidzein standard (9.6 min) (Figure 27C and D). This peak was not present in the control samples (Figure 27A and B). In the GC-MS assay, the daidzein-specific cracking pattern was found at the same retention time as the standard (8.0 min). All of the major ions of the daidzein spectrum were present (m/z: 398, 383, 218, 97). This example shows that introduction of the soybean chalcone reductase gene into corn cells together with the isoflavone synthase and CRC genes results in the production of both daidzein and genistein.

#### EXAMPLE 15

##### Alteration of Isoflavonoid Levels in Soybean Somatic Embryos

The ability to change the levels of isoflavonoids by overexpressing the gene from soybean clone sgs1c.pk006.o20 in soybean somatic embryos was tested by preparing transgenic soybean somatic embryos and assaying the isoflavonoid levels. The entire insert from clone sgs1c.pk006.o20 (SEQ ID NO:1) was amplified in a standard PCR reaction on a Perkin Elmer Applied Biosystems GeneAmp PCR System using Pfu polymerase (Stratagene) with the primers shown in SEQ ID NO:49 and SEQ ID NO:50:

5'-GAATTCGCGGCCGCTCTAGAACTAGTGGAT-3' [SEQ ID NO:49]

5'-GAATTCGCGGCCGCGAATTGGGTACCGGGC-3' [SEQ ID NO:50]

The resulting fragment is bound by Not I sites in the primer sequences and contains a 5' leader sequence, the coding region for isoflavone synthase, the untranslated 3' region from SEQ ID NO:1, and a stretch of 18 A residues at the 3' end. This fragment was digested with Not I and ligated to Not I-digested and phosphatase-treated pKS67. The plasmid pKS67 was prepared by replacing in pRB20 (described in U.S. 5,846,784) the 800 bp Nos 3' fragment, described in Example 9, with the 285 bp Nos 3' fragment, described in Example 12. Clones were screened for the sense orientation of the isoflavone synthase insert fragment by digestion with Bam HI. The resulting plasmid pKS93s, shown in Figure 24, has the beta-conglycinin promoter operably linked to the fragment encoding isoflavone synthase followed by the Nos 3' end. Plasmid pKS93s contains a T7 promoter/HPT/T7 terminator cassette for expression of the HPT enzyme in certain strains of *E. coli*, such as NovaBlue (DE3) (from Novagen), that are lysogenic for lambda DE3 (which carries the T7 RNA Polymerase gene under lacV5 control). Plasmid pK93s also contains the 35S/HPT/NOS 3' cassette for constitutive expression of the HPT enzyme in plants. These two expression systems allow selection for growth in the presence of hygromycin to be used as a means of identifying cells that contain plasmid DNA sequences in both bacterial and plant systems.

*Transformation of Soybean Somatic Embryo Cultures*

The following stock solutions and media were used for transformation and propagation of soybean somatic embryos:

Stock Solutions		Media	
<u>MS Sulfate 100x stock</u>		<u>SB55 (per Liter)</u>	
	(g/L)		
MgSO <sub>4</sub> .7H <sub>2</sub> O	37.0	10 mL of each MS stock	
MnSO <sub>4</sub> .H <sub>2</sub> O	1.69	1 mL of B5 Vitamin stock	
ZnSO <sub>4</sub> .7H <sub>2</sub> O	0.86	0.8 g NH <sub>4</sub> NO <sub>3</sub>	
CuSO <sub>4</sub> .5H <sub>2</sub> O	0.0025	3.033 g KNO <sub>3</sub>	
		1 mL 2,4-D (10 mg/mL stock)	
		0.667 g asparagine	
		pH 5.7	
<u>MS Halides 100x stock</u>		<u>SB103 (per Liter)</u>	
CaCl <sub>2</sub> .2H <sub>2</sub> O	44.0		
KI	0.083	1 pk. Murashige & Skoog salt mixture*	
CoCl <sub>2</sub> .6H <sub>2</sub> O	0.00125	60 g maltose	
KH <sub>2</sub> PO <sub>4</sub>	17.0	2 g gelrite	
H <sub>3</sub> BO <sub>3</sub>	0.62	pH 5.7	
Na <sub>2</sub> MoO <sub>4</sub> .2H <sub>2</sub> O	0.025		
Na <sub>2</sub> EDTA	3.724		
FeSO <sub>4</sub> .7H <sub>2</sub> O	2.784		
Stock Solutions		Media	
<u>B5 Vitamin stock</u>		<u>SB148 (per Liter)</u>	
<i>myo</i> -inositol	100.0	1 pk. Murashige & Skoog salt mixture*	
nicotinic acid	1.0	60 g maltose	
pyridoxine HCl	1.0	1 mL B5 vitamin stock	
thiamine	10.0	7 g agarose	
		pH 5.7	
		*(Gibco BRL)	

Soybean embryonic suspension cultures were maintained in 35 mL liquid media (SB55) on a rotary shaker (150 rpm) at 28°C with a mix of fluorescent and incandescent lights providing a 16 h day 8 h night cycle. Cultures were subcultured every 2 to 3 weeks by inoculating approximately 35 mg of tissue into 35 mL of fresh liquid media.

Soybean embryonic suspension cultures were transformed with pKS93s by the method of particle gun bombardment (see Klein et al. (1987) *Nature* 327:70-73) using a DuPont Biolistic PDS1000/He instrument. Five µL of pKS93s plasmid DNA (1 g/L), 50 µL CaCl<sub>2</sub> (2.5 M), and 20 µL spermidine (0.1 M) were added to 50 µL of a 60 mg/mL 1 mm gold

particle suspension. The particle preparation was agitated for 3 minutes, spun in a microfuge for 10 seconds and the supernate removed. The DNA-coated particles were then washed once with 400  $\mu$ L of 70% ethanol and resuspended in 40  $\mu$ L of anhydrous ethanol. The DNA/particle suspension was sonicated three times for 1 second each. Five  $\mu$ L of the DNA-coated gold particles were then loaded on each macro carrier disk.

Approximately 300 to 400 mg of two-week-old suspension culture was placed in an empty 60 mm X 15 mm petri dish and the residual liquid removed from the tissue using a pipette. The tissue was placed about 3.5 inches away from the retaining screen and bombarded twice. Membrane rupture pressure was set at 1100 psi and the chamber was evacuated to -28 inches of Hg. Two plates were bombarded, and following bombardment, the tissue was divided in half, placed back into liquid media, and cultured as described above.

Fifteen days after bombardment, the liquid media was exchanged with fresh SB55 containing 50 mg/mL hygromycin. The selective media was refreshed weekly. Six weeks after bombardment, green, transformed tissue was isolated and inoculated into flasks to generate new transformed embryonic suspension cultures.

Transformed embryonic clusters were removed from liquid culture media and placed on a solid agar media, SB103, containing 0.5% charcoal to begin maturation. After 1 week, embryos were transferred to SB103 media minus charcoal. After 5 weeks on SB103 media, maturing embryos were separated and placed onto SB148 media. During maturation embryos were kept at 26°C with a mix of fluorescent and incandescent lights providing a 16 h day 8 h night cycle. After 3 weeks on SB148 media, embryos were analyzed for the expression of the isoflavonoids. Each embryonic cluster gave rise to 5 to 20 somatic embryos.

Non-transformed somatic embryos were cultured by the same method as used for the transformed somatic embryos.

#### *Analysis of Transformed Somatic Embryos*

At the end of the 8<sup>th</sup> week on SB103 medium somatic embryos were harvested from 12 independently transformed lines. Somatic embryos were collected individually and stored in 96-well plates at -80° until lyophilized. Somatic embryos were lyophilized for 24 hours. Three to five lyophilized somatic embryos were pooled in a micro centrifuge tube and the dry weight was measured three times. Three samples of dried embryos were assayed for each transformed line. An 80% methanol solution was added to the lyophilized somatic embryos and the samples incubated for 24 h in the dark at room temperature to extract isoflavonoids. The 80% methanol solution was filtered through a Costar nylon membrane microcentrifuge filter with 0.22  $\mu$ m pore size (Sigma).

For HPLC analysis of the extracts, twenty  $\mu$ l of the 80% methanol sample was applied to a Phenomenex Luna 3 $\mu$  C18 (2) column (size: 150 x 4.6 mm). Separation occurred during the gradient elution of 10 mM ammonium buffer, pH 8.35 (solvent A) and methanol (solvent B) as the mobile phase. Continuous increasing of solvent B in solvent A, from 20 to 100% for 10 min was employed. Standards for the isoflavonoids daidzin, daidzein, glycitin, glycitein, genistin, genistein, liquiritigenin and naringenin were prepared by the gradual addition of 80% methanol to each powder. The peaks and spectra corresponding to daidzein, glycitin and genistein conjugated with malonylated glucosides were determined by LC/MS. Isoflavonoids were monitored through the absorption spectra at 260 and 280 nm. The isoflavonoid signals observed in the soybean somatic embryo samples were verified by comparisons of the retention times and diode array detected absorption spectra with those of the standards. The areas of all peaks corresponding to the isoflavones in a sample were added and divided by the dry weight of that sample. These dry weight based normalized area sums were used for statistical analysis.

An analysis of variance test (ANOVA; Steel, R. G. D. and Torrie, J. H. (1996) *Principles and Procedures of Statistics : A Biometrical Approach* (McGraw-Hill Series in Probability and Statistics, New York) was conducted using Microsoft Excel 97 (Microsoft). Data were analyzed as a single factor design with single gene transformation as the main effect. Experimental units were the sum of peak areas of identified isoflavonoids normalized to dry weight. The mean square from the ANOVA was used to calculate the least significant difference (LSD) for each comparison. The sum of isoflavonoid peak areas of samples from a non-transformed control line were compared with those of 25 independent pKS93s-transformed, hygromycin resistant lines. Figure 25 shows a graph depicting the distribution of the sum of isoflavone area per mg of dry weight of soybean somatic embryos transgenic for the isoflavone synthase gene and a control line. The results are depicted in the graph in ascending order of the amount of total isoflavones produced. Some lines, such as the ones represented in bars 7 through 14, contained approximately the same levels of isoflavones as the control line. While most of the lines showed intermediate increases or decreases in the amounts of isoflavones produced, there are clear examples of lines having markedly increased or decreased amounts of isoflavones. For example, bar 25 represents a line which expresses 208% as much isoflavones as the control line, bar 24 represents a line which expresses 184% as much isoflavones as the control line, and bar 1 represents a line which produces only 25% of the isoflavones as the control line. These differences in the amounts of isoflavones produced may be caused by the position of the transgene in the chromosome, the number of copies of the gene that are integrated in the chromosome, DNA methylation, gene silencing, etc. These results indicate that transgenic expression of isoflavone synthase affords the ability to manipulate isoflavonoid levels as desired for a particular application;

i.e., transformants may be chosen for advancement that have large changes in isoflavonoid levels (i.e., very high as in IS19 or very low as in IS6) or more subtle changes in the content of isoflavonoids.

#### EXAMPLE 16

##### Amplification and Analysis of Soybean Genomic Isoflavone Synthase DNA

Genomic sequences encoding isoflavone synthase may be used to express isoflavone synthase as well as the cDNA sequences. Therefore the genomic sequences containing the coding regions for the soybean isoflavone synthase genes were isolated.

Soybean genomic DNA was prepared from *Glycine max* cv. Wye following standard protocols (DNeasy Plant Maxi Kit, Qiagen, Valencia, CA). Using this DNA as template, a genomic DNA fragment including the sequence corresponding to the soybean insert in sgs1c.pk006.o20 was produced by PCR with the primers listed as SEQ ID NO:41 and SEQ ID NO:42. A genomic DNA fragment including the sequence of CYP93C1 was produced with the primers listed as SEQ ID NO:7 and SEQ ID NO:51:

5'-AAAATTAGCCTCACAAAAGCAAAG-3' [SEQ ID NO:7]

5'-GCAAACGAAGACAAATGGGAGATGATA-3' [SEQ ID NO:51]

Amplification was performed on a Perkin Elmer Applied Biosystems GeneAmp PCR System using the Expand™ Hi fidelity PCR system from Boehringer Mannheim (Indianapolis, Indiana). These PCR fragments were cloned into the pCR2.1 vector (Invitrogen) and sequenced as described in Example 6. The nucleotide sequence of the genomic fragment comprising the isoflavone synthase sequence from clone sgs1c.pk006.o20 is given in SEQ ID NO:52. The nucleotide sequence of the genomic fragment comprising the isoflavone synthase sequence of CYP93C1 is given in SEQ ID NO:53. Both genes were found to contain one intron. The splice junction for both introns is within the codon for amino acid 300. The intron sequence in SEQ ID NO:52 corresponds to nucleotides 895 to 1112 (217 nucleotides), while the intron sequence in SEQ ID NO:53 corresponds to nucleotides 947 to 1082 (135 nucleotides) in SEQ ID NO:53. Alignment of the intron nucleotide sequences using the Clustal method of alignment and the default parameters (KTUPLE 2, GAP PENALTY=5, WINDOW=4 and DIAGONALS SAVED=4) shows that the intron sequences are 46.3% identical.

#### EXAMPLE 17

##### Alteration of Isoflavonoid Levels in Soybean Plants

The ability to alter the isoflavonoid levels in transgenic soybean plants expressing the gene from soybean clone sgs1c.pk006.o20 was tested by transforming somatic embryo cultures with a vector containing the gene, allowing the plant to regenerate, and measuring

the levels of isoflavonoids produced. In addition, the soybean IFS gene was transformed in conjunction with the CRC gene.

*Construction of Vectors for Transformation of Glycine max*

A vector containing a chimeric isoflavone synthase gene was constructed as follows.

5 The 1.6 Kb isoflavone synthase coding region from clone sgs1c.pk006.o20 (SEQ ID NO:1) was amplified using a standard PCR reaction in a GeneAmp PCR System using Pfu polymerase (Stratagene) with the primers shown in SEQ ID NO:41 and SEQ ID NO:42 as in Example 9. The plasmid pCW109 (World Patent Publication No. WO94/11516) was digested with Nco I. The resulting DNA fragments were treated with T4 DNA polymerase  
10 in the presence of dATP; dCTP, dGTP and dTTP to obtain blunt ends followed by digestion with Kpn I. The ligation of these two DNA fragments created the plasmid pCW109-IFS, shown in Figure 28, which has operably linked:

- the beta -conglycinin promoter
- the isoflavone synthase coding region
- 15 • the phaseolin 3' end

The 3.2 Kb fragment containing the beta-conglycinin/P-IFS-phaseolin 3' chimeric gene was purified from pCW109-IFS as a Hind III fragment and ligated with Hind III-digested and phosphatase-treated pZBL102. pZBL102 is derived from pKS18HH (described in US  
20 Patent No. 5,846,784) by replacing the long Nos 3' fragment in pKS18HH with the short Nos 3' fragment described in Example 13. The Sal I site between the two hygromycin phosphotransferase coding regions was deleted, and a Not I site was added between the Hind III and Sal I sites 5' to the 35S promoter of the 35S-HPT gene.

The resulting plasmid, named pWSJ001, has a T7 promoter/HPT/T7 terminator cassette for expression of the HPT enzyme in certain strains of *E. coli* that are lysogenic for  
25 lambda DE3. The lambda DE3 carries the T7 RNA Polymerase gene under lacV5 control and is found in commercially available *E. coli* strains such as NovaBlue (DE3) (from Novagen). Plasmid pWSJ001 also contains the 35S/HPT/NOS 3' cassette for constitutive expression of the HPT enzyme in plants. These two expression systems allow selection for growth in the presence of hygromycin to be used as a means of identifying cells that contain  
30 plasmid DNA sequences in both bacterial and plant systems.

A vector containing a chimeric CRC gene was constructed as follows. The plasmid pDP7951 of Example 13, Figure 22, was digested with SmaI and the fragment containing the CRC coding region was purified. This CRC fragment was ligated to a modified vector containing the sequences of pCW109 (World Patent Publication No. WO94/11516) with the  
35 substitution of a phaseolin promoter fragment extending to -410 and including leader sequences to +77 (Slightom et al., 1991 Plant Mol Biol Man B16:1) instead of the beta-conglycinin promoter. Modification included digestion with NcoI and S1 nuclease treatment



followed by religation to remove the ATG sequence of the NcoI site that follows the promoter fragment. The vector was then digested with KpnI and the ends filled in so that the SmaI CRC fragment was inserted in a blunt-end ligation. From the resulting plasmid, the HindIII fragment containing the phaseolin promoter-CRC-phaseolin 3' chimeric gene was isolated and ligated with HindIII digested pZBL102 (described above). The resulting plasmid was called pOY203.

*Transformation Of Somatic Soybean Embryo Cultures and Regeneration Of Soybean Plants*

Soybean embryogenic suspension cultures were transformed with pWSJ001 or pWSJ001 in conjunction with pOY203 by the method of particle gun bombardment as in Example 15. Besides the media used for the soybean somatic embryo cultures described in Example 15, the following media were used:

Media
<u>SBP6</u>
SB55 with only 0.5 mL 2,4-D
<u>SB71-1 (per liter)</u>
B5 salts
1ml B5 vitamin stock
30 g sucrose
750mg MgCl <sub>2</sub>
2 g gelrite
pH 5.7

Eleven days post bombardment, the liquid media was exchanged with fresh SB55 containing 50 mg/mL hygromycin. The selective media was refreshed weekly. Seven weeks post bombardment, green, transformed tissue was observed growing from untransformed, necrotic embryogenic clusters. Isolated green tissue was removed and inoculated into individual flasks to generate new, clonally propagated, transformed embryogenic suspension cultures. Thus each new line was treated as independent transformation event. These suspensions can then be maintained as suspensions of embryos clustered in an immature developmental stage through subculture or regenerated into whole plants by maturation and germination of individual somatic embryos.

Transformed embryogenic clusters were removed from liquid culture and placed on a solid agar media (SB103) containing no hormones or antibiotics. Embryos were cultured for eight weeks at 26°C with mixed florescent and incandescent lights on a 16:8 h day/night schedule. During this period, individual embryos were removed from the clusters and analyzed at various stages of embryo development. Selected lines were assayed by PCR for

the presence of the an additional IFS gene using the primers shown in SEQ ID NO:43 and SEQ ID NO:44. Separation of the PCR products on an agarose gel yielded a 1062 bp fragment indicative of the endogenous IFS gene (i.e., containing introns) and an 845 bp fragment in the embryos containing the transgene IFS. Somatic embryos become suitable for germination after eight weeks and were then removed from the maturation medium and dried in empty petri dishes for 1 to 5 days. The dried embryos were then planted in SB71-1 medium where they were allowed to germinate under the same lighting and germination conditions described above. Germinated embryos were transferred to sterile soil and grown to maturity. Seed were harvested.

Seed from IFS-transformed and IFS + CRC-transformed soybean plants are analyzed for isoflavonoid levels. Extracts are prepared and analyzed by HPLC as described in Example 15 except that a 150 to 200 mg chip of soybean seed is used for the analysis. Seeds with statistically significant variation in the level of isoflavonoid concentration are further analyzed.

Various modifications of the invention in addition to those shown and described herein will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims.

The disclosure of each reference set forth above is incorporated herein by reference in its entirety.

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>6</u> . line <u>19</u>	
<b>B. IDENTIFICATION OF DEPOSIT</b> <span style="float: right;">Further deposits are identified on an additional sheet <input checked="" type="checkbox"/></span>	
Name of depositary institution AMERICAN TYPE CULTURE COLLECTION	
Address of depositary institution (including postal code and country) 10801 University Blvd. Manassas, Virginia 20110-2209 USA	
Date of deposit 27 January 1999	Accession Number ATCC 203606
<b>C. ADDITIONAL INDICATIONS</b> (leave blank if not applicable) <span style="float: right;">This information is continued on an additional sheet <input type="checkbox"/></span>	
In respect of those designations in which a European patent is sought, a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample. (Rule 28(4) EPC)	
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> (if the indications are not for all designated States)	
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<b>For receiving Office use only</b> <input type="checkbox"/> This sheet was received with the international application Authorized officer	<b>For International Bureau use only</b> <input type="checkbox"/> This sheet was received by the International Bureau on: Authorized officer
---	--

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>6</u> , line <u>20</u>	
<b>B. IDENTIFICATION OF DEPOSIT</b> <span style="float: right;">Further deposits are identified on an additional sheet <input type="checkbox"/></span>	
Name of depositary institution AMERICAN TYPE CULTURE COLLECTION	
Address of depositary institution (including postal code and country) 10801 University Blvd. Manassas, Virginia 20110-2209 USA	
Date of deposit 20 July 1999	Accession Number ATCC PTA-371
<b>C. ADDITIONAL INDICATIONS</b> (leave blank if not applicable) <span style="float: right;">This information is continued on an additional sheet <input type="checkbox"/></span>	
In respect of those designations in which a European patent is sought, a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample. (Rule 28(4) EPC)	
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> (if the indications are not for all designated States)	
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<b>For receiving Office use only</b> <input type="checkbox"/> This sheet was received with the international application <hr/> Authorized officer	<b>For International Bureau use only</b> <input type="checkbox"/> This sheet was received by the International Bureau on: <hr/> Authorized officer
---	--

CLAIMS

What is claimed is:

1. An isolated nucleic acid sequence encoding a polypeptide with isoflavone synthase activity having the amino acid sequence set forth in SEQ ID NO:66 wherein

5           Xaa<sub>10</sub> is Phe or Leu  
          Xaa<sub>16</sub> is Ser or Leu  
          Xaa<sub>23</sub> is Ser or Thr  
          Xaa<sub>25</sub> is Ile or Lys  
          Xaa<sub>39</sub> is Lys or Arg  
10          Xaa<sub>48</sub> is Pro or Leu  
          Xaa<sub>60</sub> is Pro or Leu  
          Xaa<sub>73</sub> is Leu or His  
          Xaa<sub>74</sub> is Ser or Tyr  
          Xaa<sub>95</sub> is Ala or Thr  
15          Xaa<sub>96</sub> is Asn or His  
          Xaa<sub>102</sub> is Asn or Ser  
          Xaa<sub>110</sub> is Ile, Val, or Thr  
          Xaa<sub>112</sub> is Arg or His  
          Xaa<sub>117</sub> is Asn or Ser  
20          Xaa<sub>118</sub> is Ser or Leu  
          Xaa<sub>121</sub> is Met or Arg  
          Xaa<sub>122</sub> is Ala or Val  
          Xaa<sub>124</sub> is Phe or Ile  
          Xaa<sub>129</sub> is Lys or Arg  
25          Xaa<sub>147</sub> is Lys or Glu  
          Xaa<sub>159</sub> is Leu or Phe  
          Xaa<sub>162</sub> is Ala or Val  
          Xaa<sub>166</sub> is Ser or Gly  
          Xaa<sub>170</sub> is Gln or Arg  
30          Xaa<sub>175</sub> is Val or Leu  
          Xaa<sub>183</sub> is Ala or Thr  
          Xaa<sub>187</sub> is Thr or Ile  
          Xaa<sub>191</sub> is Met or Val  
          Xaa<sub>209</sub> is Phe or Tyr  
35          Xaa<sub>219</sub> is Arg or Trp  
          Xaa<sub>223</sub> is Tyr or His  
          Xaa<sub>253</sub> is Gly or Glu  
          Xaa<sub>259</sub> is Lys or Glu

Xaa<sub>263</sub> is Val or Asp  
 Xaa<sub>264</sub> is Val, Asp, or Ile  
 Xaa<sub>268</sub> is Ala or Val  
 Xaa<sub>272</sub> is Phe or Leu  
 5 Xaa<sub>285</sub> is Thr or Met  
 Xaa<sub>293</sub> is Glu or Asp  
 Xaa<sub>294</sub> is Thr, or Ile  
 Xaa<sub>301</sub> is Phe or Leu  
 Xaa<sub>306</sub> is Thr or Ile  
 10 Xaa<sub>311</sub> is Val or Glu  
 Xaa<sub>312</sub> is Val or Ala  
 Xaa<sub>325</sub> is Arg or Lys  
 Xaa<sub>328</sub> is Gln or Glu  
 Xaa<sub>334</sub> is Val or Ala  
 15 Xaa<sub>342</sub> is Arg or Ile  
 Xaa<sub>377</sub> is Thr or Ile  
 Xaa<sub>381</sub> is Glu or Gly  
 Xaa<sub>385</sub> is Tyr, His, or Cys  
 Xaa<sub>387</sub> is Ile or Thr  
 20 Xaa<sub>393</sub> is Val or Ile  
 Xaa<sub>394</sub> is Leu or Pro  
 Xaa<sub>402</sub> is Arg or Lys  
 Xaa<sub>404</sub> is Ser or Pro  
 Xaa<sub>413</sub> is Ser or Phe  
 25 Xaa<sub>422</sub> is Glu or Gly  
 Xaa<sub>428</sub> is Gly or Arg  
 Xaa<sub>429</sub> is Pro or Leu  
 Xaa<sub>435</sub> is Gln or Arg  
 Xaa<sub>447</sub> is Arg or Gly  
 30 Xaa<sub>453</sub> is Asn, Ser, or Ile  
 Xaa<sub>459</sub> is Met or Thr, and  
 Xaa<sub>485</sub> is Asp or Gly.

2. An isolated polypeptide sequence of SEQ ID NO: 66 wherein

Xaa<sub>10</sub> is Phe or Leu  
 35 Xaa<sub>16</sub> is Ser or Leu  
 Xaa<sub>23</sub> is Ser or Thr  
 Xaa<sub>25</sub> is Ile or Lys  
 Xaa<sub>39</sub> is Lys or Arg

Xaa<sub>48</sub> is Pro or Leu  
Xaa<sub>60</sub> is Pro or Leu  
Xaa<sub>73</sub> is Leu or His  
Xaa<sub>74</sub> is Ser or Tyr  
5 Xaa<sub>95</sub> is Ala or Thr  
Xaa<sub>96</sub> is Asn or His  
Xaa<sub>102</sub> is Asn or Ser  
Xaa<sub>110</sub> is Ile, Val, or Thr  
Xaa<sub>112</sub> is Arg or His  
10 Xaa<sub>117</sub> is Asn or Ser  
Xaa<sub>118</sub> is Ser or leu  
Xaa<sub>121</sub> is Met or Arg  
Xaa<sub>122</sub> is Ala or Val  
Xaa<sub>124</sub> is Phe or Ile  
15 Xaa<sub>129</sub> is Lys or Arg  
Xaa<sub>147</sub> is Lys or Glu  
Xaa<sub>159</sub> is Leu or Phe  
Xaa<sub>162</sub> is Ala or Val  
Xaa<sub>166</sub> is Ser or Gly  
20 Xaa<sub>170</sub> is Gln or Arg  
Xaa<sub>175</sub> is Val or Leu  
Xaa<sub>183</sub> is Ala or Thr  
Xaa<sub>187</sub> is Thr or Ile  
Xaa<sub>191</sub> is Met or Val  
25 Xaa<sub>209</sub> is Phe or Tyr  
Xaa<sub>219</sub> is Arg or Trp  
Xaa<sub>223</sub> is Tyr or His  
Xaa<sub>253</sub> is Gly or Glu  
Xaa<sub>259</sub> is Lys or Glu  
30 Xaa<sub>263</sub> is Val or Asp  
Xaa<sub>264</sub> is Val, Asp, or Ile  
Xaa<sub>268</sub> is Ala or Val  
Xaa<sub>272</sub> is Phe or Leu  
Xaa<sub>285</sub> is Thr or Met  
35 Xaa<sub>293</sub> is Glu or Asp  
Xaa<sub>294</sub> is Thr, or Ile  
Xaa<sub>301</sub> is Phe or Leu  
Xaa<sub>306</sub> is Thr or Ile

Xaa<sub>311</sub> is Val or Glu  
Xaa<sub>312</sub> is Val or Ala  
Xaa<sub>325</sub> is Arg or Lys  
Xaa<sub>328</sub> is Gln or Glu  
5 Xaa<sub>334</sub> is Val or Ala  
Xaa<sub>342</sub> is Arg or Ile  
Xaa<sub>377</sub> is Thr or Ile  
Xaa<sub>381</sub> is Glu or Gly  
Xaa<sub>385</sub> is Tyr, His, or Cys  
10 Xaa<sub>387</sub> is Ile or Thr  
Xaa<sub>393</sub> is Val or Ile  
Xaa<sub>394</sub> is Leu or Pro  
Xaa<sub>402</sub> is Arg or Lys  
Xaa<sub>404</sub> is Ser or Pro  
15 Xaa<sub>413</sub> is Ser or Phe  
Xaa<sub>422</sub> is Glu or Gly  
Xaa<sub>428</sub> is Gly or Arg  
Xaa<sub>429</sub> is Pro or Leu  
Xaa<sub>435</sub> is Gln or Arg  
20 Xaa<sub>447</sub> is Arg or Gly  
Xaa<sub>453</sub> is Asn, Ser, or Ile  
Xaa<sub>459</sub> is Met or Thr, and  
Xaa<sub>485</sub> is Asp or Gly.

- 25 3. An isolated nucleic acid sequence encoding a polypeptide with isoflavone synthase activity.
4. An isolated nucleic acid sequence encoding a polypeptide with isoflavone synthase activity wherein the nucleic acid sequence is not the nucleic acid sequence set forth in SEQ ID NO:9.
- 30 5. The isolated nucleic acid sequence of Claim 1 at least 85% identical to the nucleic acid set forth in SEQ ID NO:1.
6. The isolated nucleic acid sequence of Claim 1 at least 90% identical to the nucleic acid set forth in SEQ ID NO:1.
7. The isolated nucleic acid sequence of Claim 1 wherein the nucleic acid hybridizes to the nucleic acid set forth in SEQ ID NO:1
- 35 8. The isolated nucleic acid sequence of Claim 1 wherein the encoded polypeptide comprises an amino acid sequence that is at least 95% identical to the amino acid sequence set forth in SEQ ID NO:2.



9. The isolated nucleic acid sequence of Claim 1 selected from the group consisting of SEQ ID NOs:1, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 47, 54, 56, 58, and 60.

10. The isolated nucleic acid sequence of Claim 1 encoding the amino acid sequence set forth in a member selected from the group consisting of SEQ ID NOs:2, 10, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 48, 55, 57, 59, 61, and 66.

11. A chimeric sequence comprising the nucleic acid sequence of Claim 1 operably linked to suitable regulatory sequences.

12. A transformed host cell comprising the chimeric sequence of Claim 11.

13. The transformed host cell of Claim 12 further comprising a second chimeric sequence comprising a nucleic acid sequence encoding a polypeptide that regulates expression of at least one enzyme of the phenylpropanoid pathway.

14. The transformed host cell of Claim 13 wherein the second chimeric sequence comprises a chimera containing the maize R region between the region encoding the C1 DNA binding domain and the C1 activation domain.

15. The transformed host cell of Claim 12 wherein the host cell is a eukaryotic cell.

16. The eukaryotic cell of Claim 13 wherein the cell is a yeast cell.

17. The eukaryotic cell of Claim 15 wherein the cell is a plant cell.

18. The plant cell of Claim 17 wherein the cell is a soybean cell.

19. The plant cell of Claim 17 wherein the cell is a corn cell.

20. A plant comprising in its genome the chimeric sequence of Claim 11.

21. The plant of Claim 20 further comprising in its genome a second chimeric sequence comprising a nucleic acid sequence encoding a polypeptide that regulates expression of at least one enzyme of the phenylpropanoid pathway.

22. The plant of Claim 20 wherein the plant is a soybean plant.

23. The plant of Claim 20 wherein the plant is a corn plant.

24. A seed from the plant of Claim 20.

25. A seed from the plant of Claim 21.

26. A method of altering the level of expression of isoflavone synthase in a host cell comprising:

(a) transforming a host cell with the chimeric sequence of Claim 11;

(b) optionally transforming the host cell with a second chimeric sequence comprising a nucleic acid sequence encoding a polypeptide that regulates expression of at least one enzyme of the phenylpropanoid pathway; and

(c) growing the transformed host cell produced in step (a) or step (b) under conditions that are suitable for expression of the chimeric sequence

wherein expression of the chimeric sequences result in production of altered levels of isoflavone synthase in the transformed host cell.

27. A method of increasing the amount of an isoflavonoid in a host cell comprising:

- (a) transforming a host cell with the chimeric sequence of Claim 11;
- (b) optionally transforming the host cell with a second chimeric sequence comprising a nucleic acid sequence encoding a polypeptide that regulates expression of at least one enzyme of the phenylpropanoid pathway; and
- (c) growing the transformed host cell produced in step (a) or step (b) under conditions that are suitable for expression of the chimeric sequence

wherein expression of the chimeric sequences results in production of an amount of an isoflavonoid in the transformed host cell that is greater than the amount of the isoflavonoid that is produced in a cell that is not transformed with the chimeric sequence of Claim 11.

28. The method of Claim 26 wherein the isoflavonoid is selected from the group consisting of genestein and daidzein.

29. The method of Claim 26 or Claim 27 wherein the host cell is a eukaryotic cell.

30. The method of Claim 26 or Claim 27 wherein the eukaryotic cell is a yeast cell.

31. The method of Claim 26 or Claim 27 wherein the eukaryotic cell is a plant cell.

32. The method of Claim 31 wherein the plant cell is a soybean cell.

33. The method of Claim 31 wherein the plant cell is a corn cell.

34. A method of producing a plant with increased isoflavonoid content comprising

- (a) transforming a plant cell with the chimeric sequence of Claim 11;
- (b) optionally transforming the plant cell with a second chimeric sequence comprising a nucleic acid sequence encoding a polypeptide that regulates expression of at least one enzyme of the phenylpropanoid pathway; and
- (c) growing the transformed plant cell under conditions that promote the regeneration of a whole plant from the transformed cell

wherein the transformed plant regenerated from the transformed cell produces an amount of an isoflavonoid that is greater than the amount of the isoflavonoid that is produced in a plant that is regenerated from a plant cell that is not transformed with the chimeric sequence of Claim 11.

35. The method of Claim 34 wherein the plant is a soybean plant.

36. The method of Claim 34 wherein the plant is a corn plant.

37. The transgenic plant produced by the method of Claim 34.

38. The transgenic plant of Claim 37 wherein the plant is a soybean plant.

39. The transgenic plant of Claim 37 wherein the plant is a corn plant.

40. A seed from the plant of Claim 37.

41. A method of obtaining a nucleic acid sequence encoding all or a substantial portion of the amino acid sequence encoding a plant isoflavone synthase comprising

- (a) probing a cDNA or genomic library with the nucleic acid sequence of Claim 1;
- (b) identifying a DNA clone that hybridizes with the nucleic acid sequence of Claim 1;
- (c) isolating the DNA clone identified in step (b);
- (d) sequencing the cDNA or genomic sequence that comprises the clone isolated in step (c); and
- (e) demonstrating the functional expression of isoflavone synthase mediated by the cDNA or genomic sequence sequenced in step (d)

wherein the sequenced nucleic acid sequence encodes all or a substantial portion of the amino acid sequence encoding a plant isoflavone biosynthetic enzyme.

42. A method of obtaining a nucleic acid sequence encoding all or a substantial portion of an amino acid sequence encoding a plant isoflavone synthase comprising:

- (a) synthesizing an oligonucleotide primer corresponding to a portion of the sequence set forth in a member of selected from the group consisting of SEQ ID NOs:1, 9, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 47, 54, 56, 58, and 60;
- (b) amplifying a cDNA insert present in a cloning vector using the oligonucleotide primer of step (a) and a primer representing sequences of the cloning vector to produce an amplified nucleic acid sequence; and
- (c) demonstrating the functional expression of isoflavone synthase mediated by the amplified nucleic acid sequence produced in step (b)

wherein the amplified nucleic acid sequence encodes all or a substantial portion of an amino acid sequence encoding a plant isoflavone synthase.

43. The method of Claim 42 wherein the oligonucleotide primer is selected from the group consisting of SEQ ID NOs:5, 6, 7, 8, 11, 12, 13, 14, 41, 42, 49, 50, and 51.

44. The product of the method of Claim 41.

45. The product of the method of Claim 42.

46. A method of altering the level of isoflavonoids in a cell of Claim 12 comprising exposing said cell to a phenylpropanoid pathway altering agent.

47. The method of Claim 46 wherein said agent is selected from the group consisting of a transcription factor and stress.


48. The method of Claim 47 wherein stress is selected from the group consisting of ultraviolet light, temperature, pressure, and phosphate level.

49. The method of Claim 47 wherein said transcription factor is a maize C1 myb-type transcription factor and a myc-type transcription factor R

50. The method of Claim 47 wherein said transcription factor is a chimera containing the maize R region between the C1 DNA binding domain and the C1 activation domain.


5

Figure 1



IC18 Rec'd PCT/PTO 0 5 JUN 2001

Figure 2



A

B

JC18 Rec'd PCT/PTO 0 5 JUN 2001



Figure 3







Figure 4




A

B

IC18 Rec'd PCT/PTO 0 5 JUN 2001

Figure 5




A

B



Figure 6




A

B

IC18 Rec'd PCT/PTO 0 5 JUN 2001




Figure 7



IC18 Rec'd PCT/PTO 0 5 JUN 2001

Figure 8




A

B




Figure 9



**THIS PAGE BLANK (USPTO)**

Figure 10




A

B

**THIS PAGE BLANK (USPTO)**




Figure 11



IC18 Rec'd PCT/PTO 0 5 JUN 2001

Figure 12




A

B


18 Rec'd PCT/PTO 0 5 JUN 2007

Figure 13



10410 Rec'd OCT/PTO 0 5 JUN 2001


Figure 14



1018 Rec'd PCT/PTO 0 5 JUN 2001



Figure 15




A

B


**THIS PAGE BLANK (USPTO)**

Figure 16




JG18 Rec'd DCT/PTO 05 JUN 2001

FIGURE 17



**THIS PAGE BLANK (USPTO)**


FIGURE 18



JC18 Rec'd PCT/PTO 0 5 JUN 2001




## Figure 19




JC18 Rec'd DOT/PTO 05 JUN 2001

FIGURE 20




JC18 Rec'd DOT/PTO 05 JUN 2001

FIGURE 21



**THIS PAGE BLANK (USPTO)**


FIGURE 22



JC18 Rec'd PCT/PTO 0 5 JUN, 2001.




FIGURE 23



JC18 Rec'd DCT/PTO 0 5 JUN 2001


FIGURE 24



JC16 Rec'd OCT/PTO n 5 JUN 2001 :

**THIS PAGE BLANK (USPTO)**


Figure 25



JC18 Rec'd PCT/PTO 0 5 JUN 2001

**THIS PAGE BLANK (USPTO)**


Figure 26



**THIS PAGE BLANK (USPTO)**




Figure 27



JC18 Rec'd PCT/PTO 0 5 JUN 2001

Figure 28





## SEQUENCE LISTING

<110> E. I. du Pont de Nemours and Company  
 <120> Nucleic Acid Sequences Encoding Isoflavone Synthase  
 <130> BB1339 PCT  
 <140>  
 <141>  
 <150> 60/117,769  
 <151> 1999-01-27  
 <150> 60/144,783  
 <151> 1999-07-20  
 <150> 60/156,094  
 <151> 1999-09-24  
 <160> 66  
 <170> Microsoft Office 97  
 <210> 1  
 <211> 1756  
 <212> DNA  
 <213> Glycine max

<400> 1  
 gtaattaacc tcaactcaaac tcgggatcac agaaaccaac aacagttctt gcactgaggt 60  
 ttcacgatgt tgctggaact tgcacttggg ttgtttgtgt tagctttgtt tctgcacttg 120  
 cgtcccaacac caagtgc aaa atcaaaagca cttcgccacc tcccaaacc tccaagccca 180  
 aagcctcgtc ttcccttcat tggccacctt cactctttaa aagataaact tctccactat 240  
 gcactcatcg atctctccaa aaagcatggc ccttattctt ctctctctt cggtccatg 300  
 ccaaccgctg ttgcctccac ccctgagttg ttcaagctct tctccaaac ccacgaggca 360  
 acttcttca acacaaggtt ccaaacctct gccataagac gcctcactta cgacaactct 420  
 gtggccatgg ttccattcgg accttactgg aagttcgtga ggaagctcat catgaacgac 480  
 cttctcaacg ccaccacgt caacaagctc aggcctttga ggaccaaca gatccgcaag 540  
 ttcttaggg ttatggcca aagcgcagag gccagaagc cccttgacgt caccgaggag 600  
 cttctcaaat ggaccaacag caccatctcc atgatgatgc tcggcgaggc tgaggagatc 660  
 agagacatcg ctgcgcagggt tcttaagatc ttccggcaat acagcctcac tgacttcac 720  
 tggcctttga agtatctcaa ggttgaaag tatgagaaga ggattgatga catcttgaa 780  
 aagttcgacc ctgtcgttga aagggtcctc aagaagcgcc gtgagatcgt cagaaggaga 840  
 aagaacggag aagttgttga gggcgaggcc agcggcgtct tctcgcacac tttgcttgaa 900  
 ttcgctgagg acgagaccat ggagatcaaa attaccaagg agcaaataca gggccttggt 960  
 gtcgactttt tctctgcagg gacagattcc acagcgttg caacagagtg ggcattggca 1020  
 gagctcatca acaatcccag ggtgttgcaa aaggctcgtg aggaggtcta cagtgttg 1080  
 ggcaaagata gactcgttga cgaagttgac actcaaaacc ttccttacct tagggccatt 1140  
 gtgaaggaga cattccgaat gcacccacca ctcccagtg tcaaaagaaa gtgcacagaa 1200  
 gagtgtgaga ttaatgggta tgtgatccca gagggagcat tggttctttt caatgtttgg 1260  
 caagtaggaa gggaccccaa atactgggac agaccatcag aattccgtcc cgagagggtc 1320  
 ttagaaactg gtgctgaagg ggaagcaggg cctcttgatc ttaggggcca gcatttccaa 1380  
 ctctcccat ttgggtctgg gaggagaatg tgccctgggt tcaatttggc tacttcagga 1440  
 atggcaacac ttcttgcatc tcttatccaa tgctttgacc tgcaagtgtt ggccctcaa 1500  
 ggacaaatat tgaaaggtga tgatgccaaa gttagcatgg aagagagagc tggcctcaca 1560  
 gttccaaggg cacatagtct cgtttgtgtt ccacttgcaa ggatcggcgt tgcactctaa 1620  
 ctctttctt aattaagata atcatcatat acaatagtag tgtcttgcca tcgcagttgc 1680  
 tttttatgta ttcataatca tcatttcaat aaggtgtgac tgggtactta tcaagtaatt 1740  
 aaggttacat acatgc 1756

<210> 2  
 <211> 521  
 <212> PRT  
 <213> Glycine max



&lt;400&gt; 2

Met Leu Leu Glu Leu Ala Leu Gly Leu Phe Val Leu Ala Leu Phe Leu  
 1 5 10 15  
 His Leu Arg Pro Thr Pro Ser Ala Lys Ser Lys Ala Leu Arg His Leu  
 20 25 30  
 Pro Asn Pro Pro Ser Pro Lys Pro Arg Leu Pro Phe Ile Gly His Leu  
 35 40 45  
 His Leu Leu Lys Asp Lys Leu His Tyr Ala Leu Ile Asp Leu Ser  
 50 55 60  
 Lys Lys His Gly Pro Leu Phe Ser Leu Ser Phe Gly Ser Met Pro Thr  
 65 70 75 80  
 Val Val Ala Ser Thr Pro Glu Leu Phe Lys Leu Phe Leu Gln Thr His  
 85 90 95  
 Glu Ala Thr Ser Phe Asn Thr Arg Phe Gln Thr Ser Ala Ile Arg Arg  
 100 105 110  
 Leu Thr Tyr Asp Asn Ser Val Ala Met Val Pro Phe Gly Pro Tyr Trp  
 115 120 125  
 Lys Phe Val Arg Lys Leu Ile Met Asn Asp Leu Leu Asn Ala Thr Thr  
 130 135 140  
 Val Asn Lys Leu Arg Pro Leu Arg Thr Gln Gln Ile Arg Lys Phe Leu  
 145 150 155 160  
 Arg Val Met Ala Gln Ser Ala Glu Ala Gln Lys Pro Leu Asp Val Thr  
 165 170 175  
 Glu Glu Leu Leu Lys Trp Thr Asn Ser Thr Ile Ser Met Met Met Leu  
 180 185 190  
 Gly Glu Ala Glu Glu Ile Arg Asp Ile Ala Arg Glu Val Leu Lys Ile  
 195 200 205  
 Phe Gly Glu Tyr Ser Leu Thr Asp Phe Ile Trp Pro Leu Lys Tyr Leu  
 210 215 220  
 Lys Val Gly Lys Tyr Glu Lys Arg Ile Asp Asp Ile Leu Asn Lys Phe  
 225 230 235 240  
 Asp Pro Val Val Glu Arg Val Ile Lys Lys Arg Arg Glu Ile Val Arg  
 245 250 255  
 Arg Arg Lys Asn Gly Glu Val Val Glu Gly Glu Ala Ser Gly Val Phe  
 260 265 270  
 Leu Asp Thr Leu Leu Glu Phe Ala Glu Asp Glu Thr Met Glu Ile Lys  
 275 280 285  
 Ile Thr Lys Glu Gln Ile Lys Gly Leu Val Val Asp Phe Phe Ser Ala  
 290 295 300  
 Gly Thr Asp Ser Thr Ala Val Ala Thr Glu Trp Ala Leu Ala Glu Leu  
 305 310 315 320  
 Ile Asn Asn Pro Arg Val Leu Gln Lys Ala Arg Glu Glu Val Tyr Ser  
 325 330 335  
 Val Val Gly Lys Asp Arg Leu Val Asp Glu Val Asp Thr Gln Asn Leu  
 340 345 350





Pro Tyr Ile Arg Ala Ile Val Lys Glu Thr Phe Arg Met His Pro Pro  
 355 360 365

Leu Pro Val Val Lys Arg Lys Cys Thr Glu Glu Cys Glu Ile Asn Gly  
 370 375 380

Tyr Val Ile Pro Glu Gly Ala Leu Val Leu Phe Asn Val Trp Gln Val  
 385 390 395 400

Gly Arg Asp Pro Lys Tyr Trp Asp Arg Pro Ser Glu Phe Arg Pro Glu  
 405 410 415

Arg Phe Leu Glu Thr Gly Ala Glu Gly Glu Ala Gly Pro Leu Asp Leu  
 420 425 430

Arg Gly Gln His Phe Gln Leu Leu Pro Phe Gly Ser Gly Arg Arg Met  
 435 440 445

Cys Pro Gly Val Asn Leu Ala Thr Ser Gly Met Ala Thr Leu Leu Ala  
 450 455 460

Ser Leu Ile Gln Cys Phe Asp Leu Gln Val Leu Gly Pro Gln Gly Gln  
 465 470 475 480

Ile Leu Lys Gly Asp Asp Ala Lys Val Ser Met Glu Glu Arg Ala Gly  
 485 490 495

Leu Thr Val Pro Arg Ala His Ser Leu Val Cys Val Pro Leu Ala Arg  
 500 505 510

Ile Gly Val Ala Ser Lys Leu Leu Ser  
 515 520

<210> 3  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Oligonucleotide

<400> 3  
 cgggatccat gcaaccggaa accgtcg

27

<210> 4  
 <211> 32  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Oligonucleotide

<400> 4  
 ccggaattct caccaaaccat cacggaggta tc

32

<210> 5  
 <211> 47  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Oligonucleotide

<400> 5  
 tcaaggagaa aaaaccccg atccatgttg ctggaacttg cacttgg

47



<210> 6  
 <211> 35  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Oligonucleotide

<400> 6  
 ggccagtgaa ttgtaatacg actcactata gggcg 35

<210> 7  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:PCR primer

<400> 7  
 aaaattagcc tcacaaaagc aaag 24

<210> 8  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:PCR primer

<400> 8  
 atataaggat tgatagttta tagtagg 27

<210> 9  
 <211> 1824  
 <212> DNA  
 <213> Glycine max

<400> 9  
 ggaaaattag cctcacaaaa gcaaagatca aacaaaccaa ggacgagaac acgatgttgc 60  
 ttgaacttgc acttggttta ttggttttgg ctctgtttct gcacttgcg cccacaccca 120  
 ctgcaaaatc aaaagcactt cgccatctcc caaaccaccc aagcccaaag cctcgtcttc 180  
 ccttcatagg acaccttcat ctcttaaaaag acaaaacttct ccactacgca ctcatcgacc 240  
 tctccaaaaa acatgggtccc ttattctctc tctactttgg ctccatgcca accgtttgtt 300  
 cctccacacc agaattgttc aagctcttcc tccaaacgca cgaggcaact tccttcaaca 360  
 caaggttcca aacctcagcc ataagacgcc tcacctatga tagctcagt gccatggttc 420  
 ccttcggacc ttactggaag ttctgtgagga agctcatcat gaacgacctt cccaacgcca 480  
 ccactgtaaa caagttgagg cctttgagga cccaacagac ccgcaagttc cttagggtta 540  
 tggcccaagg cgagaggcca cagaagcccc ttgacttgac cgaggagctt ctgaaatgga 600  
 ccaacagcac catctccatg atgatgctcg gcgaggctga ggagatcaga gacatcgctc 660  
 gcgaggttct taagatcttt ggcgaaataca gcctcactga cttcatctgg ccattgaagc 720  
 atctcaaggt tggaaagtat gagaagagga tcgacgacat cttgaacaag ttcgaccctg 780  
 tcgttgaaag ggtcatcaag aagcgccgtg agatcgtgag gaggagaaaag aacggagagg 840  
 ttgttgaggg tgaggtcagc ggggttttcc ttgacacttt gcttgaattc gctgaggatg 900  
 agaccatgga gatcaaaatc accaaggacc acatcgaggg tcttgttgtc gactttttct 960  
 cggcaggaac agactccaca gcggtggcaa cagagtgggc attggcagaa ctcatcaaca 1020  
 atcctaagggt gttggaagg gctcgtgagg aggtctacag tgttgtggga aaggacagac 1080  
 ttgtggacga agttgacact caaaaccttc cttacattag agcaatcgtg aaggagacat 1140  
 tccgcatgca cccgccactc ccagtgggtca aaagaaagtg cacagaagag tgtgagatta 1200  
 atggatatgt gatcccagag ggagcattga ttctcttcaa tgtatggcaa gtaggaagag 1260  
 accccaaata ctgggacaga ccatcgaggt tccgtcctga gaggttccta gagacagggg 1320  
 ctgaagggga agcagggcct cttgatctta ggggacaaca ttttcaactt ctcccatttg 1380  
 ggtctgggag gagaatgtgc cctggaagtca atctggctac ttcgggaatg gcaacacttc 1440  
 ttgcatctct tattcagtg cttcgacttg aagtgtctgg tccacaagga cagatattga 1500  
 aggggtggtga cgccaaaagt agcatggaag agagagccgg cctcactgtt ccaagggcac 1560



atagtcttgt ctgtgttcca cttgcaagga tcggcggttg atctaaactc ctttcttaat 1620  
 taagatcatc atcatatata atatttactt tttgtgtgtt gataatcatc atttcaataa 1680  
 ggtctcgttc atctactttt tatgaagtat ataagccctt ccatgcacat tgtatcatct 1740  
 cccatttgct ttcgtttgct acctaaggca atcttttttt ttttagaatc acatcatcct 1800  
 actataaact atcaatcctt atat 1824

<210> 10  
 <211> 521  
 <212> PRT  
 <213> Glycine max

<400> 10

Met Leu Leu Glu Leu Ala Leu Gly Leu Leu Val Leu Ala Leu Phe Leu  
 1 5 10 15

His Leu Arg Pro Thr Pro Thr Ala Lys Ser Lys Ala Leu Arg His Leu  
 20 25 30

Pro Asn Pro Pro Ser Pro Lys Pro Arg Leu Pro Phe Ile Gly His Leu  
 35 40 45

His Leu Leu Lys Asp Lys Leu Leu His Tyr Ala Leu Ile Asp Leu Ser  
 50 55 60

Lys Lys His Gly Pro Leu Phe Ser Leu Tyr Phe Gly Ser Met Pro Thr  
 65 70 75 80

Val Val Ala Ser Thr Pro Glu Leu Phe Lys Leu Phe Leu Gln Thr His  
 85 90 95

Glu Ala Thr Ser Phe Asn Thr Arg Phe Gln Thr Ser Ala Ile Arg Arg  
 100 105 110

Leu Thr Tyr Asp Ser Ser Val Ala Met Val Pro Phe Gly Pro Tyr Trp  
 115 120 125

Lys Phe Val Arg Lys Leu Ile Met Asn Asp Leu Pro Asn Ala Thr Thr  
 130 135 140

Val Asn Lys Leu Arg Pro Leu Arg Thr Gln Gln Thr Arg Lys Phe Leu  
 145 150 155 160

Arg Val Met Ala Gln Gly Ala Glu Ala Gln Lys Pro Leu Asp Leu Thr  
 165 170 175

Glu Glu Leu Leu Lys Trp Thr Asn Ser Thr Ile Ser Met Met Met Leu  
 180 185 190

Gly Glu Ala Glu Glu Ile Arg Asp Ile Ala Arg Glu Val Leu Lys Ile  
 195 200 205

Phe Gly Glu Tyr Ser Leu Thr Asp Phe Ile Trp Pro Leu Lys His Leu  
 210 215 220

Lys Val Gly Lys Tyr Glu Lys Arg Ile Asp Asp Ile Leu Asn Lys Phe  
 225 230 235 240

Asp Pro Val Val Glu Arg Val Ile Lys Lys Arg Arg Glu Ile Val Arg  
 245 250 255

Arg Arg Lys Asn Gly Glu Val Val Glu Gly Glu Val Ser Gly Val Phe  
 260 265 270

Leu Asp Thr Leu Leu Glu Phe Ala Glu Asp Glu Thr Met Glu Ile Lys  
 275 280 285



Ile Thr Lys Asp His Ile Glu Gly Leu Val Val Asp Phe Phe Ser Ala  
 290 295 300

Gly Thr Asp Ser Thr Ala Val Ala Thr Glu Trp Ala Leu Ala Glu Leu  
 305 310 315 320

Ile Asn Asn Pro Lys Val Leu Glu Lys Ala Arg Glu Glu Val Tyr Ser  
 325 330 335

Val Val Gly Lys Asp Arg Leu Val Asp Glu Val Asp Thr Gln Asn Leu  
 340 345 350

Pro Tyr Ile Arg Ala Ile Val Lys Glu Thr Phe Arg Met His Pro Pro  
 355 360 365

Leu Pro Val Val Lys Arg Lys Cys Thr Glu Glu Cys Glu Ile Asn Gly  
 370 375 380

Tyr Val Ile Pro Glu Gly Ala Leu Ile Leu Phe Asn Val Trp Gln Val  
 385 390 395 400

Gly Arg Asp Pro Lys Tyr Trp Asp Arg Pro Ser Glu Phe Arg Pro Glu  
 405 410 415

Arg Phe Leu Glu Thr Gly Ala Glu Gly Glu Ala Gly Pro Leu Asp Leu  
 420 425 430

Arg Gly Gln His Phe Gln Leu Leu Pro Phe Gly Ser Gly Arg Arg Met  
 435 440 445

Cys Pro Gly Val Asn Leu Ala Thr Ser Gly Met Ala Thr Leu Leu Ala  
 450 455 460

Ser Leu Ile Gln Cys Phe Asp Leu Gln Val Leu Gly Pro Gln Gly Gln  
 465 470 475 480

Ile Leu Lys Gly Gly Asp Ala Lys Val Ser Met Glu Glu Arg Ala Gly  
 485 490 495

Leu Thr Val Pro Arg Ala His Ser Leu Val Cys Val Pro Leu Ala Arg  
 500 505 510

Ile Gly Val Ala Ser Lys Leu Leu Ser  
 515 520

<210> 11  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:PCR primer

<400> 11  
 atgttgctgg aacttgcact t

21

<210> 12  
 <211> 25  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:PCR primer

<400> 12  
 ttaagaaagg agttagatg caacg

25





<210> 13  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:PCR primer

<400> 13  
 tgtttctgca cttgcgtccc ac

22

<210> 14  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:PCR primer

<400> 14  
 ccgaccccttg caagtggaaac ac

22

<210> 15  
 <211> 1501  
 <212> DNA  
 <213> Medicago sativa

<400> 15  
 tgtttctgca cttgcgtccc acaccaagtg caaaatcaaa agcacttcgc cacctcccaa 60  
 accccccaag cccaaagcct cgtcttccct tcattggcca ccttcacctc ttaaaagata 120  
 aacttctcca ctatgcactc atcgatctct ccaaaaagca tggccctta ttctctctct 180  
 ccttcgggctc catgccaacc gtcgttgccct ccacccctga gttgttcaag ctcttcctcc 240  
 aaacccacga ggcaacttcc ttcaacacaa gggtccaaac ctctgccaca agacgcctca 300  
 cttacgacaa ctctgtggcc atggttccat tcggacctta ctggagggtc gtgaggaagc 360  
 tcatcatgaa cgaccttctc aacgccacca ccgtcaacaa gctcaggcct ttgaggaccc 420  
 aacagatccg caagtccctt aggggttatgg cccaaagcgc agaggcccag aagccccttg 480  
 acgtcaccga ggagcttctc aaatggacca acagcaccat ctccatgatg atgctcggcg 540  
 aggtcgagga gatcagagac atcgctcgcg aggttcttaa gatcttcggc gaatacagcc 600  
 tcaactgactt catctggcct ttgaagtatc tcaagggttg aaagtatgag aagaggattg 660  
 atgacatctt gaacaagtcc gaccctgtcg ttgaaagggt catcaagaag cgccgtggga 720  
 tcgtcagaag gagagagaac ggagaagttg ttgagggcga ggccagcggc gtcttcctcg 780  
 acactttgct tgaattcgct gaggacgaga ccatggagat caaaattacc aaggagcaaa 840  
 tcaagggcct tgttgcgac ctttctctg caggacaga ttccacagcg gtggcaacag 900  
 agtgggcatt ggcagagctc atcaacaatc ccagggtgtt gcaaaaggct cgtgaggagg 960  
 tctacagtgt tgtgggcaaa gatagactcg ttgacgaagt tgacactcaa aaccttcctt 1020  
 acattagggc catttgtgaag gagacattcc gaatgcaccc accactccca gtggtcaaaa 1080  
 gaaagtgcac agaagagtgt gagattaatg ggtatgtgat cccagaggga gcattgggtc 1140  
 ttttcaatgt ttggcaagta ggaagggacc ccaaatactg ggacagacca tccgaattcc 1200  
 gtcccgagag gttcttagaa actgggtgctg aagggggaagc agggcctctt gatcttaggg 1260  
 gccagcattt ccaactcctc ccatttgggt ctgggaggag aatgtgccct ggtgtcaatt 1320  
 tggctacttc aggaatggca acacttcttg catctcttat ccaatgcttt gacctgcaag 1380  
 tgctgggccc tcaaggacaa atattgaaag gtgatgatgc caaagttagc atggaagaga 1440  
 gagctggcct cacagttcca agggcacata gtctcgtttg tgttcactt gcaaggatcg 1500  
 g 1501

<210> 16  
 <211> 499  
 <212> PRT  
 <213> Medicago sativa

<400> 16  
 Phe Leu His Leu Arg Pro Thr Pro Ser Ala Lys Ser Lys Ala Leu Arg  
 1 5 10 15



His Leu Pro Asn Pro Pro Ser Pro Lys Pro Arg Leu Pro Phe Ile Gly  
 20 25 30  
 His Leu His Leu Leu Lys Asp Lys Leu Leu His Tyr Ala Leu Ile Asp  
 35 40 45  
 Leu Ser Lys Lys His Gly Pro Leu Phe Ser Leu Ser Phe Gly Ser Met  
 50 55 60  
 Pro Thr Val Val Ala Ser Thr Pro Glu Leu Phe Lys Leu Phe Leu Gln  
 65 70 75 80  
 Thr His Glu Ala Thr Ser Phe Asn Thr Arg Phe Gln Thr Ser Ala Thr  
 85 90 95  
 Arg Arg Leu Thr Tyr Asp Asn Ser Val Ala Met Val Pro Phe Gly Pro  
 100 105 110  
 Tyr Trp Arg Phe Val Arg Lys Leu Ile Met Asn Asp Leu Leu Asn Ala  
 115 120 125  
 Thr Thr Val Asn Lys Leu Arg Pro Leu Arg Thr Gln Gln Ile Arg Lys  
 130 135 140  
 Phe Leu Arg Val Met Ala Gln Ser Ala Glu Ala Gln Lys Pro Leu Asp  
 145 150 155 160  
 Val Thr Glu Glu Leu Leu Lys Trp Thr Asn Ser Thr Ile Ser Met Met  
 165 170 175  
 Met Leu Gly Glu Ala Glu Glu Ile Arg Asp Ile Ala Arg Glu Val Leu  
 180 185 190  
 Lys Ile Phe Gly Glu Tyr Ser Leu Thr Asp Phe Ile Trp Pro Leu Lys  
 195 200 205  
 Tyr Leu Lys Val Gly Lys Tyr Glu Lys Arg Ile Asp Asp Ile Leu Asn  
 210 215 220  
 Lys Phe Asp Pro Val Val Glu Arg Val Ile Lys Lys Arg Arg Gly Ile  
 225 230 235 240  
 Val Arg Arg Arg Glu Asn Gly Glu Val Val Glu Gly Glu Ala Ser Gly  
 245 250 255  
 Val Phe Leu Asp Thr Leu Leu Glu Phe Ala Glu Asp Glu Thr Met Glu  
 260 265 270  
 Ile Lys Ile Thr Lys Glu Gln Ile Lys Gly Leu Val Val Asp Leu Phe  
 275 280 285  
 Ser Ala Gly Thr Asp Ser Thr Ala Val Ala Thr Glu Trp Ala Leu Ala  
 290 295 300  
 Glu Leu Ile Asn Asn Pro Arg Val Leu Gln Lys Ala Arg Glu Glu Val  
 305 310 315 320  
 Tyr Ser Val Val Gly Lys Asp Arg Leu Val Asp Glu Val Asp Thr Gln  
 325 330 335  
 Asn Leu Pro Tyr Ile Arg Ala Ile Val Lys Glu Thr Phe Arg Met His  
 340 345 350  
 Pro Pro Leu Pro Val Val Lys Arg Lys Cys Thr Glu Glu Cys Glu Ile  
 355 360 365

**THIS PAGE BLANK (USPTO)**

Asn Gly Tyr Val Ile Pro Glu Gly Ala Leu Val Leu Phe Asn Val Trp  
 370 375 380  
 Gln Val Gly Arg Asp Pro Lys Tyr Trp Asp Arg Pro Ser Glu Phe Arg  
 385 390 395 400  
 Pro Glu Arg Phe Leu Glu Thr Gly Ala Glu Gly Glu Ala Gly Pro Leu  
 405 410 415  
 Asp Leu Arg Gly Gln His Phe Gln Leu Leu Pro Phe Gly Ser Gly Arg  
 420 425 430  
 Arg Met Cys Pro Gly Val Asn Leu Ala Thr Ser Gly Met Ala Thr Leu  
 435 440 445  
 Leu Ala Ser Leu Ile Gln Cys Phe Asp Leu Gln Val Leu Gly Pro Gln  
 450 455 460  
 Gly Gln Ile Leu Lys Gly Asp Asp Ala Lys Val Ser Met Glu Glu Arg  
 465 470 475 480  
 Ala Gly Leu Thr Val Pro Arg Ala His Ser Leu Val Cys Val Pro Leu  
 485 490 495

Ala Arg Ile

<210> 17  
 <211> 1501  
 <212> DNA  
 <213> Vicia villosa

<400> 17  
 tgtttctgca cttgcgtccc acaccactg caaaatcaaa agcacttcgc catctcccaa 60  
 acccaccaag cccaaagcct cgtcttccct tcataggaca ccttcatctc ttaaaagaca 120  
 aacttctcca ctacgcactc atcgacctct ccaaaaaaca tgggtccctta ttctctctct 180  
 actttggctc catgccaaac gttgttgccct ccacaccaga attgttcaag ctcttccctcc 240  
 aaacgcacga ggcaacttcc ttcaacacaa ggttccaaac ctgagccata agacgcctca 300  
 cctatgatag cttagtggcc atgggtccct tcggacctta ctggaagttc gtgaggaagc 360  
 tcatcatgaa cgaccttctc aacgccacca ctgtaaacaa gttgaggcct ttgaggaccc 420  
 aacagatccg caagttcctt agggttatgg cccaaggcgc agaggcacag aagccccttg 480  
 acttgaccga ggagcttctg aaatggacca acagcaccat ctctatgatg atgctcggcg 540  
 aggctgagga gatcagagac atcgctcgcg aggttcttaa gatctatggc gaatacagcc 600  
 tcactgactt catctggcca ttgaagcatc tcaaggttgg aaagtatgag aagaggatcg 660  
 acgacatctt gaacaagttc gacctgtcgt ttgaaagagt catcaagaag cgccgtgaga 720  
 tcgtgaggag gagaaagaac ggagaggttg ttgagggtga ggtcagcggg gttttccttg 780  
 acactttgct tgaattcgct gaggatgaga ccacgggat caaaatcacc aaggaccaca 840  
 tcaagggtct tgttgtcgac tttttctcgg caggaataga ctccacagcg gtggcaacag 900  
 agtgggcatt ggcagaactc atcaacaatc ctaaggtgtt ggaaaaggct cgtgaggagg 960  
 tctacagtgt tgtgggaaag gacagacttg tggacgaagt tgacactcaa aaccttctt 1020  
 acattagagc aatcgtgaag gagacattcc gcatgcaccc gccactccca gtgggtcaaaa 1080  
 gaaagtgcac agaagagtgt gagattaatg gatatgtgat ccagaggga gcattgattc 1140  
 tcttcaatgt atggcaagta ggaagggacc ccaaatactg ggacagacca tcggagttcc 1200  
 gtccctgagag gttcctagag acaggggctg aaggggaagc aaggcctctt gatcttaggg 1260  
 gacaacattt tcaacttctc ccatttgggt ctgggagggg aatgtgccct ggagtcaatc 1320  
 tggctacttc ggggaatggca acacttcttg catctcttat tcagtgtttt gacttgcaag 1380  
 tgctgggtcc acaaggacag atattgaagg gtggtgacgc caaagttagc atggaagaga 1440  
 gggccggcct cactgttcca agggcacata gtcttgtctg tgttccactt gcaaggatcg 1500  
 g 1501

<210> 18  
 <211> 499  
 <212> PRT  
 <213> Vicia villosa

**THIS PAGE BLANK (USPTO)**

<400> 18  
 Phe Leu His Leu Arg Pro Thr Pro Thr Ala Lys Ser Lys Ala Leu Arg  
 1 5 10 15  
 His Leu Pro Asn Pro Pro Ser Pro Lys Pro Arg Leu Pro Phe Ile Gly  
 20 25 30  
 His Leu His Leu Leu Lys Asp Lys Leu Leu His Tyr Ala Leu Ile Asp  
 35 40 45  
 Leu Ser Lys Lys His Gly Pro Leu Phe Ser Leu Tyr Phe Gly Ser Met  
 50 55 60  
 Pro Thr Val Val Ala Ser Thr Pro Glu Leu Phe Lys Leu Phe Leu Gln  
 65 70 75 80  
 Thr His Glu Ala Thr Ser Phe Asn Thr Arg Phe Gln Thr Ser Ala Ile  
 85 90 95  
 Arg Arg Leu Thr Tyr Asp Ser Leu Val Ala Met Val Pro Phe Gly Pro  
 100 105 110  
 Tyr Trp Lys Phe Val Arg Lys Leu Ile Met Asn Asp Leu Leu Asn Ala  
 115 120 125  
 Thr Thr Val Asn Lys Leu Arg Pro Leu Arg Thr Gln Gln Ile Arg Lys  
 130 135 140  
 Phe Leu Arg Val Met Ala Gln Gly Ala Glu Ala Gln Lys Pro Leu Asp  
 145 150 155 160  
 Leu Thr Glu Glu Leu Leu Lys Trp Thr Asn Ser Thr Ile Ser Met Met  
 165 170 175  
 Met Leu Gly Glu Ala Glu Glu Ile Arg Asp Ile Ala Arg Glu Val Leu  
 180 185 190  
 Lys Ile Tyr Gly Glu Tyr Ser Leu Thr Asp Phe Ile Trp Pro Leu Lys  
 195 200 205  
 His Leu Lys Val Gly Lys Tyr Glu Lys Arg Ile Asp Asp Ile Leu Asn  
 210 215 220  
 Lys Phe Asp Pro Val Val Glu Arg Val Ile Lys Lys Arg Arg Glu Ile  
 225 230 235 240  
 Val Arg Arg Arg Lys Asn Gly Glu Val Val Glu Gly Glu Val Ser Gly  
 245 250 255  
 Val Phe Leu Asp Thr Leu Leu Glu Phe Ala Glu Asp Glu Thr Thr Glu  
 260 265 270  
 Ile Lys Ile Thr Lys Asp His Ile Lys Gly Leu Val Val Asp Phe Phe  
 275 280 285  
 Ser Ala Gly Ile Asp Ser Thr Ala Val Ala Thr Glu Trp Ala Leu Ala  
 290 295 300  
 Glu Leu Ile Asn Asn Pro Lys Val Leu Glu Lys Ala Arg Glu Glu Val  
 305 310 315 320  
 Tyr Ser Val Val Gly Lys Asp Arg Leu Val Asp Glu Val Asp Thr Gln  
 325 330 335  
 Asn Leu Pro Tyr Ile Arg Ala Ile Val Lys Glu Thr Phe Arg Met His  
 340 345 350





Pro Pro Leu Pro Val Val Lys Arg Lys Cys Thr Glu Glu Cys Glu Ile  
 355 360 365

Asn Gly Tyr Val Ile Pro Glu Gly Ala Leu Ile Leu Phe Asn Val Trp  
 370 375 380

Gln Val Gly Arg Asp Pro Lys Tyr Trp Asp Arg Pro Ser Glu Phe Arg  
 385 390 395 400

Pro Glu Arg Phe Leu Glu Thr Gly Ala Glu Gly Glu Ala Arg Pro Leu  
 405 410 415

Asp Leu Arg Gly Gln His Phe Gln Leu Leu Pro Phe Gly Ser Gly Arg  
 420 425 430

Gly Met Cys Pro Gly Val Asn Leu Ala Thr Ser Gly Met Ala Thr Leu  
 435 440 445

Leu Ala Ser Leu Ile Gln Cys Phe Asp Leu Gln Val Leu Gly Pro Gln  
 450 455 460

Gly Gln Ile Leu Lys Gly Gly Asp Ala Lys Val Ser Met Glu Glu Arg  
 465 470 475 480

Ala Gly Leu Thr Val Pro Arg Ala His Ser Leu Val Cys Val Pro Leu  
 485 490 495

Ala Arg Ile

<210> 19  
 <211> 1501  
 <212> DNA  
 <213> Lens culinaris

<400> 19

tgtttctgca	cttgcgctccc	acacccactg	caaaatcaaa	agcacttcgc	catctcccaa	60
acccaccaag	cccaaagcct	cgtcttccct	tcataggaca	ccctcatctc	ttaaaagaca	120
aactttctcca	ctacgcactc	atcgacctct	ccaaaaaaca	tggtccctta	ttctccctct	180
actttggctc	catgccaacc	gttggtgcct	ccacaccaga	attgttcaag	ctcttccctc	240
aaacgcacga	ggcaacttcc	ttcaacacaa	ggttccaaac	ctcagccata	agacgcctca	300
cctatgatag	ctcagtggcc	atgggtccat	tccggacctta	ctggaagtgc	gtgaggaagc	360
tcatcatgaa	cgaccttctc	aacgccacca	ccgtcaacaa	gctcaggcct	ttgaggaccc	420
aacagatccg	caagttcctt	agggttatgg	cccaaagcgc	agaggcccag	aagccccttg	480
acgtcaccga	ggagcttctc	aaatggacca	acagcaccat	ctccatgatg	atgctcggcg	540
aggctgagga	gatcagagac	atcgctcgcg	aggttcttaa	gatcttcggc	gaatacagcc	600
tactgactt	catctggcct	ttgaagtatc	tcaaggttgg	aaagtatgag	aagaggattg	660
atgacatctt	gaacaagtcc	gaccctgtcg	ttgaaagggg	catcaagaag	cgccgtgaga	720
tcgtcagaag	gagaaagaac	ggagaagtgg	ttgagggcga	ggccagcggc	gtcttccctc	780
acactttgct	tgaattcgct	gaggacgaga	ccatggagat	caaaattacc	aaggagcaaa	840
tcaagggcct	tggtgtcgac	tttttctctg	cagggacaga	ttccacagcg	gtggcaacag	900
agtgggcatt	ggcagagctc	atcaacaatc	ccagggtggt	gcaaaaggct	cgtgaggagg	960
tctacagtgt	tgtgggcaaa	gatatactcg	ttgacgaagt	tgacactcaa	aaccttccct	1020
acattagggc	cattgtgaag	gagacattcc	gaatgcaccc	accactccca	gtggtcaaaa	1080
gaaagtgcac	agaagagtgt	gagattaatg	ggcatgtgat	cccagagggg	gcatttggtc	1140
ttttcaatgt	ttggcaagta	ggaagggacc	ccaaatactg	ggacagacca	tcagaattcc	1200
gtcccagagag	gttcttagaa	actggtgctg	aaggggaagc	agggcctctt	gatcttaggg	1260
gccagcattt	ccaactcctc	ccatttgggt	ctgggaggag	aatgtgccct	ggtgtcaatt	1320
tggtacttc	aggaatggca	acacttcttg	catctcttat	ccaatgcttt	gacctgcaag	1380
tgctgggccc	tcaaggacaa	atattgaaag	gtgatgatgc	caaagttagc	atggaagaga	1440
gagctggcct	cacagttcca	agggcacata	gtctcgtttg	tgttccactt	gcaaggatcg	1500
g						1501

<210> 20  
 <211> 499



&lt;212&gt; PRT

&lt;213&gt; Lens culinaris

&lt;400&gt; 20

Phe Leu His Leu Arg Pro Thr Pro Thr Ala Lys Ser Lys Ala Leu Arg  
 1 5 10 15  
 His Leu Pro Asn Pro Pro Ser Pro Lys Pro Arg Leu Pro Phe Ile Gly  
 20 25 30  
 His Pro His Leu Leu Lys Asp Lys Leu Leu His Tyr Ala Leu Ile Asp  
 35 40 45  
 Leu Ser Lys Lys His Gly Pro Leu Phe Ser Leu Tyr Phe Gly Ser Met  
 50 55 60  
 Pro Thr Val Val Ala Ser Thr Pro Glu Leu Phe Lys Leu Phe Leu Gln  
 65 70 75 80  
 Thr His Glu Ala Thr Ser Phe Asn Thr Arg Phe Gln Thr Ser Ala Ile  
 85 90 95  
 Arg Arg Leu Thr Tyr Asp Ser Ser Val Ala Met Val Pro Phe Gly Pro  
 100 105 110  
 Tyr Trp Lys Phe Val Arg Lys Leu Ile Met Asn Asp Leu Leu Asn Ala  
 115 120 125  
 Thr Thr Val Asn Lys Leu Arg Pro Leu Arg Thr Gln Gln Ile Arg Lys  
 130 135 140  
 Phe Leu Arg Val Met Ala Gln Ser Ala Glu Ala Gln Lys Pro Leu Asp  
 145 150 155 160  
 Val Thr Glu Glu Leu Leu Lys Trp Thr Asn Ser Thr Ile Ser Met Met  
 165 170 175  
 Met Leu Gly Glu Ala Glu Glu Ile Arg Asp Ile Ala Arg Glu Val Leu  
 180 185 190  
 Lys Ile Phe Gly Glu Tyr Ser Leu Thr Asp Phe Ile Trp Pro Leu Lys  
 195 200 205  
 Tyr Leu Lys Val Gly Lys Tyr Glu Lys Arg Ile Asp Asp Ile Leu Asn  
 210 215 220  
 Lys Phe Asp Pro Val Val Glu Arg Val Ile Lys Lys Arg Arg Glu Ile  
 225 230 235 240  
 Val Arg Arg Arg Lys Asn Gly Glu Val Val Glu Gly Glu Ala Ser Gly  
 245 250 255  
 Val Phe Leu Asp Thr Leu Leu Glu Phe Ala Glu Asp Glu Thr Met Glu  
 260 265 270  
 Ile Lys Ile Thr Lys Glu Gln Ile Lys Gly Leu Val Val Asp Phe Phe  
 275 280 285  
 Ser Ala Gly Thr Asp Ser Thr Ala Val Ala Thr Glu Trp Ala Leu Ala  
 290 295 300  
 Glu Leu Ile Asn Asn Pro Arg Val Leu Gln Lys Ala Arg Glu Glu Val  
 305 310 315 320  
 Tyr Ser Val Val Gly Lys Asp Ile Leu Val Asp Glu Val Asp Thr Gln  
 325 330 335



Asn Leu Pro Tyr Ile Arg Ala Ile Val Lys Glu Thr Phe Arg Met His  
 340 345 350  
 Pro Pro Leu Pro Val Val Lys Arg Lys Cys Thr Glu Glu Cys Glu Ile  
 355 360 365  
 Asn Gly His Val Ile Pro Glu Gly Ala Leu Val Leu Phe Asn Val Trp  
 370 375 380  
 Gln Val Gly Arg Asp Pro Lys Tyr Trp Asp Arg Pro Ser Glu Phe Arg  
 385 390 395 400  
 Pro Glu Arg Phe Leu Glu Thr Gly Ala Glu Gly Glu Ala Gly Pro Leu  
 405 410 415  
 Asp Leu Arg Gly Gln His Phe Gln Leu Leu Pro Phe Gly Ser Gly Arg  
 420 425 430  
 Arg Met Cys Pro Gly Val Asn Leu Ala Thr Ser Gly Met Ala Thr Leu  
 435 440 445  
 Leu Ala Ser Leu Ile Gln Cys Phe Asp Leu Gln Val Leu Gly Pro Gln  
 450 455 460  
 Gly Gln Ile Leu Lys Gly Asp Asp Ala Lys Val Ser Met Glu Glu Arg  
 465 470 475 480  
 Ala Gly Leu Thr Val Pro Arg Ala His Ser Leu Val Cys Val Pro Leu  
 485 490 495

Ala Arg Ile

<210> 21  
 <211> 1501  
 <212> DNA  
 <213> Lens culinaris

<400> 21  
 tgtttctgca cttgcgtccc acacccactg caaaatcaaa agcacttcgc catctcccaa 60  
 acccaccaag cccaaagcct cgtcttccct tcataggaca ccttcatctc ttaaaagaca 120  
 aacttctcca atcgacactc atcgacctct ccaaaaaaca tgggtccctta ttctctctct 180  
 actttggctc catgccaacc gttgttgccct ccacaccaga attgttcaag ctcttctctc 240  
 aaacgcacga ggcaacttcc ttcaacacaa ggttccaaac ctacagccata agacgcctca 300  
 cctatgatag ctacgtggcc atggttccct tcggacctta ctggaagttc gtgaggaagc 360  
 tcatcatgaa cgaccttctc aacgccacca ctgtaaaca gttgaggcct ttgaggaccc 420  
 aacagatccg caagttcctt agggttatgg cccaaggcgc agaggcacag aagccccttg 480  
 acttgaccga ggagcttctg aaatggacca acagcaccat ctccatgatg gtgctcggcg 540  
 aggctgagga gatcagagac atcgctcgcg aggttcttaa gatctttggc gaatacagcc 600  
 tcaactgactt catctggcca ttgaagcatc tcaaggttgg aaagtatgag aagaggatcg 660  
 acgacatctt gaacaagttc gaccctgtcg ttgaaagagt catcaagaag cgccgtgaga 720  
 tcgtgaggag gagaaagaac ggagaggttg ttgagggtga ggtcagcggg gttttccttg 780  
 acactttgct tgaattcgct gaggatgaga ccatggagat caaaatcacc aaggaccaca 840  
 tcaagggctt tgttgctcgac tttttctcgg caggaacaga ctccacagcg gtggcaacag 900  
 agtgggcatt ggcagaactc atcaacaatc ctaaggtgtt ggaaaaggct cgtgaggagg 960  
 tctacagtgt tgtgggaaag gacagacttg tggacgaagt tgacactcaa aaccttccct 1020  
 acattagagc aatcgtgaag gagacattcc gcatgcaccc gccactccca gtgggtcaaaa 1080  
 gaaagtgcac agaagagtgt gagattaatg gatgtgtgac cccagaggga gcattgattc 1140  
 tcttcaatgt atggcaagta ggaagagacc ccaaatactg ggacagacca tcggagttcc 1200  
 gtcctgagag gttcctagag acaggggctg aaggggaagc aaggcctctt gatcttaggg 1260  
 gacgacattt tcaacttctc ccatgtgggt ctgggaggag aatgtgccct ggagtcaatc 1320  
 tggctacttc gggaaatggca acacttcttg catctcttat tcagtgtttt gacttgcagg 1380  
 tgctgggtcc acaaggacag atattgaagg gtggtgacgc caaagttagc atggaagaga 1440  
 gagccggcct cactgttcca agggcacata gtcttgtctg tgttccactt gcaaggatcg 1500  
 9 1501



<210> 22  
 <211> 499  
 <212> PRT  
 <213> Lens culinaris

<400> 22  
 Phe Leu His Leu Arg Pro Thr Pro Thr Ala Lys Ser Lys Ala Leu Arg  
 1 5 10 15  
 His Leu Pro Asn Pro Pro Ser Pro Lys Pro Arg Leu Pro Phe Ile Gly  
 20 25 30  
 His Leu His Leu Leu Lys Asp Lys Leu Leu His Tyr Ala Leu Ile Asp  
 35 40 45  
 Leu Ser Lys Lys His Gly Pro Leu Phe Ser Leu Tyr Phe Gly Ser Met  
 50 55 60  
 Pro Thr Val Val Ala Ser Thr Pro Glu Leu Phe Lys Leu Phe Leu Gln  
 65 70 75 80  
 Thr His Glu Ala Thr Ser Phe Asn Thr Arg Phe Gln Thr Ser Ala Ile  
 85 90 95  
 Arg Arg Leu Thr Tyr Asp Ser Ser Val Ala Met Val Pro Phe Gly Pro  
 100 105 110  
 Tyr Trp Lys Phe Val Arg Lys Leu Ile Met Asn Asp Leu Leu Asn Ala  
 115 120 125  
 Thr Thr Val Asn Lys Leu Arg Pro Leu Arg Thr Gln Gln Ile Arg Lys  
 130 135 140  
 Phe Leu Arg Val Met Ala Gln Gly Ala Glu Ala Gln Lys Pro Leu Asp  
 145 150 155 160  
 Leu Thr Glu Glu Leu Leu Lys Trp Thr Asn Ser Thr Ile Ser Met Met  
 165 170 175  
 Val Leu Gly Glu Ala Glu Glu Ile Arg Asp Ile Ala Arg Glu Val Leu  
 180 185 190  
 Lys Ile Phe Gly Glu Tyr Ser Leu Thr Asp Phe Ile Trp Pro Leu Lys  
 195 200 205  
 His Leu Lys Val Gly Lys Tyr Glu Lys Arg Ile Asp Asp Ile Leu Asn  
 210 215 220  
 Lys Phe Asp Pro Val Val Glu Arg Val Ile Lys Lys Arg Arg Glu Ile  
 225 230 235 240  
 Val Arg Arg Arg Lys Asn Gly Glu Val Val Glu Gly Glu Val Ser Gly  
 245 250 255  
 Val Phe Leu Asp Thr Leu Leu Glu Phe Ala Glu Asp Glu Thr Met Glu  
 260 265 270  
 Ile Lys Ile Thr Lys Asp His Ile Lys Gly Leu Val Val Asp Phe Phe  
 275 280 285  
 Ser Ala Gly Thr Asp Ser Thr Ala Val Ala Thr Glu Trp Ala Leu Ala  
 290 295 300  
 Glu Leu Ile Asn Asn Pro Lys Val Leu Glu Lys Ala Arg Glu Glu Val  
 305 310 315 320





Tyr Ser Val Val Gly Lys Asp Arg Leu Val Asp Glu Val Asp Thr Gln  
 325 330 335  
 Asn Leu Pro Tyr Ile Arg Ala Ile Val Lys Glu Thr Phe Arg Met His  
 340 345 350  
 Pro Pro Leu Pro Val Val Lys Arg Lys Cys Thr Glu Glu Cys Glu Ile  
 355 360 365  
 Asn Gly Cys Val Thr Pro Glu Gly Ala Leu Ile Leu Phe Asn Val Trp  
 370 375 380  
 Gln Val Gly Arg Asp Pro Lys Tyr Trp Asp Arg Pro Ser Glu Phe Arg  
 385 390 395 400  
 Pro Glu Arg Phe Leu Glu Thr Gly Ala Glu Gly Glu Ala Arg Pro Leu  
 405 410 415  
 Asp Leu Arg Gly Arg His Phe Gln Leu Leu Pro Phe Gly Ser Gly Arg  
 420 425 430  
 Arg Met Cys Pro Gly Val Asn Leu Ala Thr Ser Gly Met Ala Thr Leu  
 435 440 445  
 Leu Ala Ser Leu Ile Gln Cys Phe Asp Leu Gln Val Leu Gly Pro Gln  
 450 455 460  
 Gly Gln Ile Leu Lys Gly Gly Asp Ala Lys Val Ser Met Glu Glu Arg  
 465 470 475 480  
 Ala Gly Leu Thr Val Pro Arg Ala His Ser Leu Val Cys Val Pro Leu  
 485 490 495

Ala Arg Ile

<210> 23  
 <211> 1566  
 <212> DNA  
 <213> Phaseolus aureus

<400> 23  
 atgttgctgg aacttgcaact tggttttattg gttttggctc tgtttctgca cttgcgtccc 60  
 actcccactg caaaatcaaaa agcacttcgc catctcccaa acccacciaag cccaaagcct 120  
 cgtcttccct tcataggaca ccttcattctc ttaaaagaca aacttctcca ctacgcactc 180  
 atcgacctct ccaaaaaaca tgggtccctta ttctctctct actttggctc catgccaacc 240  
 gttgttgctt ccacaccaga attgttcaag ctcttctctc aaacgcacga ggcaacttcc 300  
 ttcaacacaa ggttccaaac ctcagccata agacgcctca cctatgatag ctcaagtggc 360  
 atggttccct tcggacctta ctggaagttc gtgaggaagc tcatcatgaa cgaccttctc 420  
 aacgccacca ctgtaaacaa gttgaggcct ttgaggaccc aacagatccg caagttcctt 480  
 aggggttatgg cccaaggcgc agaggcacag aagccccttg acttgaccga ggagcttctg 540  
 aaatggacca acagcaccat ctccatgatg atgctcggcg aggttgaggc gatcagagac 600  
 atcgctcgcg aggttcttaa gatctttggc gaatacagcc tcactgactt catctggcca 660  
 ttgaagcatc tcaaggttgg aaagtatgag aagaggatcg acgacatctt gaacaagttc 720  
 gaccctgtcg ttgaaagagt catcaagaag cgccgtgaga tcgtgaggag gagaagaac 780  
 ggagaggttg ttgagggtga ggtcagcggg gttttccttg acactttgct tgaattcgct 840  
 gaggatgaga ccatggagat caaaatcacc aaggaccaca tcaagggctc tgttgctcgac 900  
 ttttctcgg caggaacaga ctccacagcg gtggcaacag agtgggcatt ggcagaactc 960  
 atcaacaatc ctaagggtgtt ggaaaaggct cgtgaggagg cctacagtgt tgtgggaaag 1020  
 gacagacttg tggacgaagt tgacactcaa aaccttctt acattagagc aatcgtgaag 1080  
 gagacattcc gcatgcaccc gccactccca gtggtcaaaa gaaagtgcac agaagagtgt 1140  
 gagattaatg gatattgtgat ccagagggga gcattgattc tcttcaatgt atggcaagta 1200  
 ggaagagacc ccaaatactg ggacagacca tcggagttcc gtcctgagag gttcctagag 1260  
 acaggggctg aaggggaagc aaggcctctt gatcttaggg gacaacattt tcaacttctc 1320  
 ccatttgggt ctgggaggag aatgtgccct ggagtcaatc tggctacttc gggaatggca 1380

**THIS PAGE BLANK (USPTO)**

```

acacttctcg catctcttat tcagtgcctt gacttgcaag tgctgggtcc acaaggacag 1440
atattgaagg gtggtgacgc caaagtttagc atggaagaga gagccggcct cactgttcca 1500
agggcacata gtcttgtctg tgttcactt gcaaggatcg gcgttgcatc taaactcctt 1560
tctaaa 1566

```

```

<210> 24
<211> 522
<212> PRT
<213> Phaseolus aureus

```

```

<400> 24
Met Leu Leu Glu Leu Ala Leu Gly Leu Leu Val Leu Ala Leu Phe Leu
 1          5          10          15

His Leu Arg Pro Thr Pro Thr Ala Lys Ser Lys Ala Leu Arg His Leu
      20          25          30

Pro Asn Pro Pro Ser Pro Lys Pro Arg Leu Pro Phe Ile Gly His Leu
      35          40          45

His Leu Leu Lys Asp Lys Leu Leu His Tyr Ala Leu Ile Asp Leu Ser
      50          55          60

Lys Lys His Gly Pro Leu Phe Ser Leu Tyr Phe Gly Ser Met Pro Thr
      65          70          75          80

Val Val Ala Ser Thr Pro Glu Leu Phe Lys Leu Phe Leu Gln Thr His
      85          90          95

Glu Ala Thr Ser Phe Asn Thr Arg Phe Gln Thr Ser Ala Ile Arg Arg
      100          105          110

Leu Thr Tyr Asp Ser Ser Val Ala Met Val Pro Phe Gly Pro Tyr Trp
      115          120          125

Lys Phe Val Arg Lys Leu Ile Met Asn Asp Leu Leu Asn Ala Thr Thr
      130          135          140

Val Asn Lys Leu Arg Pro Leu Arg Thr Gln Gln Ile Arg Lys Phe Leu
      145          150          155          160

Arg Val Met Ala Gln Gly Ala Glu Ala Gln Lys Pro Leu Asp Leu Thr
      165          170          175

Glu Glu Leu Leu Lys Trp Thr Asn Ser Thr Ile Ser Met Met Met Leu
      180          185          190

Gly Glu Ala Glu Glu Ile Arg Asp Ile Ala Arg Glu Val Leu Lys Ile
      195          200          205

Phe Gly Glu Tyr Ser Leu Thr Asp Phe Ile Trp Pro Leu Lys His Leu
      210          215          220

Lys Val Gly Lys Tyr Glu Lys Arg Ile Asp Asp Ile Leu Asn Lys Phe
      225          230          235          240

Asp Pro Val Val Glu Arg Val Ile Lys Lys Arg Arg Glu Ile Val Arg
      245          250          255

Arg Arg Lys Asn Gly Glu Val Val Glu Gly Glu Val Ser Gly Val Phe
      260          265          270

Leu Asp Thr Leu Leu Glu Phe Ala Glu Asp Glu Thr Met Glu Ile Lys
      275          280          285

```



Ile Thr Lys Asp His Ile Lys Gly Leu Val Val Asp Phe Phe Ser Ala  
 290 295 300

Gly Thr Asp Ser Thr Ala Val Ala Thr Glu Trp Ala Leu Ala Glu Leu  
 305 310 315 320

Ile Asn Asn Pro Lys Val Leu Glu Lys Ala Arg Glu Glu Ala Tyr Ser  
 325 330 335

Val Val Gly Lys Asp Arg Leu Val Asp Glu Val Asp Thr Gln Asn Leu  
 340 345 350

Pro Tyr Ile Arg Ala Ile Val Lys Glu Thr Phe Arg Met His Pro Pro  
 355 360 365

Leu Pro Val Val Lys Arg Lys Cys Thr Glu Glu Cys Glu Ile Asn Gly  
 370 375 380

Tyr Val Ile Pro Glu Gly Ala Leu Ile Leu Phe Asn Val Trp Gln Val  
 385 390 395 400

Gly Arg Asp Pro Lys Tyr Trp Asp Arg Pro Ser Glu Phe Arg Pro Glu  
 405 410 415

Arg Phe Leu Glu Thr Gly Ala Glu Gly Glu Ala Arg Pro Leu Asp Leu  
 420 425 430

Arg Gly Gln His Phe Gln Leu Leu Pro Phe Gly Ser Gly Arg Arg Met  
 435 440 445

Cys Pro Gly Val Asn Leu Ala Thr Ser Gly Met Ala Thr Leu Leu Ala  
 450 455 460

Ser Leu Ile Gln Cys Phe Asp Leu Gln Val Leu Gly Pro Gln Gly Gln  
 465 470 475 480

Ile Leu Lys Gly Gly Asp Ala Lys Val Ser Met Glu Glu Arg Ala Gly  
 485 490 495

Leu Thr Val Pro Arg Ala His Ser Leu Val Cys Val Pro Leu Ala Arg  
 500 505 510

Ile Gly Val Ala Ser Lys Leu Leu Ser Lys  
 515 520

<210> 25  
 <211> 1566  
 <212> DNA  
 <213> Phaseolus aureus

<400> 25  
 atgttgctgg aacttgcaact tggtttattg gttttggctc tgtttctgca cttgcgtccc 60  
 acacccactg caaaatcaaa agcacttcgc catctcccaa acccaccaag cccaaagcct 120  
 cgtcttccct tcataggaca ccttcattctc ttaaaaagaca aacttctcca ctacgcgtc 180  
 atcgacctct ccaaaaaaca tggctcccta ttctctctct actttggctc catgccaaacc 240  
 gttgttgccct ccacaccaga attgttcaag ctcttcctcc aaacgcacga ggcaacttcc 300  
 ttcaacacaa ggttccaaac ctacagccata agacgcctca cctatgatag ctacgtggcc 360  
 atggttcctt tcggacctta ctggaagttc gtgaggaagc tcatcatgaa cgaccttctc 420  
 aacgccacca ctgtaaaaca gttgaggcct ttgaggaccc aacagatccg caagttcctt 480  
 agggctatgg cccaaggcgc agaggcacag aagccccttg acttgaccga ggagcttctg 540  
 aaatggacca acagcaccat ctccatgatg atgctcggcg aggctgagga gatcagagac 600  
 atcgctcgcg aggttcttaa gatctttggc gaatacagcc tcaactgactt catctggcca 660  
 ttgaagcatc tcaagggttg aaagtatgag aagaggatcg acgacatctt gaacaagtcc 720  
 gaccctgtcg ttgaaagagt catcaagaag cgccgtgaga tcgtgaggag gagaaagaac 780  
 ggagagggtg ttgagggtga ggtcagcggg gtttctcttg acactttgct tgaattcgct 840  
 gaggatgaga ccatggagat caaaatcacc aaggaccaca tcaagggtct tgttgctgac 900



```

tttttctcgg caggaacaga ctccacagcg gtggcaacag agtgggcatt ggcagaactc 960
atcaacaatc ctaaggtggt ggaaaaggct cgtgaggagg tctacagtgt tgtgggaaag 1020
gacagacttg tggacgaagt tgacactcaa aaccttcctt acattagagc aatcgtgaag 1080
gagacattcc gcatgcaccc gccactccca gtggtcaaaa gaaagtgcac ggaagagtgt 1140
gagattaatg gatatgtgat ccagagggga gcaattgattc tcttcaatgt atggcaagta 1200
ggaagagacc ccaaatactg ggacagacca tcggagttcc gtcctgagag gttcctagag 1260
acaggggctg aaggggaagc aaggcctctt gatcttaggg gacaacattt tcaacttctc 1320
ccatttgggt ctgggaggag aatgtgccct ggagtcaatc tggctacttc gggaatggca 1380
acacttcttg catctcttat tcagtgtctt gacttgcaag tgetgggtcc acaaggacag 1440
atattgaagg gtgggtgacgc caaagttagc atggaagaga gagccggcct cactgttcca 1500
agggcacata gtcttgtctg tgttccactt gcaaggatcg gcgttgcatc taaactcctt 1560
tcttaa

```

<210> 26  
 <211> 521  
 <212> PRT  
 <213> Phaseolus aureus

<400> 26  
 Met Leu Leu Glu Leu Ala Leu Gly Leu Leu Val Leu Ala Leu Phe Leu  
 1 5 10 15  
 His Leu Arg Pro Thr Pro Thr Ala Lys Ser Lys Ala Leu Arg His Leu  
 20 25 30  
 Pro Asn Pro Pro Ser Pro Lys Pro Arg Leu Pro Phe Ile Gly His Leu  
 35 40 45  
 His Leu Leu Lys Asp Lys Leu Leu His Tyr Ala Leu Ile Asp Leu Ser  
 50 55 60  
 Lys Lys His Gly Pro Leu Phe Ser Leu Tyr Phe Gly Ser Met Pro Thr  
 65 70 75 80  
 Val Val Ala Ser Thr Pro Glu Leu Phe Lys Leu Phe Leu Gln Thr His  
 85 90 95  
 Glu Ala Thr Ser Phe Asn Thr Arg Phe Gln Thr Ser Ala Ile Arg Arg  
 100 105 110  
 Leu Thr Tyr Asp Ser Ser Val Ala Met Val Pro Phe Gly Pro Tyr Trp  
 115 120 125  
 Lys Phe Val Arg Lys Leu Ile Met Asn Asp Leu Leu Asn Ala Thr Thr  
 130 135 140  
 Val Asn Lys Leu Arg Pro Leu Arg Thr Gln Gln Ile Arg Lys Phe Leu  
 145 150 155 160  
 Arg Ala Met Ala Gln Gly Ala Glu Ala Gln Lys Pro Leu Asp Leu Thr  
 165 170 175  
 Glu Glu Leu Leu Lys Trp Thr Asn Ser Thr Ile Ser Met Met Met Leu  
 180 185 190  
 Gly Glu Ala Glu Glu Ile Arg Asp Ile Ala Arg Glu Val Leu Lys Ile  
 195 200 205  
 Phe Gly Glu Tyr Ser Leu Thr Asp Phe Ile Trp Pro Leu Lys His Leu  
 210 215 220  
 Lys Val Gly Lys Tyr Glu Lys Arg Ile Asp Asp Ile Leu Asn Lys Phe  
 225 230 235 240  
 Asp Pro Val Val Glu Arg Val Ile Lys Lys Arg Arg Glu Ile Val Arg  
 245 250 255





Arg Arg Lys Asn Gly Glu Val Val Glu Gly Glu Val Ser Gly Val Phe  
 260 265 270  
 Leu Asp Thr Leu Leu Glu Phe Ala Glu Asp Glu Thr Met Glu Ile Lys  
 275 280 285  
 Ile Thr Lys Asp His Ile Lys Gly Leu Val Val Asp Phe Phe Ser Ala  
 290 295 300  
 Gly Thr Asp Ser Thr Ala Val Ala Thr Glu Trp Ala Leu Ala Glu Leu  
 305 310 315 320  
 Ile Asn Asn Pro Lys Val Leu Glu Lys Ala Arg Glu Glu Val Tyr Ser  
 325 330 335  
 Val Val Gly Lys Asp Arg Leu Val Asp Glu Val Asp Thr Gln Asn Leu  
 340 345 350  
 Pro Tyr Ile Arg Ala Ile Val Lys Glu Thr Phe Arg Met His Pro Pro  
 355 360 365  
 Leu Pro Val Val Lys Arg Lys Cys Thr Glu Glu Cys Glu Ile Asn Gly  
 370 375 380  
 Tyr Val Ile Pro Glu Gly Ala Leu Ile Leu Phe Asn Val Trp Gln Val  
 385 390 395 400  
 Gly Arg Asp Pro Lys Tyr Trp Asp Arg Pro Ser Glu Phe Arg Pro Glu  
 405 410 415  
 Arg Phe Leu Glu Thr Gly Ala Glu Gly Glu Ala Arg Pro Leu Asp Leu  
 420 425 430  
 Arg Gly Gln His Phe Gln Leu Leu Pro Phe Gly Ser Gly Arg Arg Met  
 435 440 445  
 Cys Pro Gly Val Asn Leu Ala Thr Ser Gly Met Ala Thr Leu Leu Ala  
 450 455 460  
 Ser Leu Ile Gln Cys Phe Asp Leu Gln Val Leu Gly Pro Gln Gly Gln  
 465 470 475 480  
 Ile Leu Lys Gly Gly Asp Ala Lys Val Ser Met Glu Glu Arg Ala Gly  
 485 490 495  
 Leu Thr Val Pro Arg Ala His Ser Leu Val Cys Val Pro Leu Ala Arg  
 500 505 510  
 Ile Gly Val Ala Ser Lys Leu Leu Ser  
 515 520

<210> 27  
 <211> 1566  
 <212> DNA  
 <213> Phaseolus aureus

<400> 27  
 atgttgctgg aacttgcaact tggtttattg gttttggctc tgtttctgca cttgcgtccc 60  
 acaccactg caaaatcaaa agcacttcgc catctcccaa acccaccaag cccaaagcct 120  
 cgtcttccct tcataggaca cttcatctc ttaaaagaca aacttctcca ctacgcactc 180  
 atcgacctct ccaaaaaaca tggtcctta ttctctctc actttggctc catgccaacc 240  
 gttgttgctt ccacaccaga attgttcaag ctcttctcc aaacgcacga ggcaacttcc 300  
 ttcaacacaa ggttccaaac ctcagccata agacgcctca cctatgatag ctcatgtggc 360  
 atggttccct tcggacctta ctggaagttc gtgaggaagc tcatcatgaa cgaccttctc 420  
 aacgccacca ctgtaaaaca gttgaggcct ttgaggacc aacagatccg caagttcctt 480

**THIS PAGE BLANK (USPTO)**

```

agggttatgg cccaaggcgc agaggcacag aagccccttg acttgaccga ggagcttctg 540
aaatggacca acagcaccat ctccatgatg atgctcggcg aggctgagga gatcagagac 600
atcgctcgcg aggttcttaa gatctttggc gaatacagcc tctactgactt catctggcca 660
ttgaagcatc tcaaggttgg aaagtatgag aagaggatcg acgacatctt gaacaagttc 720
gaccctgtcg ttgaaagagt catcaagaag cgccgtgaga tcgtgaggag gagaaagaac 780
ggagaggttg ttgaggggtg ggtcagcggg gttttccttg acactttgct tgaattcgct 840
gaggatgaga ccacggagat caaaatcacg aaggaccaca tcaagggtct tgttgtcgac 900
tttttctcgg caggaacaga ctccacagcg gtggcaacag agtgggcatt ggcagaactc 960
atcaacaatc ctaaggtgtt ggaaaaggct cgtgaggagg tctacagtgt tgtgggaaag 1020
gacagacttg tggacgaagt tgacactcaa aaccttcctt acattagagc aatcgtgaag 1080
gagacatttc gcatgcacc gccactccca gtggtcaaaa gaaagtgcac agaagagtgt 1140
gagattaatg gatattgtat ccagagggga gcattgattc tcttcaatgt atggcaagta 1200
ggaagagacc ccaaatactg ggacagacca tcggagttcc gtcctgagag gttcctagag 1260
acaggggctg aaggggaagc aaggcctctt gatcttaggg gacaacattt tcaacttctc 1320
ccatttgggt ctgggaggag aatgtgccct ggagtcaatc tggctacttc gggaatggca 1380
acacttcttg catctcttat tcagtgtctt gacttgcaag tgctgggtcc acaaggacag 1440
atattgaagg gtggtgacgc caaagttagc atggaagaga gggccggcct cactgttcca 1500
agggcacata gtcttgtctg tgttccactt gcaaggatcg gcgttgcatc taaactcctt 1560
tcttaa

```

<210> 28  
 <211> 521  
 <212> PRT  
 <213> Phaseolus aureus

<400> 28  
 Met Leu Leu Glu Leu Ala Leu Gly Leu Leu Val Leu Ala Leu Phe Leu  
 1 5 10 15  
 His Leu Arg Pro Thr Pro Thr Ala Lys Ser Lys Ala Leu Arg His Leu  
 20 25 30  
 Pro Asn Pro Pro Ser Pro Lys Pro Arg Leu Pro Phe Ile Gly His Leu  
 35 40 45  
 His Leu Leu Lys Asp Lys Leu Leu His Tyr Ala Leu Ile Asp Leu Ser  
 50 55 60  
 Lys Lys His Gly Pro Leu Phe Ser Leu Tyr Phe Gly Ser Met Pro Thr  
 65 70 75 80  
 Val Val Ala Ser Thr Pro Glu Leu Phe Lys Leu Phe Leu Gln Thr His  
 85 90 95  
 Glu Ala Thr Ser Phe Asn Thr Arg Phe Gln Thr Ser Ala Ile Arg Arg  
 100 105 110  
 Leu Thr Tyr Asp Ser Ser Val Ala Met Val Pro Phe Gly Pro Tyr Trp  
 115 120 125  
 Lys Phe Val Arg Lys Leu Ile Met Asn Asp Leu Leu Asn Ala Thr Thr  
 130 135 140  
 Val Asn Lys Leu Arg Pro Leu Arg Thr Gln Gln Ile Arg Lys Phe Leu  
 145 150 155 160  
 Arg Val Met Ala Gln Gly Ala Glu Ala Gln Lys Pro Leu Asp Leu Thr  
 165 170 175  
 Glu Glu Leu Leu Lys Trp Thr Asn Ser Thr Ile Ser Met Met Met Leu  
 180 185 190  
 Gly Glu Ala Glu Glu Ile Arg Asp Ile Ala Arg Glu Val Leu Lys Ile  
 195 200 205

**THIS PAGE BLANK (USPTO)**

Phe Gly Glu Tyr Ser Leu Thr Asp Phe Ile Trp Pro Leu Lys His Leu  
 210 215 220  
 Lys Val Gly Lys Tyr Glu Lys Arg Ile Asp Asp Ile Leu Asn Lys Phe  
 225 230 235 240  
 Asp Pro Val Val Glu Arg Val Ile Lys Lys Arg Arg Glu Ile Val Arg  
 245 250 255  
 Arg Arg Lys Asn Gly Glu Val Val Glu Gly Glu Val Ser Gly Val Phe  
 260 265 270  
 Leu Asp Thr Leu Leu Glu Phe Ala Glu Asp Glu Thr Thr Glu Ile Lys  
 275 280 285  
 Ile Thr Lys Asp His Ile Lys Gly Leu Val Val Asp Phe Phe Ser Ala  
 290 295 300  
 Gly Thr Asp Ser Thr Ala Val Ala Thr Glu Trp Ala Leu Ala Glu Leu  
 305 310 315 320  
 Ile Asn Asn Pro Lys Val Leu Glu Lys Ala Arg Glu Glu Val Tyr Ser  
 325 330 335  
 Val Val Gly Lys Asp Arg Leu Val Asp Glu Val Asp Thr Gln Asn Leu  
 340 345 350  
 Pro Tyr Ile Arg Ala Ile Val Lys Glu Thr Phe Arg Met His Pro Pro  
 355 360 365  
 Leu Pro Val Val Lys Arg Lys Cys Thr Glu Glu Cys Glu Ile Asn Gly  
 370 375 380  
 Tyr Val Ile Pro Glu Gly Ala Leu Ile Leu Phe Asn Val Trp Gln Val  
 385 390 395 400  
 Gly Arg Asp Pro Lys Tyr Trp Asp Arg Pro Ser Glu Phe Arg Pro Glu  
 405 410 415  
 Arg Phe Leu Glu Thr Gly Ala Glu Gly Glu Ala Arg Pro Leu Asp Leu  
 420 425 430  
 Arg Gly Gln His Phe Gln Leu Leu Pro Phe Gly Ser Gly Arg Arg Met  
 435 440 445  
 Cys Pro Gly Val Asn Leu Ala Thr Ser Gly Met Ala Thr Leu Leu Ala  
 450 455 460  
 Ser Leu Ile Gln Cys Phe Asp Leu Gln Val Leu Gly Pro Gln Gly Gln  
 465 470 475 480  
 Ile Leu Lys Gly Gly Asp Ala Lys Val Ser Met Glu Glu Arg Ala Gly  
 485 490 495  
 Leu Thr Val Pro Arg Ala His Ser Leu Val Cys Val Pro Leu Ala Arg  
 500 505 510  
 Ile Gly Val Ala Ser Lys Leu Leu Ser  
 515 520

&lt;210&gt; 29

&lt;211&gt; 1566

&lt;212&gt; DNA

&lt;213&gt; Phaseolus aureus

**THIS PAGE BLANK (USPTO)**

<400> 29  
 atgttgctgg aacttgcaact tggtttattg gttttggctc tgtttctgca cttgcgtccc 60  
 acacccactg caaaatcaaa agcacttcgc catctcccaa acccaccaag cccaaagcct 120  
 cgtcttcctt tcataggaca ccttcacttc ttaaaagaca aacttctcca ctacgcactc 180  
 atcgacctct ccaaaaaaca tgggccctta ttctctctct actttggctc catgcccaacc 240  
 gttgttgccct ccacaccaga attgttcaag ctcttccctc aaacgcacga ggcaacttcc 300  
 ttcaacacaa ggttccaaac ctccagccata agacgcctca cctatgatag ctcatgtggc 360  
 atgggtccct tcggacctta ctggaagttc gtgaggaagc tcatcatgaa cgaccttctc 420  
 aacgccacca ctgtaaacia gttgaggcct ttgaggaccc aacagatccg caagttcctt 480  
 aggggttatgg cccaaggcgc agaggcacag aagccccttg acttgaccga ggagcttctg 540  
 aaatggacca acagcaccat ctccatgatg atgctcggcg aggtgagga gatcagagac 600  
 atcgctcgcg aggttcttaa gatctttggc gaatacagcc tcatgactt catctggcca 660  
 ttgaagcatc tcaaggttgg aaagtatgag aagaggatcg acgacatctt gaacaagttc 720  
 gaccctgtcg ttgaaagagt catcaagaag cgccgtgaga tcgtgaggag gagaaagaac 780  
 ggagagggtg ttgagggtga ggtcagcggg gttttccttg acactttgct tgaattcgct 840  
 gaggatgaga ccatggagat caaaatcacc aaggaccaca tcaaggggtc tgttgcgcac 900  
 tttttctcgg caggaacaga ctccacagcg gaggcaacag agtgggcatt ggcagaactc 960  
 atcaacaatc ctaaggtgtt ggaaaaggct cgtgaggagg tctacagtgt tgtgggaaag 1020  
 gacagacttg tggacgaagt tgacactcaa aaccttcctt acattagagc aatcgtgaag 1080  
 gagacattcc gcatgcaccc gccactccca gtggtcaaaa gaaagtgcac agaagagtgt 1140  
 gagattaatg gatattgtgat cccagaggga gcattgattc tcttcaatgt atggcaagta 1200  
 ggaagagacc ccaaatactg ggacagacca tcggagttcc gtcctgagag gttcctagag 1260  
 acaggggctg aaggggaagc aaggcctctt gatcttaggg gacaacattt tcaacttctc 1320  
 ccatttgggt ctgggaggag aatgtgccct ggagtcaatc tggctacttc gggaatggca 1380  
 acacttcttg catctcttat tcagtgtctt gacttgcaag tgctgggtcc acaaggacag 1440  
 atattgaagg gtggtgacgc caaagttagc atggaagaga gagccggcct cactgttcca 1500  
 agggcacata gtcttgcctg tgttccactt gcaaggatcg gcgttgcac taaactcctt 1560  
 tcttaa 1566

<210> 30  
 <211> 521  
 <212> PRT  
 <213> Phaseolus aureus

<400> 30  
 Met Leu Leu Glu Leu Ala Leu Gly Leu Leu Val Leu Ala Leu Phe Leu  
 1 5 10 15  
 His Leu Arg Pro Thr Pro Thr Ala Lys Ser Lys Ala Leu Arg His Leu  
 20 25 30  
 Pro Asn Pro Pro Ser Pro Lys Pro Arg Leu Pro Phe Ile Gly His Leu  
 35 40 45  
 His Leu Leu Lys Asp Lys Leu Leu His Tyr Ala Leu Ile Asp Leu Ser  
 50 55 60  
 Lys Lys His Gly Pro Leu Phe Ser Leu Tyr Phe Gly Ser Met Pro Thr  
 65 70 75 80  
 Val Val Ala Ser Thr Pro Glu Leu Phe Lys Leu Phe Leu Gln Thr His  
 85 90 95  
 Glu Ala Thr Ser Phe Asn Thr Arg Phe Gln Thr Ser Ala Ile Arg Arg  
 100 105 110  
 Leu Thr Tyr Asp Ser Ser Val Ala Met Val Pro Phe Gly Pro Tyr Trp  
 115 120 125  
 Lys Phe Val Arg Lys Leu Ile Met Asn Asp Leu Leu Asn Ala Thr Thr  
 130 135 140  
 Val Asn Lys Leu Arg Pro Leu Arg Thr Gln Gln Ile Arg Lys Phe Leu  
 145 150 155 160

**THIS PAGE BLANK (USPTO)**



Arg	Val	Met	Ala	Gln	Gly	Ala	Glu	Ala	Gln	Lys	Pro	Leu	Asp	Leu	Thr	165	170	175
Glu	Glu	Leu	Leu	Lys	Trp	Thr	Asn	Ser	Thr	Ile	Ser	Met	Met	Met	Leu	180	185	190
Gly	Glu	Ala	Glu	Glu	Ile	Arg	Asp	Ile	Ala	Arg	Glu	Val	Leu	Lys	Ile	195	200	205
Phe	Gly	Glu	Tyr	Ser	Leu	Thr	Asp	Phe	Ile	Trp	Pro	Leu	Lys	His	Leu	210	215	220
Lys	Val	Gly	Lys	Tyr	Glu	Lys	Arg	Ile	Asp	Asp	Ile	Leu	Asn	Lys	Phe	225	230	235
Asp	Pro	Val	Val	Glu	Arg	Val	Ile	Lys	Lys	Arg	Arg	Glu	Ile	Val	Arg	245	250	255
Arg	Arg	Lys	Asn	Gly	Glu	Val	Val	Glu	Gly	Glu	Val	Ser	Gly	Val	Phe	260	265	270
Leu	Asp	Thr	Leu	Leu	Glu	Phe	Ala	Glu	Asp	Glu	Thr	Met	Glu	Ile	Lys	275	280	285
Ile	Thr	Lys	Asp	His	Ile	Lys	Gly	Leu	Val	Val	Asp	Phe	Phe	Ser	Ala	290	295	300
Gly	Thr	Asp	Ser	Thr	Ala	Glu	Ala	Thr	Glu	Trp	Ala	Leu	Ala	Glu	Leu	305	310	315
Ile	Asn	Asn	Pro	Lys	Val	Leu	Glu	Lys	Ala	Arg	Glu	Glu	Val	Tyr	Ser	325	330	335
Val	Val	Gly	Lys	Asp	Arg	Leu	Val	Asp	Glu	Val	Asp	Thr	Gln	Asn	Leu	340	345	350
Pro	Tyr	Ile	Arg	Ala	Ile	Val	Lys	Glu	Thr	Phe	Arg	Met	His	Pro	Pro	355	360	365
Leu	Pro	Val	Val	Lys	Arg	Lys	Cys	Thr	Glu	Glu	Cys	Glu	Ile	Asn	Gly	370	375	380
Tyr	Val	Ile	Pro	Glu	Gly	Ala	Leu	Ile	Leu	Phe	Asn	Val	Trp	Gln	Val	385	390	395
Gly	Arg	Asp	Pro	Lys	Tyr	Trp	Asp	Arg	Pro	Ser	Glu	Phe	Arg	Pro	Glu	405	410	415
Arg	Phe	Leu	Glu	Thr	Gly	Ala	Glu	Gly	Glu	Ala	Arg	Pro	Leu	Asp	Leu	420	425	430
Arg	Gly	Gln	His	Phe	Gln	Leu	Leu	Pro	Phe	Gly	Ser	Gly	Arg	Arg	Met	435	440	445
Cys	Pro	Gly	Val	Asn	Leu	Ala	Thr	Ser	Gly	Met	Ala	Thr	Leu	Leu	Ala	450	455	460
Ser	Leu	Ile	Gln	Cys	Phe	Asp	Leu	Gln	Val	Leu	Gly	Pro	Gln	Gly	Gln	465	470	475
Ile	Leu	Lys	Gly	Gly	Asp	Ala	Lys	Val	Ser	Met	Glu	Glu	Arg	Ala	Gly	485	490	495
Leu	Thr	Val	Pro	Arg	Ala	His	Ser	Leu	Val	Cys	Val	Pro	Leu	Ala	Arg	500	505	510



Ile Gly Val Ala Ser Lys Leu Leu Ser  
515 520

<210> 31  
<211> 1566  
<212> DNA  
<213> *Trifolium pratense*

<400> 31  
atgttgctgg aacttgcaact tggtttattg gttttggctc tgtttctgca cttgcgtccc 60  
acaccactg caaaatcaaa agcacttcgc catctcccaa accaccaag cccaaagcct 120  
cgtcttccct tcataggaca ccttcatctc ttaaaagaca aacttctcca ctacgcactc 180  
atcgacctct ccaaaaaaca tggtcctta ttctctctct actttggctc catgccaacc 240  
gttgttgctt ccacaccaga attgttcaag ctcttcctcc aaacgcacga ggcaacttcc 300  
ttcaacacaa gggtccaaac ctccagccata agacgcctca cctatgatag ctcagtggcc 360  
atggttccca tcggacctta ctggaagttc gtgaggaagc tcatcatgaa cgaccttctc 420  
aacgccacca ctgtaaaca gttgaggcct ttgaggaccc aacagatccg caagttcctt 480  
aggggttatg cccaaggcgc agaggcacag aagccccttg acttgaccga ggagcttctg 540  
aaatggacca acagcaccat ctccatgatg atgctcggcg aggctgagga gatcagagac 600  
atcgctcgcg aggttcttaa gatctttggc gaatacagcc tcaactgactt catctggcca 660  
ttgaagcatc tcaaggtttg aaagtatgag aagaggatcg acgacatctt gaacaagttc 720  
gacctgtcgt ttgaaagagt catcaagaag cgccgtgaga tcgtgaggag gagaaagaac 780  
ggagagggtg atgaggggtg ggtcagcggg gttttccttg acactttgct tgaattcgct 840  
tggatgaga ccacgggat caaaatcacc aaggaccaca tcaagggctt tgttgtcgac 900  
gttttctcgg cagggacaga ctccacagcg gtggcaacag agtgggcatt ggcagaactc 960  
atcaacaatc ctaagggtgt ggaaaaggct cgtgaggagg tctacagtgt tgtgggaaag 1020  
gacagacttg tggacgaagt tgacactcaa aaccttcctt acattagagc aatcgtgaag 1080  
gagacattcc gcatgcaccc gccactccca gtggtcaaaa gaaagtgcac agaagagtgt 1140  
gagattaatg gatatgtgat ccagagggga gcattgattc tcttcaatgt atggcaagta 1200  
ggaagagacc ccaaatactg ggacagacca tcggagttcc gtcctgagag gttcctagag 1260  
acaggggctg aaggggaagc aaggcctctt gatcttaggg gacaacattt tcaacttctc 1320  
ccatttggtt ctgggaggag aatgtgccct ggagtcaatc tggctacttc gggaatggca 1380  
acacttcttg catctcttat tcagtgtttt gacttgcaag tgctgggtcc acaaggacag 1440  
atattgaagg gtggtgacgc caaagttagc atggaagaga gggccggcct cactgttcca 1500  
agggcacata gtcttgtctg tgttccactt gcaaggatcg gcgttgcatc taaactcctt 1566  
tcttaa 1566

<210> 32  
<211> 521  
<212> PRT  
<213> *Trifolium pratense*

<400> 32  
Met Leu Leu Glu Leu Ala Leu Gly Leu Leu Val Leu Ala Leu Phe Leu  
1 5 10 15  
His Leu Arg Pro Thr Pro Thr Ala Lys Ser Lys Ala Leu Arg His Leu  
20 25 30  
Pro Asn Pro Pro Ser Pro Lys Pro Arg Leu Pro Phe Ile Gly His Leu  
35 40 45  
His Leu Leu Lys Asp Lys Leu Leu His Tyr Ala Leu Ile Asp Leu Ser  
50 55 60  
Lys Lys His Gly Pro Leu Phe Ser Leu Tyr Phe Gly Ser Met Pro Thr  
65 70 75 80  
Val Val Ala Ser Thr Pro Glu Leu Phe Lys Leu Phe Leu Gln Thr His  
85 90 95  
Glu Ala Thr Ser Phe Asn Thr Arg Phe Gln Thr Ser Ala Ile Arg Arg  
100 105 110  
Leu Thr Tyr Asp Ser Ser Val Ala Met Val Pro Ile Gly Pro Tyr Trp  
115 120 125



Lys Phe Val Arg Lys Leu Ile Met Asn Asp Leu Leu Asn Ala Thr Thr  
 130 135 140  
 Val Asn Lys Leu Arg Pro Leu Arg Thr Gln Gln Ile Arg Lys Phe Leu  
 145 150 155 160  
 Arg Val Met Ala Gln Gly Ala Glu Ala Gln Lys Pro Leu Asp Leu Thr  
 165 170 175  
 Glu Glu Leu Leu Lys Trp Thr Asn Ser Thr Ile Ser Met Met Met Leu  
 180 185 190  
 Gly Glu Ala Glu Glu Ile Arg Asp Ile Ala Arg Glu Val Leu Lys Ile  
 195 200 205  
 Phe Gly Glu Tyr Ser Leu Thr Asp Phe Ile Trp Pro Leu Lys His Leu  
 210 215 220  
 Lys Val Gly Lys Tyr Glu Lys Arg Ile Asp Asp Ile Leu Asn Lys Phe  
 225 230 235 240  
 Asp Pro Val Val Glu Arg Val Ile Lys Lys Arg Arg Glu Ile Val Arg  
 245 250 255  
 Arg Arg Lys Asn Gly Glu Val Asp Glu Gly Glu Val Ser Gly Val Phe  
 260 265 270  
 Leu Asp Thr Leu Leu Glu Phe Ala Glu Asp Glu Thr Thr Glu Ile Lys  
 275 280 285  
 Ile Thr Lys Asp His Ile Lys Gly Leu Val Val Asp Phe Phe Ser Ala  
 290 295 300  
 Gly Thr Asp Ser Thr Ala Val Ala Thr Glu Trp Ala Leu Ala Glu Leu  
 305 310 315 320  
 Ile Asn Asn Pro Lys Val Leu Glu Lys Ala Arg Glu Glu Val Tyr Ser  
 325 330 335  
 Val Val Gly Lys Asp Arg Leu Val Asp Glu Val Asp Thr Gln Asn Leu  
 340 345 350  
 Pro Tyr Ile Arg Ala Ile Val Lys Glu Thr Phe Arg Met His Pro Pro  
 355 360 365  
 Leu Pro Val Val Lys Arg Lys Cys Thr Glu Glu Cys Glu Ile Asn Gly  
 370 375 380  
 Tyr Val Ile Pro Glu Gly Ala Leu Ile Leu Phe Asn Val Trp Gln Val  
 385 390 395 400  
 Gly Arg Asp Pro Lys Tyr Trp Asp Arg Pro Ser Glu Phe Arg Pro Glu  
 405 410 415  
 Arg Phe Leu Glu Thr Gly Ala Glu Gly Glu Ala Arg Pro Leu Asp Leu  
 420 425 430  
 Arg Gly Gln His Phe Gln Leu Leu Pro Phe Gly Ser Gly Arg Arg Met  
 435 440 445  
 Cys Pro Gly Val Asn Leu Ala Thr Ser Gly Met Ala Thr Leu Leu Ala  
 450 455 460  
 Ser Leu Ile Gln Cys Phe Asp Leu Gln Val Leu Gly Pro Gln Gly Gln  
 465 470 475 480



Ile Leu Lys Gly Gly Asp Ala Lys Val Ser Met Glu Glu Arg Ala Gly  
 485 490 495

Leu Thr Val Pro Arg Ala His Ser Leu Val Cys Val Pro Leu Ala Arg  
 500 505 510

Ile Gly Val Ala Ser Lys Leu Leu Ser  
 515 520

<210> 33  
 <211> 1566  
 <212> DNA  
 <213> Trifolium pratense

<400> 33  
 atgttgctgg aacttgcaact tggtttattg gttttggctc tgtttctgca cttgcgtccc 60  
 acacccactg caaaatcaaa agcacttcgc catctcccaa acccaccag cccaaagcct 120  
 cgtcttccct tcataggaca ccttcattctc ttaaaagaca aacttctcca ctacgcactc 180  
 atcgacctct ccaaaaaaca tggtccttta ttctctctct actttggctc catgccaaac 240  
 gttgttgccct ccacaccaga attgttcaag ctcttctctc aaacgcacga ggcaacttcc 300  
 ttcaacacaa ggttccaaac ctccagccata agacgcctca cctatgatag ctgagtgccc 360  
 atggttccct tcggacctta ctggaagtgc gtgaggaagc tcatcatgaa cgaccttctc 420  
 aacgccacca ctgtaaaca gttgaggcct ttgaggaccc aacagatccg caagtccctt 480  
 aggggttatgg cccaaggcgc agaggcacag aagccccttg acttgaccga ggagcttctg 540  
 aaatggacca acagcaccat ctccatgatg atgctcggcg aggctgagga gatcagagac 600  
 atcgctcgcg aggttcttaa gatctttggc gaatacagcc tcaactgactt catctggcca 660  
 ttgaagcatc tcaaggttgg aaagtatgag aagaggatcg acgacatctt gaacaagttc 720  
 gaccctgtcg ttgaaagagt catcaagaag cgccgtgaga tcgtgaggag gagaaagaac 780  
 ggagaggttg ttgaggggtga ggtcagcggg gttttccttg acactttgct tgaattcgct 840  
 gaggatgaga ccacggagat caaaatcacc aaggaccaca tcaaggtctt tgttgctgac 900  
 ttttctcgg caggaacaga ctccacagcg gtggcaacag agtgggcatt ggcagaactc 960  
 atcaacaatc ctaaggtgtt ggaaaaggct cgtgaggagg tctacagtgt tgtgggaaag 1020  
 gacagacttg tggacgaagt tgacactcaa aaccttctct acattagagc aatcgtagag 1080  
 gagacattcc gcatgcaccc gccactccca gtggtcaaaa gaaagtgcac agaagagtgt 1140  
 gagattaatg gatattgtgat cccagaggga gcattgattc tcttcaatgt atggcaagta 1200  
 ggaagagacc ccaaatactg ggacagacca tcggagttcc gtccctgagag gttcctagag 1260  
 acaggggctg aaggggaagc aaggcctctt gatcttaggg gacaacattt tcaacttctc 1320  
 ccatttgagg ctgggaggag aatgtgccct ggagtcaatc tggctacttc gggaatggca 1380  
 acacttcttg catctcttat tcagtgtctt gacttgcaag tgctgggtcc acaaggacag 1440  
 atattgaagg gtggtgacgc caaagttagc atggaagaga gggccggcct cactgttcca 1500  
 agggcacata gtcttgctctg tgttccactt gcaaggatcg gcgttgcatc taaactcctt 1560  
 tcttaa 1566

<210> 34  
 <211> 521  
 <212> PRT  
 <213> Trifolium pratense

<400> 34  
 Met Leu Leu Glu Leu Ala Leu Gly Leu Leu Val Leu Ala Leu Phe Leu  
 1 5 10 15  
 His Leu Arg Pro Thr Pro Thr Ala Lys Ser Lys Ala Leu Arg His Leu  
 20 25 30  
 Pro Asn Pro Pro Ser Pro Lys Pro Arg Leu Pro Phe Ile Gly His Leu  
 35 40 45  
 His Leu Leu Lys Asp Lys Leu Leu His Tyr Ala Leu Ile Asp Leu Ser  
 50 55 60  
 Lys Lys His Gly Pro Leu Phe Ser Leu Tyr Phe Gly Ser Met Pro Thr  
 65 70 75 80





Val Val Ala Ser Thr Pro Glu Leu Phe Lys Leu Phe Leu Gln Thr His  
 85 90 95  
 Glu Ala Thr Ser Phe Asn Thr Arg Phe Gln Thr Ser Ala Ile Arg Arg  
 100 105 110  
 Leu Thr Tyr Asp Ser Ser Val Ala Met Val Pro Phe Gly Pro Tyr Trp  
 115 120 125  
 Lys Phe Val Arg Lys Leu Ile Met Asn Asp Leu Leu Asn Ala Thr Thr  
 130 135 140  
 Val Asn Lys Leu Arg Pro Leu Arg Thr Gln Gln Ile Arg Lys Phe Leu  
 145 150 155 160  
 Arg Val Met Ala Gln Gly Ala Glu Ala Gln Lys Pro Leu Asp Leu Thr  
 165 170 175  
 Glu Glu Leu Leu Lys Trp Thr Asn Ser Thr Ile Ser Met Met Met Leu  
 180 185 190  
 Gly Glu Ala Glu Glu Ile Arg Asp Ile Ala Arg Glu Val Leu Lys Ile  
 195 200 205  
 Phe Gly Glu Tyr Ser Leu Thr Asp Phe Ile Trp Pro Leu Lys His Leu  
 210 215 220  
 Lys Val Gly Lys Tyr Glu Lys Arg Ile Asp Asp Ile Leu Asn Lys Phe  
 225 230 235 240  
 Asp Pro Val Val Glu Arg Val Ile Lys Lys Arg Arg Glu Ile Val Arg  
 245 250 255  
 Arg Arg Lys Asn Gly Glu Val Val Glu Gly Glu Val Ser Gly Val Phe  
 260 265 270  
 Leu Asp Thr Leu Leu Glu Phe Ala Glu Asp Glu Thr Thr Glu Ile Lys  
 275 280 285  
 Ile Thr Lys Asp His Ile Lys Gly Leu Val Val Asp Phe Phe Ser Ala  
 290 295 300  
 Gly Thr Asp Ser Thr Ala Val Ala Thr Glu Trp Ala Leu Ala Glu Leu  
 305 310 315 320  
 Ile Asn Asn Pro Lys Val Leu Glu Lys Ala Arg Glu Glu Val Tyr Ser  
 325 330 335  
 Val Val Gly Lys Asp Arg Leu Val Asp Glu Val Asp Thr Gln Asn Leu  
 340 345 350  
 Pro Tyr Ile Arg Ala Ile Val Lys Glu Thr Phe Arg Met His Pro Pro  
 355 360 365  
 Leu Pro Val Val Lys Arg Lys Cys Thr Glu Glu Cys Glu Ile Asn Gly  
 370 375 380  
 Tyr Val Ile Pro Glu Gly Ala Leu Ile Leu Phe Asn Val Trp Gln Val  
 385 390 395 400  
 Gly Arg Asp Pro Lys Tyr Trp Asp Arg Pro Ser Glu Phe Arg Pro Glu  
 405 410 415  
 Arg Phe Leu Glu Thr Gly Ala Glu Gly Glu Ala Arg Pro Leu Asp Leu  
 420 425 430



Arg Gly Gln His Phe Gln Leu Leu Pro Phe Gly Ser Gly Arg Arg Met  
 435 440 445

Cys Pro Gly Val Asn Leu Ala Thr Ser Gly Met Ala Thr Leu Leu Ala  
 450 455 460

Ser Leu Ile Gln Cys Phe Asp Leu Gln Val Leu Gly Pro Gln Gly Gln  
 465 470 475 480

Ile Leu Lys Gly Gly Asp Ala Lys Val Ser Met Glu Glu Arg Ala Gly  
 485 490 495

Leu Thr Val Pro Arg Ala His Ser Leu Val Cys Val Pro Leu Ala Arg  
 500 505 510

Ile Gly Val Ala Ser Lys Leu Leu Ser  
 515 520

<210> 35  
 <211> 1563  
 <212> DNA  
 <213> Pisum sativum

<400> 35  
 atgttgctgg aacttgcaact tggtttgttt gtgttagctt tgtttctgca cttgcgtccc 60  
 acaccaagcg caaaatcaaa agcacttcgc cacctcccaa accctccaag cccaaagcct 120  
 cgtcttcctt tcattggcca ccttcacctc ttaaaagata aacttctcca ctatgcactc 180  
 atcgatctct ccaaaaagca tggcccctta ttctctctct ccttcggctc catgccaacc 240  
 gtcgttgccct ccacccctga gttgttcaag ctcttcctcc aagcccacga ggcaacttcc 300  
 ttcagcacaa ggttccaaac ctctgccgta agacgcctca cttacgacaa ctctgtggcc 360  
 atggttccat tcggacctta ctggaagttc ttgaggaccc aacagatccg caagttcctt 420  
 aacgccacca ccgtcaacga gctcaggcct ttgaggaccc aacagatccg caagttcctt 480  
 aggggttatgg cccaaagcgc agaggcccag aagccccttg acgtcaccga ggagcttctc 540  
 aaatggacca acagcaccat ctccatgatg atgctcggcg aggttgagga gatcagagac 600  
 atcgctcgcg aggtccttaa gatcttcggc gaatacagcc tcaactgactt catctggcct 660  
 ttgaagtatc tcaagggttg aaagtatgag aagaggattg atgacatctt gaacaagttc 720  
 gaccctgtcg ttgaaagggg catcaagaag cgccgtgaga tcgtcagaag gagaaagAAC 780  
 ggagaagttg ttgagggcga ggccagcggc gtcttcctcg acactttgct tgaattcgct 840  
 gaggacgaga ccatggagat caaaattacc aaggagcaaa tcaagggcct tgttgctgac 900  
 tttttctctg cagggaacga ttccacagcg gtggcaacag agtgggcatt ggcagagctc 960  
 atcaacaatc ccagggtgtt gcaaaaggct cgtgaggagg tctacagtgt tgtgggcaaa 1020  
 gatagactcg ttgacgaagt cgacactcaa aaccttcctt acattagggc cattgtgaag 1080  
 gagacattcc gaatgcaccc accactccca gtggtcaaaa gaaagtgcac agaagagtgt 1140  
 gagattaatg ggtatgtgat ccagaggga gcattgggtt ttttcaatgt ttggcaagta 1200  
 ggaaaggacc ccaaatactg ggacagacca tcagaattcc gtcccagagag gttcttagaa 1260  
 actggcgctg aaggggaagc agggcctctt gatcttaggg gccagcattt ccaactcctc 1320  
 ccatttgggt ctgggaggag aatgtgccct ggtgtcaatt tggctacttc aggaatggca 1380  
 acacttcttg catctcttat ccaatgcttt gacctgcaag tgctgggccc tcaaggacaa 1440  
 atattgaaag gtgacgatgc caaagttagc atggaagaga gagctggcct caccgttcca 1500  
 agggcacata gtctcgtttg tgttccactt gcaaggatcg gcgttgcatc taaactcctt 1560  
 tct 1563

<210> 36  
 <211> 521  
 <212> PRT  
 <213> Pisum sativum

<400> 36  
 Met Leu Leu Glu Leu Ala Leu Gly Leu Phe Val Leu Ala Leu Phe Leu  
 1 5 10 15

His Leu Arg Pro Thr Pro Ser Ala Lys Ser Lys Ala Leu Arg His Leu  
 20 25 30

Pro Asn Pro Pro Ser Pro Lys Pro Arg Leu Pro Phe Ile Gly His Leu  
 35 40 45



His Leu Leu Lys Asp Lys Leu Leu His Tyr Ala Leu Ile Asp Leu Ser  
 50 55 60  
 Lys Lys His Gly Pro Leu Phe Ser Leu Ser Phe Gly Ser Met Pro Thr  
 65 70 75 80  
 Val Val Ala Ser Thr Pro Glu Leu Phe Lys Leu Phe Leu Gln Ala His  
 85 90 95  
 Glu Ala Thr Ser Phe Ser Thr Arg Phe Gln Thr Ser Ala Val Arg Arg  
 100 105 110  
 Leu Thr Tyr Asp Asn Ser Val Ala Met Val Pro Phe Gly Pro Tyr Trp  
 115 120 125  
 Lys Phe Val Arg Lys Leu Ile Met Asn Asp Leu Leu Asn Ala Thr Thr  
 130 135 140  
 Val Asn Glu Leu Arg Pro Leu Arg Thr Gln Gln Ile Arg Lys Phe Leu  
 145 150 155 160  
 Arg Val Met Ala Gln Ser Ala Glu Ala Gln Lys Pro Leu Asp Val Thr  
 165 170 175  
 Glu Glu Leu Leu Lys Trp Thr Asn Ser Thr Ile Ser Met Met Met Leu  
 180 185 190  
 Gly Glu Ala Glu Glu Ile Arg Asp Ile Ala Arg Glu Val Leu Lys Ile  
 195 200 205  
 Phe Gly Glu Tyr Ser Leu Thr Asp Phe Ile Trp Pro Leu Lys Tyr Leu  
 210 215 220  
 Lys Val Gly Lys Tyr Glu Lys Arg Ile Asp Asp Ile Leu Asn Lys Phe  
 225 230 235 240  
 Asp Pro Val Val Glu Arg Val Ile Lys Lys Arg Arg Glu Ile Val Arg  
 245 250 255  
 Arg Arg Lys Asn Gly Glu Val Val Glu Gly Glu Ala Ser Gly Val Phe  
 260 265 270  
 Leu Asp Thr Leu Leu Glu Phe Ala Glu Asp Glu Thr Met Glu Ile Lys  
 275 280 285  
 Ile Thr Lys Glu Gln Ile Lys Gly Leu Val Val Asp Phe Phe Ser Ala  
 290 295 300  
 Gly Thr Asp Ser Thr Ala Val Ala Thr Glu Trp Ala Leu Ala Glu Leu  
 305 310 315 320  
 Ile Asn Asn Pro Arg Val Leu Gln Lys Ala Arg Glu Glu Val Tyr Ser  
 325 330 335  
 Val Val Gly Lys Asp Arg Leu Val Asp Glu Val Asp Thr Gln Asn Leu  
 340 345 350  
 Pro Tyr Ile Arg Ala Ile Val Lys Glu Thr Phe Arg Met His Pro Pro  
 355 360 365  
 Leu Pro Val Val Lys Arg Lys Cys Thr Glu Glu Cys Glu Ile Asn Gly  
 370 375 380  
 Tyr Val Ile Pro Glu Gly Ala Leu Val Leu Phe Asn Val Trp Gln Val  
 385 390 395 400



Gly Lys Asp Pro Lys Tyr Trp Asp Arg Pro Ser Glu Phe Arg Pro Glu  
 405 410 415

Arg Phe Leu Glu Thr Gly Ala Glu Gly Glu Ala Gly Pro Leu Asp Leu  
 420 425 430

Arg Gly Gln His Phe Gln Leu Leu Pro Phe Gly Ser Gly Arg Arg Met  
 435 440 445

Cys Pro Gly Val Asn Leu Ala Thr Ser Gly Met Ala Thr Leu Leu Ala  
 450 455 460

Ser Leu Ile Gln Cys Phe Asp Leu Gln Val Leu Gly Pro Gln Gly Gln  
 465 470 475 480

Ile Leu Lys Gly Asp Asp Ala Lys Val Ser Met Glu Glu Arg Ala Gly  
 485 490 495

Leu Thr Val Pro Arg Ala His Ser Leu Val Cys Val Pro Leu Ala Arg  
 500 505 510

Ile Gly Val Ala Ser Lys Leu Leu Ser  
 515 520

<210> 37  
 <211> 1496  
 <212> DNA  
 <213> Trifolium repens

<400> 37  
 tctcacttgc gtcccacacc aagtgcata tcaaaagcac ttccgccacct cccaaaccct 60  
 ccaagcccaa ggccctcgtct tcccttcatt ggccaccttc acctctttaa agataaactt 120  
 ctccactatg caccatcgga tctctccaaa aagcatggcc ccttattctc tctctccttc 180  
 ggctccatgc caaccgtcgt tgcctccacc cctgagttgt tcaagctctt cctccaaacc 240  
 caccgaggcaa ctctccttcaa cacaagggtc caaacctctg ccataagaca cctcacttac 300  
 gacaactctg tggccatggt tccattcgga ccttactgga agttcgtgag gaagctcatc 360  
 atgaacgacc ttctcaacgc caccaccgtc aacaagctca ggcccttgag gacccaacag 420  
 atccgcaagt tccctagggt tatggcccaa agcgagagg cccagaagcc ccttgacgtc 480  
 accgaggagc ttctcaaatg gaccaacagc accatctcca tgatgatgct cggcgaggct 540  
 gaggagatca gagacatcgc tcgagagggt cttaagatct tcggcggaata cagcctcact 600  
 gacttcatct ggcccttgaa gtacctcaag gttggaaagt atgagaagag gattgatgac 660  
 atcttgaaaca agttcgaccc tgcgttgaa agggatcatca agaagcgccg tgagatcgtc 720  
 agaaggagaa agaacggaga agttgttgag ggcgaggcca gcggcgctct cctcgacact 780  
 ttgcttgaat tcgctgagga cgagaccatg gagatcaaaa ttaccaagga gcaaatcaag 840  
 ggcccttggtg tcgacttttt ctctgcaggg acagattcca cagcggtggt aacagagtgg 900  
 gcattggcag agctcatcaa caatcccagg gtgttgcaaa aggcctcgtg ggaggtctac 960  
 agtgttggtg gcaaagatag actcgttgac gaagttgaca ctcaaaacct tccttacatt 1020  
 agggccattg tgaaggagac attccgaatg caccaccac tcccagtggt caaaagaaag 1080  
 tgcacagaag agtgtgagat taatgggtat gtgatcccag agggagcatt gggtcttttc 1140  
 aatgtttggc aagtaggaag ggaccccaaa tactgggaca gaccatcaga atcccgctccc 1200  
 gagaggttct tagaaactgg tgctgaaggg gaagcagggc ctcttgatct taggggccag 1260  
 catttccaac tcttcccatt tgggtctggg aggagaatgt gccctggtgt cagtttggct 1320  
 acttcaggaa tggcaacact tcttgcatct cttatccaat gctttgacct gcaagtgtctg 1380  
 ggccctcaag gacaaatatt gaaaggtgat gatgccaaag ttagcatgga agagagagct 1440  
 ggccctcacag ttccaagggc acatagtctc gtttgtgttc cacttgcaag gatcgg 1496

<210> 38  
 <211> 498  
 <212> PRT  
 <213> Trifolium repens

<400> 38  
 Ser His Leu Arg Pro Thr Pro Ser Ala Ile Ser Lys Ala Leu Arg His  
 1 5 10 15





Leu Pro Asn Pro Pro Ser Pro Arg Pro Arg Leu Pro Phe Ile Gly His  
                     20                                    25                                    30  
 Leu His Leu Leu Lys Asp Lys Leu Leu His Tyr Ala Pro Ile Asp Leu  
                     35                                    40                                    45  
 Ser Lys Lys His Gly Pro Leu Phe Ser Leu Ser Phe Gly Ser Met Pro  
                     50                                    55                                    60  
 Thr Val Val Ala Ser Thr Pro Glu Leu Phe Lys Leu Phe Leu Gln Thr  
                     65                                    70                                    75                                    80  
 His Glu Ala Thr Ser Phe Asn Thr Arg Phe Gln Thr Ser Ala Ile Arg  
                                     85                                    90                                    95  
 His Leu Thr Tyr Asp Asn Ser Val Ala Met Val Pro Phe Gly Pro Tyr  
                                     100                                    105                                    110  
 Trp Lys Phe Val Arg Lys Leu Ile Met Asn Asp Leu Leu Asn Ala Thr  
                     115                                    120                                    125  
 Thr Val Asn Lys Leu Arg Pro Leu Arg Thr Gln Gln Ile Arg Lys Phe  
                     130                                    135                                    140  
 Leu Arg Val Met Ala Gln Ser Ala Glu Ala Gln Lys Pro Leu Asp Val  
                     145                                    150                                    155                                    160  
 Thr Glu Glu Leu Leu Lys Trp Thr Asn Ser Thr Ile Ser Met Met Met  
                                     165                                    170                                    175  
 Leu Gly Glu Ala Glu Glu Ile Arg Asp Ile Ala Arg Glu Val Leu Lys  
                     180                                    185                                    190  
 Ile Phe Gly Glu Tyr Ser Leu Thr Asp Phe Ile Trp Pro Leu Lys Tyr  
                     195                                    200                                    205  
 Leu Lys Val Gly Lys Tyr Glu Lys Arg Ile Asp Asp Ile Leu Asn Lys  
                     210                                    215                                    220  
 Phe Asp Pro Val Val Glu Arg Val Ile Lys Lys Arg Arg Glu Ile Val  
                     225                                    230                                    235                                    240  
 Arg Arg Arg Lys Asn Gly Glu Val Val Glu Gly Glu Ala Ser Gly Val  
                                     245                                    250                                    255  
 Phe Leu Asp Thr Leu Leu Glu Phe Ala Glu Asp Glu Thr Met Glu Ile  
                     260                                    265                                    270  
 Lys Ile Thr Lys Glu Gln Ile Lys Gly Leu Val Val Asp Phe Phe Ser  
                     275                                    280                                    285  
 Ala Gly Thr Asp Ser Thr Ala Val Val Thr Glu Trp Ala Leu Ala Glu  
                     290                                    295                                    300  
 Leu Ile Asn Asn Pro Arg Val Leu Gln Lys Ala Arg Glu Glu Val Tyr  
                     305                                    310                                    315                                    320  
 Ser Val Val Gly Lys Asp Arg Leu Val Asp Glu Val Asp Thr Gln Asn  
                                     325                                    330                                    335  
 Leu Pro Tyr Ile Arg Ala Ile Val Lys Glu Thr Phe Arg Met His Pro  
                     340                                    345                                    350  
 Pro Leu Pro Val Val Lys Arg Lys Cys Thr Glu Glu Cys Glu Ile Asn  
                     355                                    360                                    365



Gly Tyr Val Ile Pro Glu Gly Ala Leu Val Leu Phe Asn Val Trp Gln  
 370 375 380

Val Gly Arg Asp Pro Lys Tyr Trp Asp Arg Pro Ser Glu Ser Arg Pro  
 385 390 395 400

Glu Arg Phe Leu Glu Thr Gly Ala Glu Gly Glu Ala Gly Pro Leu Asp  
 405 410 415

Leu Arg Gly Gln His Phe Gln Leu Leu Pro Phe Gly Ser Gly Arg Arg  
 420 425 430

Met Cys Pro Gly Val Ser Leu Ala Thr Ser Gly Met Ala Thr Leu Leu  
 435 440 445

Ala Ser Leu Ile Gln Cys Phe Asp Leu Gln Val Leu Gly Pro Gln Gly  
 450 455 460

Gln Ile Leu Lys Gly Asp Asp Ala Lys Val Ser Met Glu Glu Arg Ala  
 465 470 475 480

Gly Leu Thr Val Pro Arg Ala His Ser Leu Val Cys Val Pro Leu Ala  
 485 490 495

Arg Ile

<210> 39  
 <211> 1501  
 <212> DNA  
 <213> Trifolium repens

<400> 39  
 tgttttctgca cttgcgtcccc acaccactcg caaaatcaaa agcacttcgc catctcccaa 60  
 acccaccag cccaaagcct cgtcttccct tcataggaca ccttcatctc ttaaaagaca 120  
 aactttctcca ctacgcactc atcgacctct ccaaaaaaca tggctccctta ttctctctct 180  
 acttttggtc catgccaacc gttgttgctt ccacaccaga attgttcaag ctcttctctc 240  
 aaacgcacga ggcaacttcc ttcaacacaa ggttccaaac ctccagccata agacgcctca 300  
 cctacgacaa ctctgtggcc atgggtccat tcggacctta ctggaagttc gtgagggaagc 360  
 tcatcatgaa cgaccttctc aacgccacca ccgtcaacaa gctcaggcct ttgaggaccc 420  
 aacagatccg caagttcctt aggggttatgg cccaaagcgc agaggcccag aagccccttg 480  
 acgtcaccca ggagcttctc aaatggacca acagcaccat ctccatgatg atgctcggcg 540  
 aggctgagga gatcagagac atcgctcgcg aggttcttaa gatcttcggc gaatacagcc 600  
 tcaactgactt catctggcct ttgaagtatc tcaagggttg aaagtatgag aagaggattg 660  
 atgacatctt gaacaagttc gacctgtcg ttgaaagagt catcaagaag cgccgtgaga 720  
 tcgtcagaag gagaaagaac ggagaagttg ttgaggcgga ggccagcggc gtcttctctc 780  
 acactttgct tgaattcgct gaggacgaga ccattggagat caaaattacc aaggagcaaa 840  
 tcaagggcct tgttgtcgac tttttctctg caggacaga ttccacagcg gtggcaacag 900  
 agtgggcatt ggcagagctc atcaacaatc ccaagggtgt gcaaaaggct cgtgaggagg 960  
 cctacagtgt tgtgggcaaa gatagactcg ttgacgaagt tgacactcaa aaccttccct 1020  
 acattagggc cattgtgaag gagacattcc gaatgcaccc accactccca gtggtcaaaa 1080  
 gaaagtgcac agaagagtgt gggattaatg ggtatgtgat ccagagggga gcattgggtc 1140  
 ttttcaatgt ttggcaagta ggaagggacc ccaataactg ggacagacca tcagaattcc 1200  
 gtcccgagag gttcttagaa actggtgctg aagggggaagc agggcctctt gatcttaggg 1260  
 gccagcattt ccaactcctc ccatttgggt ctgggaggag aatgtgccct ggtgtcaatt 1320  
 tggctacttc aggaatggca acacttcttg catctcttat ccaatgcttt gacctgcaag 1380  
 tgctgggccc tcaaggacaa atattgaaag gtgatgatgc caaagttagc atggaagaga 1440  
 gagctggcct cacagttcca agggcacata gtctcgtttg tgttccactt gcaaggatcg 1500  
 g 1501

<210> 40  
 <211> 499  
 <212> PRT  
 <213> Trifolium repens



&lt;400&gt; 40

Phe Leu His Leu Arg Pro Thr Pro Thr Ala Lys Ser Lys Ala Leu Arg  
 1 5 10 15  
 His Leu Pro Asn Pro Pro Ser Pro Lys Pro Arg Leu Pro Phe Ile Gly  
 20 25 30  
 His Leu His Leu Leu Lys Asp Lys Leu Leu His Tyr Ala Leu Ile Asp  
 35 40 45  
 Leu Ser Lys Lys His Gly Pro Leu Phe Ser Leu Tyr Phe Gly Ser Met  
 50 55 60  
 Pro Thr Val Val Ala Ser Thr Pro Glu Leu Phe Lys Leu Phe Leu Gln  
 65 70 75 80  
 Thr His Glu Ala Thr Ser Phe Asn Thr Arg Phe Gln Thr Ser Ala Ile  
 85 90 95  
 Arg Arg Leu Thr Tyr Asp Asn Ser Val Ala Met Val Pro Phe Gly Pro  
 100 105 110  
 Tyr Trp Lys Phe Val Arg Lys Leu Ile Met Asn Asp Leu Leu Asn Ala  
 115 120 125  
 Thr Thr Val Asn Lys Leu Arg Pro Leu Arg Thr Gln Gln Ile Arg Lys  
 130 135 140  
 Phe Leu Arg Val Met Ala Gln Ser Ala Glu Ala Gln Lys Pro Leu Asp  
 145 150 155 160  
 Val Thr Glu Glu Leu Leu Lys Trp Thr Asn Ser Thr Ile Ser Met Met  
 165 170 175  
 Met Leu Gly Glu Ala Glu Glu Ile Arg Asp Ile Ala Arg Glu Val Leu  
 180 185 190  
 Lys Ile Phe Gly Glu Tyr Ser Leu Thr Asp Phe Ile Trp Pro Leu Lys  
 195 200 205  
 Tyr Leu Lys Val Gly Lys Tyr Glu Lys Arg Ile Asp Asp Ile Leu Asn  
 210 215 220  
 Lys Phe Asp Pro Val Val Glu Arg Val Ile Lys Lys Arg Arg Glu Ile  
 225 230 235 240  
 Val Arg Arg Arg Lys Asn Gly Glu Val Val Glu Gly Glu Ala Ser Gly  
 245 250 255  
 Val Phe Leu Asp Thr Leu Leu Glu Phe Ala Glu Asp Glu Thr Met Glu  
 260 265 270  
 Ile Lys Ile Thr Lys Glu Gln Ile Lys Gly Leu Val Val Asp Phe Phe  
 275 280 285  
 Ser Ala Gly Thr Asp Ser Thr Ala Val Ala Thr Glu Trp Ala Leu Ala  
 290 295 300  
 Glu Leu Ile Asn Asn Pro Lys Val Leu Gln Lys Ala Arg Glu Glu Ala  
 305 310 315 320  
 Tyr Ser Val Val Gly Lys Asp Arg Leu Val Asp Glu Val Asp Thr Gln  
 325 330 335  
 Asn Leu Pro Tyr Ile Arg Ala Ile Val Lys Glu Thr Phe Arg Met His  
 340 345 350



Pro Pro Leu Pro Val Val Lys Arg Lys Cys Thr Glu Glu Cys Gly Ile  
 355 360 365

Asn Gly Tyr Val Ile Pro Glu Gly Ala Leu Val Leu Phe Asn Val Trp  
 370 375 380

Gln Val Gly Arg Asp Pro Lys Tyr Trp Asp Arg Pro Ser Glu Phe Arg  
 385 390 395 400

Pro Glu Arg Phe Leu Glu Thr Gly Ala Glu Gly Glu Ala Gly Pro Leu  
 405 410 415

Asp Leu Arg Gly Gln His Phe Gln Leu Leu Pro Phe Gly Ser Gly Arg  
 420 425 430

Arg Met Cys Pro Gly Val Asn Leu Ala Thr Ser Gly Met Ala Thr Leu  
 435 440 445

Leu Ala Ser Leu Ile Gln Cys Phe Asp Leu Gln Val Leu Gly Pro Gln  
 450 455 460

Gly Gln Ile Leu Lys Gly Asp Asp Ala Lys Val Ser Met Glu Glu Arg  
 465 470 475 480

Ala Gly Leu Thr Val Pro Arg Ala His Ser Leu Val Cys Val Pro Leu  
 485 490 495

Ala Arg Ile

<210> 41  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:PCR primer

<400> 41  
 ttgctggaac ttgcacttgg t

21

<210> 42  
 <211> 32  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:PCR primer

<400> 42  
 gtatatgatg ggtaccttaa ttaagaaagg ag

32

<210> 43  
 <211> 26  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:PCR primer

<400> 43  
 gacgcctcac ttacgacaac tctgtg

26

<210> 44  
 <211> 25





<212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence:PCR primer  
  
 <400> 44  
 cctctcggga cggaattctg atggt 25  
  
 <210> 45  
 <211> 25  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence:PCR primer  
  
 <400> 45  
 gcggtgcacg ggcggactct tcttc 25  
  
 <210> 46  
 <211> 25  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence:PCR primer  
  
 <400> 46  
 cgcccaatac gcaaaccgcc tctcc 25  
  
 <210> 47  
 <211> 1501  
 <212> DNA  
 <213> Beta vulgaris  
  
 <400> 47  
 tgtttctgca cttgcgtccc acaccactg caaaatcaaa agcacttcgc catctcccaa 60  
 acccaccaag cccaaagcct cgtcttccct tcataggaca ccttcatctc ttaaaagaca 120  
 aactttctcca ctacgcactc atcgacctct ccaaaaaaca tggctccctta ttctctctct 180  
 actttggctc catgccaaacc gttgttgctt ccacaccaga attgttcaag ctcttccctcc 240  
 aaacgcacga ggcaacttcc ttcaacacaa ggttccaaac ctcagccata agacgcctca 300  
 cctatgatag ctcaagtggc atggttccct tcggacctta ctggaagtgc gtgaggaagc 360  
 tcatcatgaa cgaccttctc aacgccacca ctgtaaacaa gttgaggcct ttgaggaccc 420  
 aacagatccg caagttcctt agggttatgg cccaaggcgc agaggcacag aagccccttg 480  
 acttgaccga ggagcttctg aaatggacca acagcaccat ctccatgatg atgctcggcg 540  
 aggctgagga gatcagagac atcgctcgcg aggttcttaa gatctttggc gaatacagcc 600  
 tcaactgactt catctggcca ttgaagcatc tcaaggttgg aaagtatgag aagaggatcg 660  
 acgacatctt gaacaagtgc gaccctgtcg ttgaaagagt catcaagaag cgccgtgaga 720  
 tcgtgaggag gagaaagaac ggagaggatg ttgagggtga ggtcagcggg gttttccttg 780  
 acactttgct tgaattcgct gaggatgaga ccatggagat caaaatcacc aaggaccaca 840  
 tcaagggctt tgttgtcgac tttttctcgg caggaacaga ctccacagcg gtggcaacag 900  
 agtgggcatt ggcagaactc atcaacaatc ctaaggtgtt ggaaaaggct cgtgaggagg 960  
 tctacagtgt tgtgggaaag gacagacttg tggacgaagt agacactcaa aaccttccct 1020  
 acattagagc aatcgtgag gagacattcc gcatgcaccc gccactccca gtggtcaaaa 1080  
 gaaagtgcag agaagagtgt gagattaatg gatattgtat ccagaggga gcattgattc 1140  
 tcttcaatgt atggcaagta ggaagagacc ctaaaactcg ggacagacca tcggagttcc 1200  
 gtccctgagag gttcctagag acaggggctg aaggggaagc aaggcttctt gatcttaggg 1260  
 gacaacattt tcaacttctc ccatttgggt ctgggaggag aatgtgccct ggagtcaatc 1320  
 tggctacttc gggaatggca acacttcttg catctcttat tcagtgtctt gacttgcaag 1380  
 tgctgggtcc acaaggacag atattgaagg gtggtgacgc caaagtttagc atggaagaga 1440  
 gagccggcct cactgttcca agggcacata gtcttgtctg tgttccactt gcaaggatcg 1500  
 g 1501  
  
 <210> 48  
 <211> 499



&lt;212&gt; PRT

&lt;213&gt; Beta vulgaris

&lt;400&gt; 48

Phe Leu His Leu Arg Pro Thr Pro Thr Ala Lys Ser Lys Ala Leu Arg  
 1 5 10 15  
 His Leu Pro Asn Pro Pro Ser Pro Lys Pro Arg Leu Pro Phe Ile Gly  
 20 25 30  
 His Leu His Leu Leu Lys Asp Lys Leu Leu His Tyr Ala Leu Ile Asp  
 35 40 45  
 Leu Ser Lys Lys His Gly Pro Leu Phe Ser Leu Tyr Phe Gly Ser Met  
 50 55 60  
 Pro Thr Val Val Ala Ser Thr Pro Glu Leu Phe Lys Leu Phe Leu Gln  
 65 70 75 80  
 Thr His Glu Ala Thr Ser Phe Asn Thr Arg Phe Gln Thr Ser Ala Ile  
 85 90 95  
 Arg Arg Leu Thr Tyr Asp Ser Ser Val Ala Met Val Pro Phe Gly Pro  
 100 105 110  
 Tyr Trp Lys Phe Val Arg Lys Leu Ile Met Asn Asp Leu Leu Asn Ala  
 115 120 125  
 Thr Thr Val Asn Lys Leu Arg Pro Leu Arg Thr Gln Gln Ile Arg Lys  
 130 135 140  
 Phe Leu Arg Val Met Ala Gln Gly Ala Glu Ala Gln Lys Pro Leu Asp  
 145 150 155 160  
 Leu Thr Glu Glu Leu Leu Lys Trp Thr Asn Ser Thr Ile Ser Met Met  
 165 170 175  
 Met Leu Gly Glu Ala Glu Glu Ile Arg Asp Ile Ala Arg Glu Val Leu  
 180 185 190  
 Lys Ile Phe Gly Glu Tyr Ser Leu Thr Asp Phe Ile Trp Pro Leu Lys  
 195 200 205  
 His Leu Lys Val Gly Lys Tyr Glu Lys Arg Ile Asp Asp Ile Leu Asn  
 210 215 220  
 Lys Phe Asp Pro Val Val Glu Arg Val Ile Lys Lys Arg Arg Glu Ile  
 225 230 235 240  
 Val Arg Arg Arg Lys Asn Gly Glu Asp Val Glu Gly Glu Val Ser Gly  
 245 250 255  
 Val Phe Leu Asp Thr Leu Leu Glu Phe Ala Glu Asp Glu Thr Met Glu  
 260 265 270  
 Ile Lys Ile Thr Lys Asp His Ile Lys Gly Leu Val Val Asp Phe Phe  
 275 280 285  
 Ser Ala Gly Thr Asp Ser Thr Ala Val Ala Thr Glu Trp Ala Leu Ala  
 290 295 300  
 Glu Leu Ile Asn Asn Pro Lys Val Leu Glu Lys Ala Arg Glu Glu Val  
 305 310 315 320  
 Tyr Ser Val Val Gly Lys Asp Arg Leu Val Asp Glu Val Asp Thr Gln  
 325 330 335

**THIS PAGE BLANK (USPTO)**

Asn Leu Pro Tyr Ile Arg Ala Ile Val Lys Glu Thr Phe Arg Met His  
                   340                                  345                                  350  
 Pro Pro Leu Pro Val Val Lys Arg Lys Cys Ile Glu Glu Cys Glu Ile  
                   355                                  360                                  365  
 Asn Gly Tyr Val Ile Pro Glu Gly Ala Leu Ile Leu Phe Asn Val Trp  
                   370                                  375                                  380  
 Gln Val Gly Arg Asp Pro Lys Tyr Trp Asp Arg Pro Ser Glu Phe Arg  
                   385                                  390                                  395                                  400  
 Pro Glu Arg Phe Leu Glu Thr Gly Ala Glu Gly Glu Ala Arg Leu Leu  
                                   405                                  410                                  415  
 Asp Leu Arg Gly Gln His Phe Gln Leu Leu Pro Phe Gly Ser Gly Arg  
                                   420                                  425                                  430  
 Arg Met Cys Pro Gly Val Asn Leu Ala Thr Ser Gly Met Ala Thr Leu  
                   435                                  440                                  445  
 Leu Ala Ser Leu Ile Gln Cys Phe Asp Leu Gln Val Leu Gly Pro Gln  
                   450                                  455                                  460  
 Gly Gln Ile Leu Lys Gly Gly Asp Ala Lys Val Ser Met Glu Glu Arg  
                   465                                  470                                  475                                  480  
 Ala Gly Leu Thr Val Pro Arg Ala His Ser Leu Val Cys Val Pro Leu  
                                   485                                  490                                  495

Ala Arg Ile

<210> 49  
 <211> 30  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:PCR primer

<400> 49  
 gaattcgcg cgcgtctaga actagtggat

30

<210> 50  
 <211> 30  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:PCR primer

<400> 50  
 gaattcgcg cgcgaattg ggtaccgggc

30

<210> 51  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:PCR primer

<400> 51  
 gcaaacgaag acaaattggga gatgata

27



<210> 52  
 <211> 1801  
 <212> DNA  
 <213> Glycine max

<220>  
 <221> intron  
 <222> (895)..(1112)

<400> 52  
 ttgctggaac ttgcacttgg tttgtttgtg ttagctttgt ttctgcactt gcgtcccaca 60  
 ccaagtgcaa aatcaaaagc acttcgccac ctcccaaacc ctccaagccc aaagcctcgt 120  
 cttcccttca ttggccacct tcacctctta aaagataaac ttctccacta tgcactcatc 180  
 gatctctcca aaaagcatgg ccccttattc tctctctcct tcggctccat gccaaccgtc 240  
 gttgcctcca cccctgagtt gttcaagctc ttctccaaa cccacgaggc aacttccttc 300  
 aacacaaggt tccaaacctc tgccataaga cgcctcactt acgacaactc tgtggccatg 360  
 gttccattcg gaccttactg gaagttcgtg aggaagctca tcatgaacga ccttctcaac 420  
 gccaccaccg tcaacaagct caggcctttg aggacccaac agatccgcaa gttccttagg 480  
 gttatggccc aaagcgcaaga gcccagaag ccccttgacg tcaccgagga gcttctcaaa 540  
 tggaccaaca gcaccatctc catgatgatg ctccggcgagg ctgaggagat cagagacatc 600  
 gctcgcgagg ttcttaagat cttcggcgaa tacagcctca ctgacttcat ctggcctttg 660  
 aagtatctca aggttggaag gtatgagaag aggattgatg acatcttgaa caagttcgac 720  
 cctgtcgttg aaagggtcat caagaagcgc cgtgagatcg tcagaaggag aaagaacgga 780  
 gaagtgtgtg agggcgaggc cagcggcgct tcctctgaca ctttgcttga attcgtgag 840  
 gacgagacca tggagatcaa aattaccaag gagcaaatca agggccttgt tgcgttaagt 900  
 ttcttcttc tctctactt tattactttc ttctattcat catatgtatt ggcatataat 960  
 agtatactat atgagaaaat atgttacgca ctacaggtgt aaagatatgt ggtgtttttt 1020  
 taaaaagaga tacagaagtt gcttttatgc atgtatgtta acgtatatatt actcaagtgg 1080  
 aaactaatta attctcaatt ttgggtatgt aggacttttt ctctgcaggg acagattcca 1140  
 cagcgttggc aacagagtgg gcattggcag agctcatcaa caatcccagg gtgttgcaaa 1200  
 aggtcgtgga ggaggtctac agtgttgtgg gcaaagatag actcgttgac gaagttgaca 1260  
 ctcaaaacct tccttacatt agggccattg tgaaggagac attccgaatg caccaccac 1320  
 tcccagtggt caaaagaaaag tgcacagaag agtgtgagat taatgggtat gtgatcccag 1380  
 agggagcatt ggttcttttc aatgtttggc aagtaggaag ggaccccaaa tactgggaca 1440  
 gaccatcaga attccgtccc gagaggttct tagaaactgg tgctgaaggg gaagcagggc 1500  
 ctcttgatct taggggccag catttccaac tcctccatt tgggtctggg aggagaatgt 1560  
 gccctggtgt caatttggtt acttcaggaa tggcaacact tcttgcatct cttatccaat 1620  
 gctttgacct gcaagtgtg ggccctcaag gacaaatatt gaaaggtgat gatgccaaag 1680  
 ttagcatgga agagagagct ggccctcag ttccaagggc acatagtctc gtttgtgttc 1740  
 cacttgcaag gatcggcggt gcatctaaac tcctttctta attaagggat ccatcatata 1800  
 c 1801

<210> 53  
 <211> 1900  
 <212> DNA  
 <213> Glycine max

<220>  
 <221> intron  
 <222> (947)..(1082)

<400> 53  
 aattagcctc acaaaagcaa agatcaaaca aaccaaggac gagaacacga tgttgcttga 60  
 acttgcaactt ggtttatttg ttttggctct gtttctgcac ttgcgtccca caccactgc 120  
 aaaatcaaaa gcacttcgcc atctcccaaa cccaccaagc ccaaagcctc gtcttccctt 180  
 cataggacac cttcatctct taaaagacaa acttctccac tacgactca tcgactctc 240  
 caaaaaacat ggtcccttat tctctctcta ctttggctcc atgccaaacg ttgtgcctc 300  
 cacaccagaa ttgttcaagc tcttctcca aacgcacgag gcaacttct tcaacacaag 360  
 gttccaaacc tcagccataa gacgcctcac ctatgatagc tcagtggcca tggttccctt 420  
 cggaccttac tggagttcg tgaggaagct catcatgaac gaccttccca acgccaccac 480  
 tgtaacaag ttgaggcctt tgaggaccga acagaccgcg aagttcctta gggttatggc 540  
 ccaaggcgca gaggcacaga agccccttga cttgaccgag gagcttctga aatggaccaa 600  
 cagcaccatc tccatgatga tgctcggcga ggctgaggag atcagagaca tcgctcgcga 660  
 ggttcttaag atctttggcg aatacagcct cactgacttc atctggccat tgaagcatct 720  
 caaggttggga aagtatgaga agaggatcga cgacatcttg aacaagttcg accctgtcgt 780

**THIS PAGE BLANK (USPTO)**



```

tgaaaggggtc atcaagaagc gccgtgagat cgtgaggagg agaaagaacg gagaggttgt 840
tgaggggtgag gtcagcgggg ttttccttga cacttttgctt gaattcgctg aggatgagac 900
catggagatc aaaatcacca aggaccacat cgagggtctt gttgtcgtga gtttcctgct 960
tcattcattg atcgaaatat gcagtatttt gttaacaaga gatcgagaat tgacatttat 1020
atattcatgt ggtggcaatt aattaacggt acgcattctt aatcgatatt gtgtatgtgc 1080
aggacttttt ctcggcagga acagactcca cagcgggtggc aacagagtgg gcattggcag 1140
aactcatcaa caatcctaag gtgttggaag aggctcgtga ggaggtctac agtgttggg 1200
gaaaggacag acttgtggac gaagttgaca ctcaaaacct tccttacatt agagcaatcg 1260
tgaaggagac attccgcatg caccggccac tcccagtggt caaaagaaaag tgcacagaag 1320
agtgtgagat taatggatat gtgatcccag agggagcatt gattctcttc aatgtatggc 1380
aagtaggaag agaccccaaa tactgggaca gaccatcggg gttccgtcct gagaggttcc 1440
tagagacagg ggctgaaggg gaagcagggc ctcttgatct tagggggacaa cattttcaac 1500
ttctcccat tgggtctggg aggagaatgt gccctggagt caatctggct acttcgggaa 1560
tggcaacact tcttgcatct cttattcagt gcttcgactt gcaagtgtcg ggtccacaag 1620
gacagatatt gaagggtggt gacgccaag ttagcatgga agagagagcc ggctcactg 1680
ttccaagggc acatagtctt gtctgtgttc cacttgcaag gatcggcggt gcactctaac 1740
tcctttctta attaagatca tcgtcatcat catcatatat aatatttact ttttgtgtgt 1800
tgataatcat catttcaata aggtctcgtt catctacttt ttatgaagta tataagccct 1860
tccatgcaca ttgtatcatc tcccatttgt cttcgtttgc 1900

```

<210> 54  
 <211> 1501  
 <212> DNA  
 <213> Lupinus albus

```

<400> 54
tgtttctgca cttgcgtccc acacccactg caaaatcaaa agcacttcgc catctcccaa 60
acccaccaag cccaaagcct cgtcttccct tcataggaca ccttcatctc ttaaaagaca 120
aacttctcca ctacgcactc atcgacctct ccaaaaaaca tggctccctta ttctctctct 180
actttggctc catgccaacc gttgttgctt ccacaccaga attgttcaag ctcttctctc 240
aaacgcacga ggcaacttcc ttcaacacaa ggttccaaac ctcagccata agacgcctca 300
cctatgatag ctacgtggcc agggttccct tcggacctta ctggaagtgc gtgaggaagc 360
tcatcatgaa cgaccttctt aacgccacca ctgtaaacaa gttgaggcct ttgaggacc 420
aacagatccg caagttcctt agggttatgg cccaaggcgc agaggcacag aagccccttg 480
acttgaccga ggagcttctg aaatggacca acagcaccat ctccatgatg atgctcggcg 540
aggctgagga gatcagagac atcgctcgcg aggttcttaa gatctttggc gaatacagcc 600
tactgactt catctggcca ttgaagcatc tcaaggttgg aaagtatgag aagaggatcg 660
acgacatctt gaacaagttc gacctgtctg ttgaaagagt catcaagaag cgccgtgaga 720
tcgtgaggag gagaaagaac ggagaggttg ttgaggttga ggtcagcggg gttctccttg 780
acactttgct tgaattcgct gaggatgaga ccattggagat caaaatcacc aaggaccaca 840
tcaagggtct tgtgtcgac tttttctcgg caggaacaga ctccacagcg gtggcaacag 900
agtgggcatt ggcagaactc atcaacaatc ctaaggtgtt ggaaagggtc cgtgaggagg 960
tctacagtgt tgtgggaaag gacagacttg tggacgaagt tgacactcaa aaccttctct 1020
acattagagc aatcgtgaag gagacattcc gcatgcaccc gccactccca gtgggtcaaaa 1080
gaaagtgcac agaagagtgt gagattaatg gatatgtgat ccagagggga gcattgattc 1140
tcttcaatgt atggcaagta ggaagagacc ccaaatactg ggacagacca tcggagttcc 1200
gtcctgagag gttcctagag acagaggctg aagggggaagc aaggcctctt gatcttaggg 1260
gacaacattt tcaacttctc ccatttgggt ctgggaggag aatgtgccct ggagtcattc 1320
tggctacttc gggaatggca acacttcttg catctcttat tcagtgtctt gacttgcaag 1380
tgctgggtcc acaaggacag atattgaagg gtggtgacgc caaagttagc atggaagaga 1440
gagccggcct cactgttcca agggcacata gtcttgtctg tgttccactt gcaaggatcg 1500
g

```

<210> 55  
 <211> 499  
 <212> PRT  
 <213> Lupinus albus

```

<400> 49
Phe Leu His Leu Arg Pro Thr Pro Thr Ala Lys Ser Lys Ala Leu Arg
 1             5             10             15
His Leu Pro Asn Pro Pro Ser Pro Lys Pro Arg Leu Pro Phe Ile Gly
          20             25             30

```



His Leu His Leu Leu Lys Asp Lys Leu Leu His Tyr Ala Leu Ile Asp  
 35 40 45  
 Leu Ser Lys Lys His Gly Pro Leu Phe Ser Leu Tyr Phe Gly Ser Met  
 50 55 60  
 Pro Thr Val Val Ala Ser Thr Pro Glu Leu Phe Lys Leu Phe Leu Gln  
 65 70 75 80  
 Thr His Glu Ala Thr Ser Phe Asn Thr Arg Phe Gln Thr Ser Ala Ile  
 85 90 95  
 Arg Arg Leu Thr Tyr Asp Ser Ser Val Ala Arg Val Pro Phe Gly Pro  
 100 105 110  
 Tyr Trp Lys Phe Val Arg Lys Leu Ile Met Asn Asp Leu Leu Asn Ala  
 115 120 125  
 Thr Thr Val Asn Lys Leu Arg Pro Leu Arg Thr Gln Gln Ile Arg Lys  
 130 135 140  
 Phe Leu Arg Val Met Ala Gln Gly Ala Glu Ala Gln Lys Pro Leu Asp  
 145 150 155 160  
 Leu Thr Glu Glu Leu Leu Lys Trp Thr Asn Ser Thr Ile Ser Met Met  
 165 170 175  
 Met Leu Gly Glu Ala Glu Glu Ile Arg Asp Ile Ala Arg Glu Val Leu  
 180 185 190  
 Lys Ile Phe Gly Glu Tyr Ser Leu Thr Asp Phe Ile Trp Pro Leu Lys  
 195 200 205  
 His Leu Lys Val Gly Lys Tyr Glu Lys Arg Ile Asp Asp Ile Leu Asn  
 210 215 220  
 Lys Phe Asp Pro Val Val Glu Arg Val Ile Lys Lys Arg Arg Glu Ile  
 225 230 235 240  
 Val Arg Arg Arg Lys Asn Gly Glu Val Val Glu Gly Glu Val Ser Gly  
 245 250 255  
 Val Leu Leu Asp Thr Leu Leu Glu Phe Ala Glu Asp Glu Thr Met Glu  
 260 265 270  
 Ile Lys Ile Thr Lys Asp His Ile Lys Gly Leu Val Val Asp Phe Phe  
 275 280 285  
 Ser Ala Gly Thr Asp Ser Thr Ala Val Ala Thr Glu Trp Ala Leu Ala  
 290 295 300  
 Glu Leu Ile Asn Asn Pro Lys Val Leu Glu Arg Ala Arg Glu Glu Val  
 305 310 315 320  
 Tyr Ser Val Val Gly Lys Asp Arg Leu Val Asp Glu Val Asp Thr Gln  
 325 330 335  
 Asn Leu Pro Tyr Ile Arg Ala Ile Val Lys Glu Thr Phe Arg Met His  
 340 345 350  
 Pro Pro Leu Pro Val Val Lys Arg Lys Cys Thr Glu Glu Cys Glu Ile  
 355 360 365  
 Asn Gly Tyr Val Ile Pro Glu Gly Ala Leu Ile Leu Phe Asn Val Trp  
 370 375 380



Gln Val Gly Arg Asp Pro Lys Tyr Trp Asp Arg Pro Ser Glu Phe Arg  
 385 390 395 400

Pro Glu Arg Phe Leu Glu Thr Glu Ala Glu Gly Glu Ala Arg Pro Leu  
 405 410 415

Asp Leu Arg Gly Gln His Phe Gln Leu Leu Pro Phe Gly Ser Gly Arg  
 420 425 430

Arg Met Cys Pro Gly Val Ile Leu Ala Thr Ser Gly Met Ala Thr Leu  
 435 440 445

Leu Ala Ser Leu Ile Gln Cys Phe Asp Leu Gln Val Leu Gly Pro Gln  
 450 455 460

Gly Gln Ile Leu Lys Gly Gly Asp Ala Lys Val Ser Met Glu Glu Arg  
 465 470 475 480

Ala Gly Leu Thr Val Pro Arg Ala His Ser Leu Val Cys Val Pro Leu  
 485 490 495

Ala Arg Ile

<210> 56  
 <211> 1501  
 <212> DNA  
 <213> Medicago sativa

<400> 56  
 tgttttctgca cttgcgtccc acacccactg caaaatcaaaa agcacttcgc catctcccaa 60  
 acccaccag cccaaagcct cgtcttccct tcataggaca ccttcacatc ttaaaagaca 120  
 aacttctcca ctacgcactc atcgacctct ccaaaaaaca tggccctta ttctctctct 180  
 actttggctc catgccaaac gttgttgccr ccacaccaga attgttcaag ctcttccttc 240  
 aaacgcacga ggcaacttcc ttcaacacaa ggttccaaac ctacagccata agacgcctca 300  
 cctatgatag ctacagtggc atggctccct tggacctta ctggaagttc gtgaggaagc 360  
 tcatcatgaa cgaccttctc aacgccacca ctgtaaaca gttgaggcct ttgaggaccc 420  
 aacagatccg caagttcctt agggttatgg cccaaggcgc agaggcacag aagccccttg 480  
 acttgaccga ggagcttctg aaatggacca acagcaccac ctccatgatg atgctcggcg 540  
 aggctgagga gatcagagac atcgcccgcg aggttcttaa gatctttggc gaatacagcc 600  
 tcaactgact catccggcca ttgaagcatc tcaaggttg aaagtatgag aagaggatcg 660  
 acgacatctt gaacaagttc gacctgtcg ttgaaagagt catcaagaag cgccgtgaga 720  
 tcgtgaggag gagaaagaac ggagaggttg ttgaggggta ggtcagcggg gttttccttg 780  
 acactttgct tgaattcgct gaggatgaga ccacggagat caaaatcacc aaggaccaca 840  
 tcaagggctt tgttgctgac tttttctcgg caggaacaga ctccacagcg gtggcaacag 900  
 agtgggcatt ggcagaactc atcaacaatc ctaaggtgtt ggaaaaggct cgtgaggagg 960  
 tctacagtgt tgtgggaaag gacagacttg tggacgaagt tgacactcaa aaccttccct 1020  
 acattagagc aatcgtgaag gagacattcc gcatgcaccc gccactccca gtgggtcaaaa 1080  
 gaaagtgcac agaagagtgt gagattaatg gatattgat ccagagggga gcattgattc 1140  
 tcttcaatgt atggcaagta ggaagagact ccaaatactg ggacagacca tcggagttcc 1200  
 gtctgagag gttcttagag acaggggctg aagggaagc aaggcctctt gatcttaggg 1260  
 gacaacattt tcaacttctc ccatttgggt ctgggaggag aatgtgccct ggagtcaatc 1320  
 tggctacttc gggaaatggca acacttcttg catctcttat tcagtgttt gacttgcaag 1380  
 tgcgggtcc acaaggacag atattgaagg gtggtgacgc caaagttagc atggaagaga 1440  
 gggcggcct cactgttcca agggcacata gtcttgtctg tgttcactt gcaaggatcg 1500  
 g 1501

<210> 57  
 <211> 499  
 <212> PRT  
 <213> Medicago sativa

<400> 57  
 Phe Leu His Leu Arg Pro Thr Pro Thr Ala Lys Ser Lys Ala Leu Arg  
 1 5 10 15



His Leu Pro Asn Pro Pro Ser Pro Lys Pro Arg Leu Pro Phe Ile Gly  
                   20                  25                  30  
 His Leu His Leu Leu Lys Asp Lys Leu Leu His Tyr Ala Leu Ile Asp  
                   35                  40                  45  
 Leu Ser Lys Lys His Gly Pro Leu Phe Ser Leu Tyr Phe Gly Ser Met  
                   50                  55                  60  
 Pro Thr Val Val Ala Ser Thr Pro Glu Leu Phe Lys Leu Phe Leu Gln  
                   65                  70                  75                  80  
 Thr His Glu Ala Thr Ser Phe Asn Thr Arg Phe Gln Thr Ser Ala Ile  
                   85                  90                  95  
 Arg Arg Leu Thr Tyr Asp Ser Ser Val Ala Met Ala Pro Phe Gly Pro  
                   100                  105                  110  
 Tyr Trp Lys Phe Val Arg Lys Leu Ile Met Asn Asp Leu Leu Asn Ala  
                   115                  120                  125  
 Thr Thr Val Asn Lys Leu Arg Pro Leu Arg Thr Gln Gln Ile Arg Lys  
                   130                  135                  140  
 Phe Leu Arg Val Met Ala Gln Gly Ala Glu Ala Gln Lys Pro Leu Asp  
                   145                  150                  155                  160  
 Leu Thr Glu Glu Leu Leu Lys Trp Thr Asn Ser Thr Thr Ser Met Met  
                   165                  170                  175  
 Met Leu Gly Glu Ala Glu Glu Ile Arg Asp Ile Ala Arg Glu Val Leu  
                   180                  185                  190  
 Lys Ile Phe Gly Glu Tyr Ser Leu Thr Asp Phe Ile Arg Pro Leu Lys  
                   195                  200                  205  
 His Leu Lys Val Gly Lys Tyr Glu Lys Arg Ile Asp Asp Ile Leu Asn  
                   210                  215                  220  
 Lys Phe Asp Pro Val Val Glu Arg Val Ile Lys Lys Arg Arg Glu Ile  
                   225                  230                  235                  240  
 Val Arg Arg Arg Lys Asn Gly Glu Val Val Glu Gly Glu Val Ser Gly  
                   245                  250                  255  
 Val Phe Leu Asp Thr Leu Leu Glu Phe Ala Glu Asp Glu Thr Thr Glu  
                   260                  265                  270  
 Ile Lys Ile Thr Lys Asp His Ile Lys Gly Leu Val Val Asp Phe Phe  
                   275                  280                  285  
 Ser Ala Gly Thr Asp Ser Thr Ala Val Ala Thr Glu Trp Ala Leu Ala  
                   290                  295                  300  
 Glu Leu Ile Asn Asn Pro Lys Val Leu Glu Lys Ala Arg Glu Glu Val  
                   305                  310                  315                  320  
 Tyr Ser Val Val Gly Lys Asp Arg Leu Val Asp Glu Val Asp Thr Gln  
                   325                  330                  335  
 Asn Leu Pro Tyr Ile Arg Ala Ile Val Lys Glu Thr Phe Arg Met His  
                   340                  345                  350  
 Pro Pro Leu Pro Val Val Lys Arg Lys Cys Thr Glu Glu Cys Glu Ile  
                   355                  360                  365





Asn Gly Tyr Val Ile Pro Glu Gly Ala Leu Ile Leu Phe Asn Val Trp  
 370 375 380

Gln Val Gly Arg Asp Ser Lys Tyr Trp Asp Arg Pro Ser Glu Phe Arg  
 385 390 395 400

Pro Glu Arg Phe Leu Glu Thr Gly Ala Glu Gly Glu Ala Arg Pro Leu  
 405 410 415

Asp Leu Arg Gly Gln His Phe Gln Leu Leu Pro Phe Gly Ser Gly Arg  
 420 425 430

Arg Met Cys Pro Gly Val Asn Leu Ala Thr Ser Gly Met Ala Thr Leu  
 435 440 445

Leu Ala Ser Leu Ile Gln Cys Phe Asp Leu Gln Val Leu Gly Pro Gln  
 450 455 460

Gly Gln Ile Leu Lys Gly Gly Asp Ala Lys Val Ser Met Glu Glu Arg  
 465 470 475 480

Ala Gly Leu Thr Val Pro Arg Ala His Ser Leu Val Cys Val Pro Leu  
 485 490 495

Ala Arg Ile

<210> 58  
 <211> 1501  
 <212> DNA  
 <213> Medicago sativa

<400> 58

tgtttctgca	cttgcgctccc	acacccactg	caaaatcaaa	agcacttcgc	catctcccaa	60
acccaccaag	cccaaagcct	cgtcttcctt	tcataggaca	ccttcattct	ttaaaagaca	120
aacttctcca	ctacgcactc	atcgacctct	ccaaaaaaca	tggctccctta	ttctctctct	180
actttggctc	catgccaaac	gttggtgcct	ccacaccaga	attgttcaag	ctcttctctc	240
aaacgcacga	ggcaacttcc	ttcaacacaa	ggttccaaac	ctcagccata	agacgcctca	300
cctatgatag	ctcagtggcc	atgggtccct	tccgacctta	ctggaagtgc	gtgaggaagc	360
tcatcatgaa	cgaccttctc	aacgccacca	ctgtaaacia	gttgaggcct	ttgaggacct	420
aacagatccg	caagctcctt	agggttatgg	cccaaggcgc	agaggcacag	aagccccttg	480
acttgaccga	ggagcttctg	aaatggacca	acagcaccat	ctccatgatg	atgctcggcg	540
aggctgagga	gatcagagac	atcgctcgcg	aggttcttaa	gatctttggc	gaatacagcc	600
tactgacttt	catctggcca	ttgaagcatc	tcaagggttg	aaagtatgag	aagaggatcg	660
acgacatctt	gaacaagttc	gaccctgtcg	ttgaaagagt	catcaagaag	cgccgtgaga	720
tcgtgaggag	gagaaagaac	ggagagggtta	ttgagggtga	ggtcagcggg	gttttccttg	780
acactttgct	tgaattcgct	gaggatgaga	ccacggagat	caaaatcacc	aaggaccaca	840
tcaagggtct	tggtgtcgac	tttttctcgg	caggaacaga	ctccacagcg	gtggcaacag	900
agtgggcatt	ggcagaactc	atcaacaatc	ctaagggtgt	ggagaaggct	cgtgaggagg	960
tctacagtgt	tgtgggaaag	gacagacttg	tggaacgaag	tgacactcaa	aaccttcctt	1020
acattagagc	aatcgtgaag	gagacattcc	gcatgcaccc	gccactccca	gtggtcaaaa	1080
gaaagtgcac	agaagagtgt	gagattaatg	gatattgtat	cccagaggga	gcattgattc	1140
tcttcaatgt	atggcaagta	ggaagagacc	ccaaatactg	ggacagacca	tcggagttcc	1200
gtcctgagag	gttccttagag	acaggggctg	aaggggaagc	aaggcctctt	gatcttaggg	1260
gacaacattt	tcaacttctc	ccatttgggt	ctgggaggag	aatgtgccct	ggagtcaatc	1320
tggtacttct	gggaatggca	acacttcttg	catctcttat	tcagtgcctt	gacttgcaag	1380
tgctgggtcc	acaaggacag	atattgaagg	gtggtgacgc	caaagtttag	atggaagaga	1440
gggcccgcct	cactgttcca	agggcacata	gtcttgtctg	tgttccactt	gcaaggatcg	1500
g						1501

<210> 59  
 <211> 499  
 <212> PRT  
 <213> Medicago sativa



&lt;400&gt; 59

Phe Leu His Leu Arg Pro Thr Pro Thr Ala Lys Ser Lys Ala Leu Arg  
 1 5 10 15  
 His Leu Pro Asn Pro Pro Ser Pro Lys Pro Arg Leu Pro Phe Ile Gly  
 20 25 30  
 His Leu His Leu Leu Lys Asp Lys Leu Leu His Tyr Ala Leu Ile Asp  
 35 40 45  
 Leu Ser Lys Lys His Gly Pro Leu Phe Ser Leu Tyr Phe Gly Ser Met  
 50 55 60  
 Pro Thr Val Val Ala Ser Thr Pro Glu Leu Phe Lys Leu Phe Leu Gln  
 65 70 75 80  
 Thr His Glu Ala Thr Ser Phe Asn Thr Arg Phe Gln Thr Ser Ala Ile  
 85 90 95  
 Arg Arg Leu Thr Tyr Asp Ser Ser Val Ala Met Val Pro Phe Gly Pro  
 100 105 110  
 Tyr Trp Lys Phe Val Arg Lys Leu Ile Met Asn Asp Leu Leu Asn Ala  
 115 120 125  
 Thr Thr Val Asn Lys Leu Arg Pro Leu Arg Thr Gln Gln Ile Arg Lys  
 130 135 140  
 Leu Leu Arg Val Met Ala Gln Gly Ala Glu Ala Gln Lys Pro Leu Asp  
 145 150 155 160  
 Leu Thr Glu Glu Leu Leu Lys Trp Thr Asn Ser Thr Ile Ser Met Met  
 165 170 175  
 Met Leu Gly Glu Ala Glu Glu Ile Arg Asp Ile Ala Arg Glu Val Leu  
 180 185 190  
 Lys Ile Phe Gly Glu Tyr Ser Leu Thr Asp Phe Ile Trp Pro Leu Lys  
 195 200 205  
 His Leu Lys Val Gly Lys Tyr Glu Lys Arg Ile Asp Asp Ile Leu Asn  
 210 215 220  
 Lys Phe Asp Pro Val Val Glu Arg Val Ile Lys Lys Arg Arg Glu Ile  
 225 230 235 240  
 Val Arg Arg Arg Lys Asn Gly Glu Val Ile Glu Gly Glu Val Ser Gly  
 245 250 255  
 Val Phe Leu Asp Thr Leu Leu Glu Phe Ala Glu Asp Glu Thr Thr Glu  
 260 265 270  
 Ile Lys Ile Thr Lys Asp His Ile Lys Gly Leu Val Val Asp Phe Phe  
 275 280 285  
 Ser Ala Gly Thr Asp Ser Thr Ala Val Ala Thr Glu Trp Ala Leu Ala  
 290 295 300  
 Glu Leu Ile Asn Asn Pro Lys Val Leu Glu Lys Ala Arg Glu Glu Val  
 305 310 315 320  
 Tyr Ser Val Val Gly Lys Asp Arg Leu Val Asp Glu Val Asp Thr Gln  
 325 330 335  
 Asn Leu Pro Tyr Ile Arg Ala Ile Val Lys Glu Thr Phe Arg Met His  
 340 345 350

**THIS PAGE BLANK (USPTO)**

Pro Pro Leu Pro Val Val Lys Arg Lys Cys Thr Glu Glu Cys Glu Ile  
 355 360 365

Asn Gly Tyr Val Ile Pro Glu Gly Ala Leu Ile Leu Phe Asn Val Trp  
 370 375 380

Gln Val Gly Arg Asp Pro Lys Tyr Trp Asp Arg Pro Ser Glu Phe Arg  
 385 390 395 400

Pro Glu Arg Phe Leu Glu Thr Gly Ala Glu Gly Glu Ala Arg Pro Leu  
 405 410 415

Asp Leu Arg Gly Gln His Phe Gln Leu Leu Pro Phe Gly Ser Gly Arg  
 420 425 430

Arg Met Cys Pro Gly Val Asn Leu Ala Thr Ser Gly Met Ala Thr Leu  
 435 440 445

Leu Ala Ser Leu Ile Gln Cys Phe Asp Leu Gln Val Leu Gly Pro Gln  
 450 455 460

Gly Gln Ile Leu Lys Gly Gly Asp Ala Lys Val Ser Met Glu Glu Arg  
 465 470 475 480

Ala Gly Leu Thr Val Pro Arg Ala His Ser Leu Val Cys Val Pro Leu  
 485 490 495

Ala Arg Ile

<210> 60  
 <211> 1497  
 <212> DNA  
 <213> Beta vulgaris

<400> 60  
 tctgcacttg cgtcccacac ccactgcaaa atcaaaagca cttcgccatc tcccaaacc 60  
 accaagccca aagcctcgtc ttcccttcat aggacacctt catctcttaa aagacaaact 120  
 tctccactac gcaactcatcg accttccaa aaaacatggt cccttattct ctcaactactt 180  
 tggctccatg ccaaccgttg ttgcctccac accagaattg ttcaagctct tcctccaaac 240  
 gaacgaggca acttcttca acacaagggt ccaaacctca gccataagac gcctcaccta 300  
 tgatagctca gtggccatgg ttcccttcgg accttactgg aagttcgtga ggaagctcat 360  
 catgaacgac cttctcaacg ccaccactgt aaacaagttg aggccttga ggacccaaca 420  
 gatccgcaag ttccttaggg ctatggccca aggcgcagag gcacggaagc cccttgactt 480  
 gaccgaggag cttctgaaat gggccaacag caccatctcc atgatgatgc tcggcgaggc 540  
 tgaggagatc agagacatcg ctgcgagggt tcttaagatc tttggcgaat acagcctcac 600  
 tgacttcatc tggccattga agcatctcaa gggttgaaag tatgagaaga ggatcgacga 660  
 catcttgaac aagttcgacc ctgtcgttga aagagtcac aagaagcgcc gtgagatcgt 720  
 gaggaggaga aagaacggag aggttggtga gggtagggtc agcggggtt tccttgacac 780  
 tttgcttgaa ttcgctgagg atgagaccat ggagatcaaa atcaccaagg accacacca 840  
 gggctctgtt gtcgacttct tctcggcagg aacagactcc acagcgggtg caacagagt 900  
 ggcattggca gaactcatca acaatcctaa ggtgttgaa aaggctcgtg aggaggtcta 960  
 cagtgttgtg ggaaaggaca gacttgttga cgaagttgac actcaaaacc ttccttacat 1020  
 tagagcaatc gtgaaggaga cattccgcat gcaccgcca ctcccagtgg tcaaaagaaa 1080  
 gtgcacagaa gagtgtgaga ttaattggata tgtgatccca gagggagcat tgattccctt 1140  
 caatgtatgg caagtaggaa gagaccccaa atactgggac agaccatcgg agttccgtcc 1200  
 tgagaggttc cttagagacag gggctgaagg ggaagcaagg cctcttgatc ttaggggaca 1260  
 acattttcaa cttctcccat ttgggtctgg gaggagaatg tgccctggag tcaatctggc 1320  
 tacttcggga acggcaacac ttcttgcac tcttattcag tgctttgact tgcaagtgtc 1380  
 gggccacag ggacagatat tgaagggtgg tgacgcaaaa gttagcatgg aagagagagc 1440  
 cggcctcact gttccaaggg cacatagtct tgtctgtgtt ccacttgcaa ggatcgg 1497

<210> 61  
 <211> 498



<212> PRT  
 <213> Beta vulgaris

<400> 61

```

Leu His Leu Arg Pro Thr Pro Thr Ala Lys Ser Lys Ala Leu Arg His
  1              5              10              15

Leu Pro Asn Pro Pro Ser Pro Lys Pro Arg Leu Pro Phe Ile Gly His
              20              25              30

Leu His Leu Leu Lys Asp Lys Leu Leu His Tyr Ala Leu Ile Asp Leu
      35              40              45

Ser Lys Lys His Gly Pro Leu Phe Ser His Tyr Phe Gly Ser Met Pro
  50              55              60

Thr Val Val Ala Ser Thr Pro Glu Leu Phe Lys Leu Phe Leu Gln Thr
  65              70              75              80

Asn Glu Ala Thr Ser Phe Asn Thr Arg Phe Gln Thr Ser Ala Ile Arg
              85              90              95

Arg Leu Thr Tyr Asp Ser Ser Val Ala Met Val Pro Phe Gly Pro Tyr
              100              105              110

Trp Lys Phe Val Arg Lys Leu Ile Met Asn Asp Leu Leu Asn Ala Thr
      115              120              125

Thr Val Asn Lys Leu Arg Pro Leu Arg Thr Gln Gln Ile Arg Lys Phe
      130              135              140

Leu Arg Ala Met Ala Gln Gly Ala Glu Ala Arg Lys Pro Leu Asp Leu
      145              150              155              160

Thr Glu Glu Leu Leu Lys Trp Ala Asn Ser Thr Ile Ser Met Met Met
      165              170              175

Leu Gly Glu Ala Glu Glu Ile Arg Asp Ile Ala Arg Glu Val Leu Lys
      180              185              190

Ile Phe Gly Glu Tyr Ser Leu Thr Asp Phe Ile Trp Pro Leu Lys His
      195              200              205

Leu Lys Val Gly Lys Tyr Glu Lys Arg Ile Asp Asp Ile Leu Asn Lys
      210              215              220

Phe Asp Pro Val Val Glu Arg Val Ile Lys Lys Arg Arg Glu Ile Val
      225              230              235              240

Arg Arg Arg Lys Asn Gly Glu Val Val Glu Gly Glu Val Ser Gly Val
      245              250              255

Phe Leu Asp Thr Leu Leu Glu Phe Ala Glu Asp Glu Thr Met Glu Ile
      260              265              270

Lys Ile Thr Lys Asp His Thr Lys Gly Leu Val Val Asp Phe Phe Ser
      275              280              285

Ala Gly Thr Asp Ser Thr Ala Val Ala Thr Glu Trp Ala Leu Ala Glu
      290              295              300

Leu Ile Asn Asn Pro Lys Val Leu Glu Lys Ala Arg Glu Glu Val Tyr
      305              310              315              320

Ser Val Val Gly Lys Asp Arg Leu Val Asp Glu Val Asp Thr Gln Asn
      325              330              335
  
```





Leu Pro Tyr Ile Arg Ala Ile Val Lys Glu Thr Phe Arg Met His Pro  
 340 345 350  
 Pro Leu Pro Val Val Lys Arg Lys Cys Thr Glu Glu Cys Glu Ile Asn  
 355 360 365  
 Gly Tyr Val Ile Pro Glu Gly Ala Leu Ile Pro Phe Asn Val Trp Gln  
 370 375 380  
 Val Gly Arg Asp Pro Lys Tyr Trp Asp Arg Pro Ser Glu Phe Arg Pro  
 385 390 395 400  
 Glu Arg Phe Leu Glu Thr Gly Ala Glu Gly Glu Ala Arg Pro Leu Asp  
 405 410 415  
 Leu Arg Gly Gln His Phe Gln Leu Leu Pro Phe Gly Ser Gly Arg Arg  
 420 425 430  
 Met Cys Pro Gly Val Asn Leu Ala Thr Ser Gly Thr Ala Thr Leu Leu  
 435 440 445  
 Ala Ser Leu Ile Gln Cys Phe Asp Leu Gln Val Leu Gly Pro Gln Gly  
 450 455 460  
 Gln Ile Leu Lys Gly Gly Asp Ala Lys Val Ser Met Glu Glu Arg Ala  
 465 470 475 480  
 Gly Leu Thr Val Pro Arg Ala His Ser Leu Val Cys Val Pro Leu Ala  
 485 490 495

Arg Ile

<210> 62  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:PCR PRIMER

<400> 62  
 gttaccatgg ctgctgctat tg

22

<210> 63  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:PCR PRIMER

<400> 63  
 ttaaacgtaa aatgaaacaa gagg

24

<210> 64  
 <211> 26  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence:PCR PRIMER

<400> 64  
 gacacttcga cactgctgct gcttat

26



<210> 65  
<211> 25  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:PCR PRIMER

<400> 65  
tctcaaactc acctgggcta tggat

25

<210> 66  
<211> 521  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:Consensus

<220>  
<221> UNSURE  
<222> (10)

<220>  
<221> UNSURE  
<222> (16)

<220>  
<221> UNSURE  
<222> (23)

<220>  
<221> UNSURE  
<222> (25)

<220>  
<221> UNSURE  
<222> (39)

<220>  
<221> UNSURE  
<222> (48)

<220>  
<221> UNSURE  
<222> (60)

<220>  
<221> UNSURE  
<222> (73)

<220>  
<221> UNSURE  
<222> (74)

<220>  
<221> UNSURE  
<222> (95)

<220>  
<221> UNSURE  
<222> (102)

**THIS PAGE BLANK (USPTO)**

<220>  
<221> UNSURE  
<222> (110)

<220>  
<221> UNSURE  
<222> (112)

<220>  
<221> UNSURE  
<222> (117)

<220>  
<221> UNSURE  
<222> (118)

<220>  
<221> UNSURE  
<222> (121)

<220>  
<221> UNSURE  
<222> (122)

<220>  
<221> UNSURE  
<222> (124)

<220>  
<221> UNSURE  
<222> (129)

<220>  
<221> UNSURE  
<222> (147)

<220>  
<221> UNSURE  
<222> (159)

<220>  
<221> UNSURE  
<222> (162)

<220>  
<221> UNSURE  
<222> (166)

<220>  
<221> UNSURE  
<222> (170)

<220>  
<221> UNSURE  
<222> (175)

<220>  
<221> UNSURE  
<222> (183)

<220>  
<221> UNSURE  
<222> (187)



<220>  
<221> UNSURE  
<222> (191)

<220>  
<221> UNSURE  
<222> (209)

<220>  
<221> UNSURE  
<222> (219)

<220>  
<221> UNSURE  
<222> (223)

<220>  
<221> UNSURE  
<222> (253)

<220>  
<221> UNSURE  
<222> (259)

<220>  
<221> UNSURE  
<222> (263)

<220>  
<221> UNSURE  
<222> (264)

<220>  
<221> UNSURE  
<222> (268)

<220>  
<221> UNSURE  
<222> (272)

<220>  
<221> UNSURE  
<222> (285)

<220>  
<221> UNSURE  
<222> (293)

<220>  
<221> UNSURE  
<222> (294)

<220>  
<221> UNSURE  
<222> (301)

<220>  
<221> UNSURE  
<222> (306)

<220>  
<221> UNSURE  
<222> (311)





WO 00/44909

<220>  
<221> UNSURE  
<222> (312)

<220>  
<221> UNSURE  
<222> (325)

<220>  
<221> UNSURE  
<222> (328)

<220>  
<221> UNSURE  
<222> (334)

<220>  
<221> UNSURE  
<222> (342)

<220>  
<221> UNSURE  
<222> (377)

<220>  
<221> UNSURE  
<222> (381)

<220>  
<221> UNSURE  
<222> (385)

<220>  
<221> UNSURE  
<222> (387)

<220>  
<221> UNSURE  
<222> (393)

<220>  
<221> UNSURE  
<222> (394)

<220>  
<221> UNSURE  
<222> (402)

<220>  
<221> UNSURE  
<222> (404)

<220>  
<221> UNSURE  
<222> (413)

<220>  
<221> UNSURE  
<222> (422)

<220>  
<221> UNSURE  
<222> (428)

**THIS PAGE BLANK (USPTO)**

<220>  
 <221> UNSURE  
 <222> (429)

<220>  
 <221> UNSURE  
 <222> (435)

<220>  
 <221> UNSURE  
 <222> (447)

<220>  
 <221> UNSURE  
 <222> (453)

<220>  
 <221> UNSURE  
 <222> (459)

<220>  
 <221> UNSURE  
 <222> (485)

<400> 66  
 Met Leu Leu Glu Leu Ala Leu Gly Leu Xaa Val Leu Ala Leu Phe Xaa  
     1                    5                    10                    15  
 His Leu Arg Pro Thr Pro Xaa Ala Xaa Ser Lys Ala Leu Arg His Leu  
                     20                    25                    30  
 Pro Asn Pro Pro Ser Pro Xaa Pro Arg Leu Pro Phe Ile Gly His Xaa  
                     35                    40                    45  
 His Leu Leu Lys Asp Lys Leu Leu His Tyr Ala Xaa Ile Asp Leu Ser  
     50                    55                    60  
 Lys Lys His Gly Pro Leu Phe Ser Xaa Xaa Phe Gly Ser Met Pro Thr  
     65                    70                    75                    80  
 Val Val Ala Ser Thr Pro Glu Leu Phe Lys Leu Phe Leu Gln Xaa Xaa  
                     85                    90                    95  
 Glu Ala Thr Ser Phe Xaa Thr Arg Phe Gln Thr Ser Ala Xaa Arg Xaa  
                     100                    105                    110  
 Leu Thr Tyr Asp Xaa Xaa Val Ala Xaa Xaa Pro Xaa Gly Pro Tyr Trp  
     115                    120                    125  
 Xaa Phe Val Arg Lys Leu Ile Met Asn Asp Leu Leu Asn Ala Thr Thr  
     130                    135                    140  
 Val Asn Xaa Leu Arg Pro Leu Arg Thr Gln Gln Ile Arg Lys Xaa Leu  
     145                    150                    155                    160  
 Arg Xaa Met Ala Gln Xaa Ala Glu Ala Xaa Lys Pro Leu Asp Xaa Thr  
                     165                    170                    175  
 Glu Glu Leu Leu Lys Trp Xaa Asn Ser Thr Xaa Ser Met Met Xaa Leu  
                     180                    185                    190  
 Gly Glu Ala Glu Glu Ile Arg Asp Ile Ala Arg Glu Val Leu Lys Ile  
     195                    200                    205  
 Xaa Gly Glu Tyr Ser Leu Thr Asp Phe Ile Xaa Pro Leu Lys Xaa Leu  
     210                    215                    220



Lys Val Gly Lys Tyr Glu Lys Arg Ile Asp Asp Ile Leu Asn Lys Phe  
 225 230 235 240  
 Asp Pro Val Val Glu Arg Val Ile Lys Lys Arg Arg Xaa Ile Val Arg  
 245 250 255  
 Arg Arg Xaa Asn Gly Glu Xaa Xaa Glu Gly Glu Xaa Ser Gly Val Xaa  
 260 265 270  
 Leu Asp Thr Leu Leu Glu Phe Ala Glu Asp Glu Thr Xaa Glu Ile Lys  
 275 280 285  
 Ile Thr Lys Xaa Xaa Ile Lys Gly Leu Val Val Asp Xaa Phe Ser Ala  
 290 295 300  
 Gly Xaa Asp Ser Thr Ala Xaa Xaa Thr Glu Trp Ala Leu Ala Glu Leu  
 305 310 315 320  
 Ile Asn Asn Pro Xaa Val Leu Xaa Xaa Ala Arg Glu Glu Xaa Tyr Ser  
 325 330 335  
 Val Val Gly Lys Asp Xaa Leu Val Asp Glu Val Asp Thr Gln Asn Leu  
 340 345 350  
 Pro Tyr Ile Arg Ala Ile Val Lys Glu Thr Phe Arg Met His Pro Pro  
 355 360 365  
 Leu Pro Val Val Lys Arg Lys Cys Xaa Glu Glu Cys Xaa Ile Asn Gly  
 370 375 380  
 Xaa Val Xaa Pro Glu Gly Ala Leu Xaa Xaa Phe Asn Val Trp Gln Val  
 385 390 395 400  
 Gly Xaa Asp Xaa Lys Tyr Trp Asp Arg Pro Ser Glu Xaa Arg Pro Glu  
 405 410 415  
 Arg Phe Leu Glu Thr Xaa Ala Glu Gly Glu Ala Xaa Xaa Leu Asp Leu  
 420 425 430  
 Arg Gly Xaa His Phe Gln Leu Leu Pro Phe Gly Ser Gly Arg Xaa Met  
 435 440 445  
 Cys Pro Gly Val Xaa Leu Ala Thr Ser Gly Xaa Ala Thr Leu Leu Ala  
 450 455 460  
 Ser Leu Ile Gln Cys Phe Asp Leu Gln Val Leu Gly Pro Gln Gly Gln  
 465 470 475 480  
 Ile Leu Lys Gly Xaa Asp Ala Lys Val Ser Met Glu Glu Arg Ala Gly  
 485 490 495  
 Leu Thr Val Pro Arg Ala His Ser Leu Val Cys Val Pro Leu Ala Arg  
 500 505 510  
 Ile Gly Val Ala Ser Lys Leu Leu Ser  
 515 520

**THIS PAGE BLANK (USPTO)**

# INTERNATIONAL SEARCH REPORT

Int. Application No  
PCT/US 00/01772

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/53 C12N15/82 C12N9/02 C12Q1/68 C12P17/06  
C12N5/10 A01H5/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C12Q C12P A01H

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SIMINSZKY B. ET AL.: "AC AF022462; 048926" EBI DATABASE, 8 January 1998 (1998-01-08) - 1 June 1998 (1998-06-01), XP002141043 the whole document	3,7
A	SCHOPFER, C. R. ET AL: "Identification of elicitor-induced cytochrome P450s of soybean (Glycine max L.) using differential display of mRNA" MOLECULAR AND GENERAL GENETICS, (1998) VOL. 258, NO. 4, PP. 315-322. 29 REF. ISSN: 0026-8925, XP002141044 the whole document	1-50

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

26 June 2000

Date of mailing of the international search report

12/07/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Kania, T

# INTERNATIONAL SEARCH REPORT

Internat. Application No

PCT/US 00/01772

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	AKASHI T. ET AL.: "Cloning of cytochrome P450 cDNAs from cultured Glycyrrhiza echinata L. cells and their transcriptional activation by elicitor-treatment" PLANT SCIENCE, vol. 126, 1997, pages 39-47; XP002101412 see esp. p. 43 fig.3; p.45 r. col.	1-50
A	HAKAMATSUKA T ET AL: "ISOFLAVONE SYNTHASE FROM CELL SUSPENSION CULTURES OF PUERARIA-LOBATA" CHEMICAL & PHARMACEUTICAL BULLETIN (TOKYO), vol. 37, no. 1, 1989, pages 249-252, XP000914902 ISSN: 0009-2363 the whole document	1-50
A	COLLIVER S P ET AL: "Differential modification of flavonoid and isoflavonoid biosynthesis with an antisense chalcone synthase construct in transgenic Lotus corniculatus." PLANT MOLECULAR BIOLOGY, vol. 35, no. 4, 1997, pages 509-522, XP002141045 ISSN: 0167-4412 the whole document	27-40
P,X	STEELE C. ET AL.: "Molecular characterization of the enzyme catalyzing the aryl migration reaction of isoflavonoid biosynthesis in soybean" ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol. 367, July 1999 (1999-07), pages 146-150, XP000921489 the whole document	3,7
P,X	AKASHI TOMOYOSHI ET AL: "Cloning and functional expression of a cytochrome P450 cDNA encoding 2-hydroxyisoflavanone synthase involved in biosynthesis of the isoflavonoid skeleton in licorice." PLANT PHYSIOLOGY (ROCKVILLE), vol. 121, no. 3, November 1999 (1999-11), pages 821-828, XP002141046 ISSN: 0032-0889 the whole document	3,7
P,X	WO 99 19493 A (UNIV NORTH CAROLINA ;DEWEY RALPH E (US); CORBIN FREDERICK T (US);) 22 April 1999 (1999-04-22) see table 1; pp.66-69 SEQ ID NO:13	3,7



## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## Continuation of Box I.2

Present claims 1,2 relate to an extremely large number of possible sequences. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the sequences claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the sequences encoding the cloned isoflavone synthases as listed in the sequence listing.

\*\*\*\*\*'indicate precisely what has been covered by the search e.g those compounds etc. prepared in the examples and closely related homologous compounds etc./those compounds etc. mentioned in the description at pages YY/given in Formula 1, where A = C4, B = C6 etc.!\*\*\*\*\*

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

ernat : Application No

PCT/US 00/01772

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
---	---------------------	----------------------------	---------------------

WO 9919493 A	22-04-1999	AU 9680698 A	03-05-1999
--------------	------------	--------------	------------